UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 1 of 144PROTOCOL SP0967 AMENDMENT 3
A MULTICENTER, DOUBLE -BLIND, RANDOMIZED, 
PLACEBO -CONTROLLED, PARALLEL -GROUP STUDY TO 
INVESTIGATE THE EFFICACY AND SAFETY OF 
LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS 
WITH EPILEPSY ≥1 MONTH TO <4 YEARS OF AGE WITH 
PARTIAL -ONSET SEIZURES
PHASE 3
EudraCT Number: 2013-000717-20
IND Number: 73809
Sponsor:
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC 27617
UNITED STATES
Protocol/Amendment 
numberDate Type of amendment
Final Protocol 29 May 2014 Not applicable
Protocol Amendment 1 14 Jan 2015 Substantial
Protocol Amendment 2 09 Aug 2016 Substantial
Protocol Amendment 3 05 Apr 2018 Substantial
Confidential Material
Confidential
This document is the property of UCB and may not –in full or in part –be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.REDACTED C
rco Corco Co
RaleiRalei
UUCOPY or:or:
IENIEN
This document cannot be c
beusedol Aol Aed Amm
edto menmenosuppndmendmenport t
ppsany amarketingUNITEUNIT
arararkarauthorization CES CES 
orporarpora
igh, Ngh, Napplication and 200any extensions orTHTvariations S S 
THHthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 2of 144STUDY CONTACT INFORMATION
Sponsor
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC 27617
UNITED STATES
Principal/Coordinating Investigator
Will be listed separately.
Sponsor Study Physician
Name: , MD
Address: UCB BIOSCIENCES Inc. 
8010 Arco Corporate Drive Raleigh, NC 27617UNITED STATES
Phone:
Fax:
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES GmbH 
Alfred -Nobel-Straße 10 
40789 Monheim
GERMANY
Phone:
Fax:REDEDDACTED D
CT
EDACOPY 
This document cannoFaFnot Phoho
noanbe oneonebeused to supportUCBUC
Aor
suort any nyanmarketing authorization at
ho
aapplication nand daany aextensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 3of 144Clinical Trial Biostatistician
Name:
Address: UCB BIOSCIENCES Inc. 
8010 Arco Corporate Drive Raleigh, NC 27617 UNITED STATES
Phone:
Fax:
Clinical Monitoring Contract Research Organization
Name: Pharmaceutical Research Associates, Inc.
Address: 4130 Park Lake Avenue, Suite 400
Raleigh, NC 27612UNITED STATES
Phone: +1 919 786 8200
Fax: +1 919 786 8201
REDACTED ED
ACCOPY CO
This document cannot be used to support any marketing authorization on
iza
thapplication n and d any extensions ioor rovariations vthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 4 of 144SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA or Canada: +1 800 880 6949 or +1 866 890 3175
Email DS_ICT@ucb.com (for all regions)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions ioor orvariations vthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 5 of 144TABLE OF CONTENTS
TABLE OF CONTENTS...........................................................................................................5  
LIST OF TABLES................................................................................................................. ..10  
LIST OF FIGURES ................................................................................................................ .10 
LIST OF ABBREVIATIONS..................................................................................................11  
1 SUMMARY.....................................................................................................................14  
2 INTRODUCTION ...........................................................................................................15  
3 STUDY OBJECTIVE(S) .................................................................................................17  
4 STUDY VARIABLES.....................................................................................................18  
4.1 Efficacy variables...................................................................................................18  
4.1.1  Primary efficacy variable.............................................................................18  
4.1.2  Secondary efficacy variables .......................................................................18  
4.1.3  Other efficacy variables ...............................................................................19  
4.2 Pharmacokinetic and pharmacodynamic variables................................................19  
4.3 Safety variables......................................................................................................19  
4.3.1  Primary safety variables...............................................................................19  
4.3.2  Other safety variables ..................................................................................19  
5 STUDY DESIGN.............................................................................................................19  
5.1 Study description ...................................................................................................19  
5.1.1  Study duration per subject ...........................................................................21  
5.1.2  Planned number of subjects and sites ..........................................................21  
5.1.3  Anticipated regions and countries................................................................22  
5.2 Schedule of study assessments...............................................................................22  
5.3 Schematic diagram.................................................................................................29  
5.4 Rationale for study design a nd selection of dose...................................................32  
6 SELECTION AND WITHDRAWAL OF SUBJECTS...................................................33  
6.1 Inclusion criteria ....................................................................................................33  
6.2 Exclusion criteria ...................................................................................................33  
6.3 Withdrawal criteria ................................................................................................35  
6.3.1  Potential drug-induced liver injury IMP discontinuation criteria................36  
7 STUDY TREATMENTS.................................................................................................37  
7.1 Description of investigational medicinal products ................................................37  
7.2 Treatment(s) to be administered ............................................................................37  
7.2.1  Titration Period............................................................................................37  
7.2.2  Maintenance Period .....................................................................................38  
7.2.3  Transition Period..........................................................................................39  
7.2.4  Taper Period.................................................................................................39  
7.3 Packaging...............................................................................................................40  REDACTED ........
.........
bjectbject
f subjf subjCOPY .....
...........
This document77cannot TUDYTUDY
7.17.1be 11used sioio
ithdrathdrato c
on con csupportudy dy 
D WITWIT
criterriterany .........
y desyd emarketingects ects
and coand c
ssmentsmenauthorization ....
..........
..........
..........
sasaapplication ........
...........
...........
.....and ..........any ...........extensions ..........
..........
.........or ........variations .1515
1thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 6 of 1447.4 Labeling .................................................................................................................40  
7.5 Handling and storage requirements .......................................................................40  
7.6 Drug accountability................................................................................................40  
7.7 Procedures for monitoring subject compliance......................................................41  
7.8 Concomitant medications/treatments.....................................................................41  
7.8.1  Permitted and prohibited concomitan t treatments (medications and 
therapies)......................................................................................................41  
7.8.2  Rescue medication .......................................................................................42  
7.9 Blinding..................................................................................................................42  
7.9.1  Procedures for maintaining and breaking the treatment blind.....................42  
7.9.1.1  Maintenance of study treatment blind................................................42  
7.9.1.2  Breaking the treatment blind in an emergency situation....................42  
7.10  Randomization and numbering of subjects............................................................43  
8 STUDY PROCEDURES BY VISIT ...............................................................................43  
8.1 Baseline Period: Visit 1 (Day -7) to Visit 2 (Day -3 to Day -1) ............................43  
8.1.1  Baseline Period: Visit 1 (Day -7).................................................................43  
8.1.2  Baseline Period: Visit 2 (Day -3 to Day -1).................................................44  
8.2 Titration Period: Visit 3 (Day 1) to Telephone Contact 3 (Day 20) ......................45  
8.2.1  Titration Period: Visit 3 (Day 1)..................................................................45  
8.2.2  Titration Period: Telephone Contact 1 (Day 5), Telephone Contact 2 (Day 13), and Telephone Contact 3 (Day 20)..............................................46
 
8.2.3  Titration Period: Visit 4 (Day 9)..................................................................46  
8.2.4  Titration Period: Visit 5 (Day 17)................................................................47  
8.3 Maintenance Period: Visit 6/Early Termination (Day 24 to Day 27)....................48  
8.3.1  Maintenance Period: Visit 6/Earl y Termination (Day 24, Day 25, and 
Day 26) ........................................................................................................48  
8.3.2  Maintenance Period: Visit 6/Early Termination (Day 27)...........................49  
8.4 Transition Period: Transition Visit 1 (Day 32) to Transition Visit 2 (Day 40) .....50  
8.4.1  Transition Period: Transition Visit 1 (Day 32)............................................50  
8.4.2  Transition Period: Transition Telephone Contact 1 (Day 36) .....................50  
8.4.3  Transition Period: Transition Visit 2 (Day 40)............................................51  
8.5 Taper Period: Telephone Contact 4 (Day  32) and Taper Visit (Day 36, Day 40, or 
Day 44)...................................................................................................................51  
8.5.1  Taper Period: Telephone Contact 4 (Day 32)..............................................51  
8.5.2  Taper Period: Taper Visit (Day 36, Day 40, or Day 44) .............................52  
8.6 Safety Follow-Up Period .......................................................................................52  
8.6.1  Safety Follow-Up Period: Safety Follow-Up Clinic Visit (Day 50, Day 54,or Day 58) ....................................................................................................52
 REDACTED Day 1)Day 1)
hone Chone C
hone Chone C
Visit Visit COPYo Day Day
elepheleph
This document cannot 44
5be .3.3usedTraTra
Tto on Pn 
ansupport ..........
tenanceenanc
PeriPeranye Peri Permarketing4 (Da4 (Da
Visit 5 (sit 5 
Visit 6/Visit 6authorizationhone Cone 
............
ContaConta
ContaContaapplicationo Dayo Day
..............
-1)1)..
Cand ....
.........anytiontio
......extensions.........
..........
..........
onnor ...variations 411
4242thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 7 of 1448.6.2  Safety Follow-Up Period: Safety Follow-Up Telephone Contact (Day 66,
Day 70, Day 74, or Day 93).........................................................................53  
8.7 Unscheduled Visit..................................................................................................53  
9 ASSESSMENT OF EFFICACY......................................................................................54  
9.1 Primary and secondary efficacy variables .............................................................54  
9.2 Other efficacy assessments ....................................................................................54  
9.2.1  Global Impression of Change ......................................................................54  
9.2.2  PedsQL.........................................................................................................54  
9.2.3  Healthcare resource use ...............................................................................55  
10 ASSESSMENT OF PHARMACOKINETIC AND PHARMACODYNAMIC 
VARIABLES ...................................................................................................................55  
11 ASSESSMENT OF SAFETY..........................................................................................55  
11.1  Adverse events .......................................................................................................55  
11.1.1  Definition of adverse event..........................................................................55  
11.1.1.1  Signs and symptoms of depression ....................................................56  
11.1.2  Procedures for reporting and recording adverse events...............................56  
11.1.3  Description of adverse events ......................................................................56  
11.1.4  Follow up of adverse events ........................................................................56  
11.1.5  Rule for repetition of an adverse event........................................................56  
11.1.6  Suspected transmission of an infecti ous agent via a medicinal product......57  
11.1.7  Overdose of investigational medicinal product ...........................................57  
11.1.8  Safety signal detection .................................................................................57  
11.2  Serious adverse events ...........................................................................................57  
11.2.1  Definition of serious adverse event .............................................................57  
11.2.2  Procedures for reporting serious adverse events..........................................58  
11.2.3  Follow up of serious adverse events ............................................................59  
11.3  Adverse events of special interest..........................................................................59  
11.4  Immediate reporting of adverse events ..................................................................60  
11.5  Anticipated serious adverse events ........................................................................60  
11.6  Laboratory measurements......................................................................................61  
11.6.1  Liver function tests and evaluation of PDILI ..............................................62  
11.6.1.1  Consultation with Medical Monitor and local hepatologist...............66  
11.6.1.2  Immediate action: determination of IMP discontinuation .................66  
11.6.1.3  Testing: identification/exclusion of alternative etiology ...................66  
11.6.1.4  Follow-up evaluation .........................................................................68  
11.7  Other safety measurements....................................................................................69  
11.7.1  Physical examination ...................................................................................69  
11.7.1.1  Complete physical examination.........................................................69  
11.7.1.2  Brief physical examination ................................................................69  REDACTEDverseverse
of an of an 
gationgation
ctionctionCOPY ............
............
This document cannot 1.6.6be Lab
6.161usedicipatipat
boraboratoate rate supportup of p of 
ents ofents o
repreanyfor repor re
semarketing ..............
...........
rious aious authorization .........
eventevent
infectinfect
al medl medapplication .............
erse everse ev
............and ..........any ..
.........extensions.........
C 
...........
......or ...variations 544
5454thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 8 of 14411.7.2  Neurological examination............................................................................69  
11.7.2.1  Complete neurological examination ..................................................69  
11.7.2.2  Brief neurological examination..........................................................69  
11.7.3  Vital signs, body weight, and height............................................................69  
11.7.4  12-lead ECG ................................................................................................70  
11.7.5  Overall ECG interpretation..........................................................................70  
11.7.6  Achenbach CBCL........................................................................................70  
11.7.7  BRIEF-P.......................................................................................................71  
11.7.8  Bayley Scales of Infant and Toddler Development, Third Edition .............71  
12 STUDY MANAGEMENT AND ADMINISTRATION .................................................72  
12.1  Adherence to protocol............................................................................................72  
12.2  Monitoring .............................................................................................................72  
12.2.1  Definition of source data..............................................................................72  
12.2.2  Source data verification ...............................................................................73  
12.3  Data handling.........................................................................................................73  
12.3.1  Case Report form completion ......................................................................73  
12.3.2  Database entry and reconciliation................................................................73  
12.3.3  Subject Screening and Enrollment log/ Subject Identification Code list......74  
12.4  Termination of the study........................................................................................74  
12.5  Archiving and data retention..................................................................................74  
12.6  Audit and inspection ..............................................................................................74  
12.7  Good Clinical Practice ...........................................................................................75  
13 STATISTICS ...................................................................................................................75  
13.1  Definition of analysis sets......................................................................................75  
13.1.1  Analysis of the primary efficacy variable....................................................75  
13.1.1.1  Analysis of the primary efficacy variable for the US ........................76  
13.1.1.2  Analysis of the primary efficacy variable for the EU ........................77  
13.1.2  Analysis of secondary efficacy variables.....................................................78  
13.1.3  Other efficacy analyses................................................................................78  
13.2  Planned safety and other analyses..........................................................................78  
13.2.1  Safety analyses.............................................................................................78  
13.2.2  Pharmacokinetics and pharmacodynamics ..................................................79  
13.2.2.1  Descriptive statistics of LCM and AED plasma concentrations........79  
13.2.2.2  Population pharmacokinetics .............................................................79  
13.3  Handling of protocol deviations.............................................................................79  
13.4  Handling of dropouts or missing data....................................................................79  
13.5  Planned interim analysis and data monitoring .......................................................80  
13.6  Determination of sample size.................................................................................80  REDACTED me
............
...........
............COPY ..........
ent lent l
This document cannot13.23.2
1313bePlanPlaused AnA
OtOt
nntoAnalynalsupport f t
Analysinaly
AnaAnaany s ss s
the prhe pmarketing ..
............
...........
setssetsauthorizationlog/Suog/Su
..........
...........
....application ..
............
............
...........and .......
.....any .........
..extensions ..........
.........
..........or ......variations 7070
717thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 9 of 14414 ETHICS AND REGULATORY REQUIREMENTS......................................................81  
14.1  Informed consent ...................................................................................................81  
14.2  Subject identification cards....................................................................................81  
14.3  Institutional Review Boards and Independent Ethics Committees........................82  
14.4  Subject privacy.......................................................................................................82  
14.5  Protocol amendments.............................................................................................83  
15 FINANCE, INSURANCE, AND PUBLICATION .........................................................83  
16 REFERENCES ................................................................................................................84  
17 APPENDICES .................................................................................................................86  
17.1  AMENDMENT 1...................................................................................................86  
17.2  AMENDMENT 2.................................................................................................111  
17.3  AMENDMENT 3.................................................................................................136  
18 DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................143  
19 SPONSOR DECLARATION ........................................................................................144  
REDACTED COPY 
This document cannot be used to support any marketing authorization application ..and .......
.....any .........
..extensions ..........
.........
..........or ......variations 8383
848thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 10 of 144LIST OF TABLES
Table 5‒1: Schedule of study assessments (Bas eline and Treatment Periods).......................23  
Table 5‒2: Schedule of study assessment s (Transition Period)..............................................27  
Table 5‒3: Schedule of study assessments (Taper  and Safety Follow-Up Periods)...............28  
Table 7‒1: Recommended dosing schedule for LCM (or matching PBO) during the 
Titration Period.....................................................................................................38  
Table 7‒2: Transition Period LCM dosing schedule for subjects randomized to PBO..........39  
Table 7-3:  Dosing of LCM (or matching PBO) during the Taper Period ..............................39  
Table 11‒1: Anticipated SAEs for the pediatric epilepsy population..............................61  
Table 11‒2: Laboratory measurements............................................................................62  
Table 11‒3: Required investigations and follow up of PDILI.........................................64  
Table 11‒4: PDILI laboratory measurements..................................................................67  
Table 11‒5: PDILI information to be collected ...............................................................68  
Appendix Table 1:  Summary of changes in SP0967 Amendment 2 ..............................112  
Appendix Table 2:  Summary of changes in SP0967 Amendment 3 ..............................137  
LIST OF FIGURES
Figure 5‒1:  Subjects entering EP0034 open-label extension study ................................30  
Figure 5‒2:  Subjects not entering EP0034 open-label extension study ..........................31  REDACTED T OFOF
P0034P0034
ngngCOPY 67 7
P0967096
This document cannot be used to support any marketing 4 o
g EP00EP00uthorization 7 A
F FIGF FIG
openopenapplication .............
mendmendm
AmenAmeand ..........any ..........extensions ..........
...........
.........or ....variations 88
3939thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 11 of 144LIST OF ABBREVIATIONS
ADF average daily frequency
AE adverse event
AED antiepileptic drug
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AV atrioventricular
bid twice daily
BMI body mass index
BP blood pressure
BRIEF®-P Behavior Rating Inventory of Executive Function®-Preschool Version
BZD benzodiazepine
CBCL Childhood Behavior Checklist
CDMS clinical data management system
CPM Clinical Project Manager
CPMP Committee for Proprietary Medicinal Products
CRO contract research organization
DAP Data Analysis Plan
eCRF electronic Case Report form
ECG electrocardiogram
EEG electroencephalogram
EMA European Medicines Agency
FAS Full Analysis Set
FDA Food and Drug AdministrationREDACTED toryory
ehaviehaviCOPY ry ofyo
This document EEGEEcannot GGbe used to supportommiommi
concoany ProPromarketing or Cr C
managmana
ojejauthorization f ExecfE x e
ChChapplication and any extensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 12 of 144GCP Good Clinical Practice
GMP Good Manufacturing Practice
HRQoL health -related quality of life
ICH International Council for Harmonisation
IDMC Independent Data Monitoring Committee 
IEC Independent Ethics Committee
IMP investigational medicinal product
IRB Institutional Review Board
iv intravenous
IXRS interactive voice/web response system
LCM lacosamide
LFT liver function test
LSM least square means 
MedDRA®Medical Dictionary for Regulatory Activities®
PBO placebo
PDILI potential drug -induced liver injury
PedsQLTMPediatric Quality of Life InventoryTM
PET polyethylene terephthalate
PK pharmacokinetic(s)
PK-PPS Pharmacokinetic Per Protocol Set
PPS Per Protocol Set
PT preferred term
QTc corrected QT interval
RDC remote data captureREDACTED ns s 
tionationaCOPY 
This document PTPTcannot Sbe used to support Pediatrediat
popanyal drual drmarketingary foary foauthorization application and any extensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 13 of 144SAE serious adverse event
SAP Statistical Analysis Plan
SOC system organ class
SOP Standard Operating Procedure
SS Safety Set
TEAE treatment -emergent adverse event
ULN upper limit of normal
VNS vagus nerve stimulation
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 14 of 1441S U M M A R Y
SP0967 is a Phase 3, multicenter, double-bli nd, randomized, placebo (PBO)-controlled, 
parallel-group study to evaluate the efficacy  and safety of lacosamide (LCM) (VIMPAT®; SPM 
927; previously referred to as harkoseride; [R]-2-acetamido-N-benzyl-3-methoxypropionamide, 
ADD 234037) 8mg/kg/day to LCM 12mg/kg/day as adjunctive therapy in subjects with epilepsy 
≥1 month to <4 years of age with uncontrolled partial -onset seizures. This study is 1 of 2 pivotal 
studies in a pediatric partial-onset seizure population. In addition to SP0967, SP0969 is a Phase 3, multicenter, double-blind, randomized, PBO- controlled, parallel-group study to evaluate 
the efficacy and safety of LCM as an adjunctive therapy in subjects with epilepsy ≥4 years to 
<17 years of age with partial-onset seizures. 
The primary objective of SP0967 is to evaluate the efficacy of LCM administered concomitantly 
with 1 to 3 antiepileptic drugs (AEDs) in pediatric subjects ( ≥1 month to <4 years of age) with 
epilepsy who currently have uncontrolled partial-onset seizures. The secondary objective is to evaluate the safety and tolerability of LCM in pedi atric subjects with partial-onset seizures. An 
additional objective is to evaluate the pharmacokinetics (PK) of LCM in subjects ≥1 month to <4 
years of age.
A total of approximately 244 subjects (122 subjects  per treatment arm) are planned to be 
randomized at approximately 140 sites in North America, Europe, Asia Pacific, and Latin 
America, with possible extension to other countries  and regions. Stratification of subjects will be 
done by age category ( ≥1 month to <6 months of age, ≥6 months to <1 year of age, ≥1 year to 
<2years of age, and ≥2 years to <4 years of age). A target of 50% of the randomized subjects 
should consist of subjects <2 years of age. The maximum duration of study medication administration in SP0967 is 55 days (this includes a 20-day Titration Period, a 7-day 
Maintenance Period, a 12-day Transition Period, and/or up to a 16-day Taper Period), and the 
maximum study duration is 93 days (not withstanding visit windows).
The study is comprised of the following: a 7-day Baseline Period; a 20-day blinded Titration 
Period (with study medication dosing flexibility allo wed based on tolerability) to attain the target 
dose of study medication for the 7-day blinde d Maintenance Period (LCM 8mg/kg/day to 
LCM 12mg/kg/day, or matching PBO, with no adjustments to study medication dose allowed 
during the Maintenance Period); and a 12-day blinded Transition Period for subjects who 
complete the study and choose to enter the open-label extension study (EP0034) or a Taper Period (up to 16 days) followed by a 30-day Safety Follow-Up Period for subjects who are not 
eligible or who choose not to enter EP0034. The Tr ansition Period will be required for eligible 
subjects who complete the Maintenance Period and choose to enter EP0034. The Taper Period 
and Safety Follow-Up Period are required for subjects who complete the study but choose not to 
enroll in EP0034 or for subjects who do not comp lete the Titration, Maintenance, and Transition 
Periods.
Based on US Food and Drug Administration (FDA ) and European Medicines Agency (EMA) 
requirements, 2 (co-) primary efficacy variable s have been defined for this study based on 
electrographic partial-onset seizures with or without clinical correlate depending upon subject age. The primary efficacy variable will be th e change in average daily frequency (ADF) of 
electrographic partial- onset seizures (US) or proportion of subjects experiencing ≥50% reduction 
in their ADF of electrographic partial-onset seizures (EU) as measured on the REDACTEDs ofs ofa
f age)f age)
ge. Thee. Th
(this inthis in
itionitionCOPYmericaeric
ies andies an
agag
This documentPerioerio
BaBcannotwhwh
afety Ffety F
oll in ll in 
oddbe who
ho coho csedyy
6 day6 day
o cho chtoandandsupportor thr th
matchinmatch
ce Perce Pe
dcanydosindosi
he 7hemarketingnc
n Perin Peri
(not winot w
owingowinauthorizationnd red re
ge, ≥6e, ≥6
). A ta A ta
he maxe max
cludeludapplication tment ament 
, EuropEuro
egioegioandpartiart
M in M in anyndaryndar
tialtialextensions yea
red cored co
yearsyearsorars tarsvariations al al 
valuvaluthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 15 of 144End-of-Maintenance Period video-electroencephalogram (EEG) compared to the 
End-of-Baseline Period video-EEG. Partial-onset  seizures will be counted locally by the 
investigator, subinvestigator, or qualified designat ed reader based on evaluating the characteristic 
ictal patterns of electrographic seizures. At the request of FDA, a contingent primary efficacy 
variable has also been defined based on the percentage of subjects who discontinue early from 
the study prior to completing the End-of-Maintenance Period video-EEG. Contingent upon >10% of subjects discontinuing early from the study, the primary efficacy parameter for the US 
will become identical to the primary efficacy parameter for the EU. The endpoint not designated 
as primary will still be summarized as a secondary efficacy parameter. 
Secondary and other efficacy variables will aid further exploration of the effect of LCM on 
partial-onset seizure frequency, global impressions of change, quality of life assessment 
(Pediatric Quality of Life Inventory
TM[PedsQLTM]), and healthcare resource use. Plasma 
concentrations of LCM will be obtained in order to develop a population PK model of LCM, to 
investigate the effect of LCM on the steady-state plasma concentrations of concomitant AEDs, 
and to investigate the correlation between LCM plasma concentrations and efficacy or safety.
Safety and tolerability will be  assessed primarily based on the occurrence of adverse events 
(AEs) reported spontaneously by the subject’s parent(s) and/or his/her legal 
representative(s)/caregiver(s) or observed by the investigator, and subject withdrawals due to AEs. Other safety variables will include asse ssment for change in hematology and clinical 
chemistry parameters; results of periodic physical and neurological examination, body mass 
index (BMI), 12-lead electrocardiogram (ECG),  and vital sign measurements. Baseline 
behavioral function assessment (Achenbach Childhood Behavior Checklist [CBCL]) and 
cognitive function assessment (Behavior Rating Inventory of Executive Function
®-Preschool 
Version [BRIEF®-P]) will be conducted for analysis in EP0034.
2 INTRODUCTION
Epilepsy is the second most prevalent neurological disorder in the world. It is estimated that 
almost 70 million people suffer from epilepsy (Ngugi et al, 2011). Although some forms of 
epilepsy may respond to surgical treatment and others may not require any treatment at all, most patients with epilepsy require appropriate pharmac ological therapy (Perucca, 1996). The Institute 
of Medicine of the National Academies recently provided a review of the burdens of epilepsy, 
global incidence and prevalence of epilepsy, classification systems for seizure types and syndromes, gaps in information about epilepsy, and general recommendations (Institute of 
Medicine, 2012). Several newer options for the medical treatment of epilepsy have been 
introduced, including novel AEDs and vagus nerve stimulation (VNS).
The classification of epilepsies in children was described in 1989 by the Commission on 
Classification and Terminology of the Internation al League Against Epilepsy (1989; Aicardi, 
1994). Seizures are categorized based on whether th e onset is focal or generalized and whether 
the disorder is idiopathic, symptomatic, or cryptogenic. Specific syndromes are further classified 
according to a number of criteria including seizure  type, cause, anatomy, precipitating factors, 
age at onset, and sometimes prognosis.
The newer AEDs differ from older agents in several important ways, including mechanism of 
action, spectrum of activity, and PK characteris tics (Herman and Pedley, 1998). However, more 
than 30% of patients have inadequate seizure c ontrol on currently available AEDs or experience REDACTEDG), aG), a
h Chilh Chil
r RatinRati
ted fored for
NNCOPYfor cfor 
al and l and 
andand
This document1994994
the thecannotassificssific
ssificasifica
4)4)be, inc, incuseds in iin i
12). S2). S
lltond prd p
ininsupportgigi
quire auire a
tional Aional
prevprevanyfromfro
cal trcal trmarketing r a
alent neent n
omomauthorizationneuneu
d vitalvita
ldhooddhood
ng Invng Inv
analyanalapplicationurreurre
his/herhis/he
r, and s, and
hange hange
urolurolands anan
rencencanyf conf co
nd end eextensionsCM oM 
smentmen
se. Plae. Pla
modmodor onvariations S S 
nated ated thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 16 of 144significant adverse drug effects (CHMP/EWP/566/98, 2010). Therefore, a need remains for 
AEDs with improved effectiveness and tolerability (Sander, 1998).
Among the newer AEDs, only 6 (gabapentin, lamotrigine, oxcarbazepine, topiramate, 
levetiracetam, and perampanel) have successfully demonstrated efficacy as adjunctive therapy in 
children with difficult to treat partial-onset s eizures (Rheims and Ryvlin, 2013; Glauser et al, 
2006; Glauser et al, 2000; Appleton et al, 1999; Duchowny et al, 1999; Elterman et al, 1999;). Despite the availability of new AEDs, more than 25% of pediatric patients have inadequate 
seizure control on currently available AEDs or experience significant adverse drug effects 
(Hadjiloizou and Bourgeois, 2007).
Lacosamide belongs to a novel class of functi onalized amino acids. It has minimal protein 
binding and effect on cytochrome P450 enzyme system function (reducing the risk of drug-drug 
interactions), high oral bioavailability, and a half-life of approximately 13 hours (in adults), 
which allows a twice daily (bid) dose regimen. It also displays dose-proportional PK following 
administration over a range of doses up to 800mg in adults.
In the US, LCM has been approved as monotherapy and adjunctive therapy in the treatment of 
partial-onset seizures in patients 4 years of age and older for tablets and oral solution, and 
17 years of age and older for intravenous [iv] infusion. In the EU, LCM has been approved as 
monotherapy and adjunctive therapy in the trea tment of partial-onset seizures with or without 
secondary generalization in adults , adolescents, and children from 4 years of age with epilepsy 
(tablets, oral solution, and solution for iv infusion). The oral solution (also referred to as syrup) is 
a formulation suitable for administration to ch ildren. Bioequivalence has been shown between 
the tablet and oral solution formulations, comparing 2 tablets of LCM 100mg and the oral 
solution containing LCM 200mg, after single-dose administration in healthy subjects. The PK of 
LCM and SPM 12809 (major LCM metabolite in human s) in plasma, urine, and saliva were 
identical or very similar after single oral doses of LCM 200mg administered as tablets or as oral solution.
In the clinical development program for LCM, safety and tolerability of multiple doses of up to 
LCM 400mg bid (LCM 800mg/day) were evaluated in approximately 800 unique volunteers who 
received LCM in Phase 1 studies. The safety and efficacy of LCM has also been evaluated in 
Phase 2/3 studies as adjunctive oral therapy in over 1300 adult subjects with partial-onset seizures and as oral monotherapy in over 2400 ad ult subjects in other indications (neuropathic 
pain, osteoarthritis, fibromyalgia, and migraine prophylaxis). In addition, LCM solution for 
infusion was evaluated as short-term replace ment therapy in a subset of subjects with 
partial-onset seizures (220 patients) who were receiving adjunctive LCM tablets.
Three double-blind, PBO-controlled, multi center studies (SP667, SP754, and SP755) in 
1308 adult subjects, aged 16 to 70 years, established the efficacy of oral LCM as adjunctive therapy (1 to 3 concomitant AEDs) in subjects with difficult to control partial-onset seizures. In 
these studies, LCM was initiated at a dose of 100mg/day (in 2 divided doses) and escalated to the 
randomized dose (LCM 200mg/day, LCM 400mg/day, or LCM 600mg/day) in LCM 100mg/day per week increments.
When oral LCM was administered as adjunctive  therapy at doses up to LCM 600mg/day in the 
3 double-blind, PBO-controlled, multicenter studies in subjects with partial-onset seizures, the 
most frequently reported treatment-emergent adverse events (TEAEs) were central nervous REDACTEDhildrehildr
compaompa
singlesingle
metabmetab
oraorCOPY of pof
d childd chil
n). Thn). T
This documentherahera
thesthe
rcannotdoubloubl
8aduladu
apyapbeet seet seusedtis, fs, f
valuavalua
eizeizto mo
fibfibsupport studitudi
djunctivunct
monotonoanygramra
g/dayg/daymarketingbolitolit
al doseal dose
am famauthorizationld
The orhe or
en. Bioen. Bi
aring 2aring 2
e-dosedose
iteiteapplicationets anets a
EU, LCEU, L
rtialial--ono
dren frren fand therapherapany tiotioextensionsproteirotei
sk of k of 
urs (inrs (in
onalonaor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 17 of 144system- and gastrointestinal-associated events. A dose relationship was seen for the most 
frequently reported common TEAEs, including dizz iness, nausea, and diplopia. The nature and 
frequency of AEs were comparable to adjunctiv e therapy with other marketed AEDs. Safety 
evaluations support the further development of LCM as an AED.
Pellock et al have recently c onducted a systematic review of AEDs used in the treatment of 
partial-onset seizures (Bourgeois and Goodkin, 20 12; Pellock et al, 2012). The AEDs that were 
shown to be superior to PBO for the adjunctiv e treatment of partial-onset seizures in adult 
clinical studies were also shown to be superior  to PBO for adjunctive treatment of partial-onset 
seizures in the pediatric clinical studies (subjects >2 years of age) in which they were investigated. The efficacy and safety of LCM observed in clinical studies in adults and 
preclinical data, as well as many additional attributes of LCM, render the drug appropriate to 
investigate in pediatric subjects. These attributes include predictable and linear PK, lack of 
drug-drug interactions, easy bid dosing, and the availability of 3 different types of formulations 
in multiple strengths (allowing for flexibility in dose range and individualizing treatment).
Lacosamide is being evaluated in pediatric subjects 1 month to 17 years of age with partial-onset 
seizures in completed and ongoing studies. The completed pediatric studies include: SP847 
(open-label, safety, tolerability, and PK stud y) and SP1047 (PK study for subjects prescribed 
LCM). The ongoing pediatric studies include: SP848 and EP0034 (open-label, long-term safety studies). In SP847, SP848, and EP0034, subjects with  uncontrolled partial-onset seizures have 
received LCM oral solution at doses up to 12mg/kg/day based on tolerability. In SP1047, 
subjects with epilepsy received LCM oral tablets (50mg, 100mg, 150mg, or 200mg), or LCM oral solution (syrup; LCM 10mg/mL) that they had been prescribed for epilepsy and brought 
with them to the clinic for dosing. Preliminary data have not demonstrated any clinically relevant 
changes in vital signs, in ECGs, or in clinical laboratory values; or evidence of cardiac related 
TEAEs or body weight changes.
SP0967 is a Phase 3, multicenter, double-blind, randomized, PBO-controlled, parallel-group 
study to evaluate the efficacy and safety of LCM (LCM 8mg/kg/day to 12mg/kg/day, or matching PBO) as adjunctive therapy in subjects ≥1 month to <4 years of age wit h epilepsy with 
uncontrolled partial-onset seizures.
3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the efficacy of LCM administered 
concomitantly with 1 to 3 AEDs in subjects ≥1 month to <4 years of age with epilepsy who 
currently have uncontrolled partial-onset seizures.
The secondary objective is to evaluate the safety and tolerability of LCM in subjects ≥1 month to 
<4 years of age with epilepsy who currently have uncontrolled partial-onset seizures.
An additional objective is to e valuate the PK of LCM in children ≥1 month to <4 years of age. REDACTEDets (ets 
they hthey h
minaryinar
clinicclinicCOPYth unth un
kg/dakg/da
(5(5
This documentAn an acannotondanda
ears ofars of
addadbe ve
aryarsedct
with with 
e uncuntoive ive supporteizueizu
DY OBY O
ofanytherapthera
zureurmarketing ca
oubleuble b
safetysafeauthorizationay bay ba
0mg, 0mg,
had bead be
y datadata
al labl labapplicationric sc s
K studystud
P0034 (0034
controlontro
aseaseandars ors o
studstuanyizingzin
fextensions nd d 
propriropri
PK, lPK, l
pes ofes ofor variations nset nset thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 18 of 1444 STUDY VARIABLES
4.1 Efficacy variables
Primary and secondary efficacy variables w ill be based on video-EEGs (up to 72 hours of 
continuous recording with every attempt to obtai n at least 48 hours of interpretable recording). 
4.1.1 Primary efficacy variable
For the US, the primary efficacy variable will be contingent on the percentage of subjects that 
discontinue from the study after the first dose of study medication but prior to performance of the 
End-of-Maintenance Period video- EEG (ie, early discontinuation).
The following variable will be considered primary for the US given that ≤10% of subjects 
discontinue early from the study:
x The change in ADF of electrographic partial-onset seizures as measured on the End-of-
Maintenance Period video-EEG compared to  the End-of-Baseline Period video-EEG. 
If >10% of subjects discontinue early from the study, the following contingency endpoint will be 
considered primary for the US (same as the primary efficacy variable for the EU):
x The proportion of responders where a responder is a subject experiencing a 50% or greater 
reduction in their ADF of electrographic partial-onset seizures recorded on the End-of-
Maintenance Period video-EEG compared to  the End-of-Baseline Period video-EEG.
For the EU:
The primary efficacy variable will be the proportion of responders where a responder is a subject 
experiencing a 50% or greater reduction in thei r ADF of electrographic partial-onset seizures 
recorded on the End-of-Maintenance Period video-EEG compared to the End-of-Baseline Period 
video-EEG.
4.1.2 Secondary efficacy variables
The secondary efficacy variables are described below.
x Percent and absolute change in ADF of electrographic partial-onset seizures from the 
End-of-Baseline Period video-EEG to the End-of-Maintenance Period video-EEG
x Proportion of subjects who achieved “seizure -free” status (yes/no) from all seizure types, and 
from partial-onset seizure types only for subjects who completed at least 48 hours of interpretable video-EEG recording during the End-of-Maintenance Period video-EEG
x Proportion of subjects experiencing a ≥25% to <50%, 50% to 75%, or >75% reduction in 
ADF of electrographic partial-onset seizures from the end-of-Baseline Period video-EEG to 
the End-of-Maintenance Period video-EEG
x Proportion of subjects experiencing no change in ADF of electrographic partial-onset 
seizures (between <25% reduction and <25% in crease) from the End-of-Baseline Period 
video-EEG to the End-of-Maintenance Period video-EEG
x Proportion of subjects experiencing an increase in ADF of electrographic partial-onset 
seizures of ≥25% from the End -of-Baseline Period video-EEG to the End-of-Maintenance 
Period video-EEGREDACTED propoprop
on in ton in t
e Pe PererCOPYonseonse
the Enthe E
This document xxcannotportiorti
ADF oDF o
the the be tab
ioiousedsusu
al-onseonse
ble vble vtoubjeubjesupport changchang
eriodriodanyles arles amarketing iod vod v
acy vacy vauthorization ndd-
ortionortion
their Aheir A
iiapplicationiabiable le
ect expect ex
seizureizu
ofofBand continontin
ffany oo
riod vriod vextensions subjecubjec
oon tntor variations at t 
e of te of tthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 19 of 1444.1.3 Other efficacy variables
Other efficacy variables to be examined include:
x Clinical Global Impression of Change at the end of the Maintenance Period
x Caregiver’s Global Impression of Change at the end of the Maintenance Period
x Change from Baseline in PedsQL health sum mary score at the end of the Maintenance Period
x Healthcare resource use: concomitant medications, medical procedures, healthcare provider 
consultations not related to the study, and hospitalizations not related to the study
4.2 Pharmacokinetic and pharmacodynamic variables
Plasma concentrations of LCM will be obtained in order to:
x Develop a population PK model of LCM
x Investigate the correlation between LCM plasma concentrations and efficacy or safety
4.3 Safety variables
4.3.1 Primary safety variables
Safety and tolerability will  be assessed using the following primary safety variables:
x Adverse events reported spontaneously by the subject’s parent(s) and/or legal 
representative(s)/caregiver(s) (in accordance with local regulation) or observed by the investigator
x Subject withdrawals due to AEs
4.3.2 Other safety variables
x Change in hematology and clinical chemistry parameters
x Change in 12-lead ECGs
x Change in vital signs measurements (ie, blood pressure [BP] and pulse rate)
x Physical and neurological examination findings
x Changes in body weight, height, and calculated BMI
5 STUDY DESIGN
5.1 Study description
SP0967 is a Phase 3, multicenter, double-blind, randomized, PBO-controlled, parallel-group 
study to evaluate the efficacy and safety of LCM 8mg/kg/day to LCM 12mg/kg/day as 
adjunctive therapy in subjects ≥1 month to <4 years of age with epilepsy with part ial-onset 
seizures.
Primary and secondary efficacy variables w ill be based on video-EEGs (up to 72 hours of 
continuous recording with every attempt to obtai n at least 48 hours of interpretable recording). 
The video-EEGs will be conducted in an i npatient setting. Assessment of video-EEG seizure 
count will be performed locally by the investigator, subinvestigator, or qualified designated 
reader for the purpose of both assessment of eligibility and study analyses.REDACTEDnce wnce w
blesblesCOPYowinowi
e subje subj
wii
This documentudud
adjunadjun
seseannot 967 is 67 is 
dy toy tobe used STUSTUtody wy wsuppormeasueas
ologicalogic
eiany suresurmarketing ess
ical checal chauthorizationject’ject’
ith locth locapplication g primaprim
spand d ed eany efficefficextensions or variations odod
vider ider thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 20 of 144Baseline Period
At Visit 1 (Day -7), subjects who meet the sele ction criteria will begin a 7-day Baseline Period 
(Day -7 to Day -1). In the event that additional ti me is needed to access inpatient facilities to 
perform the video-EEG, a maximum of 7 days may be added to the period between Visit 1 and 2.
From Visit 2 (Day -3 to Day -1) to Visit 3 (Day  1), an End-of-Baseline Period video-EEG will be 
performed. 
After completion of the End-of-Baseline video-EE G at Visit 3, subjects who meet the selection 
criteria will be randomized in a double-blind manne r to 1 of 2 parallel treatment arms: LCM or 
PBO in a 1:1 ratio.
Titration Period
Subjects will begin a 20-day blinded Titration Period (Day 1 to Day 20) to attain the target dose 
for the Maintenance Period (LCM 8mg/kg/day to LCM 12mg/kg/day, or matching PBO). 
Subjects will be dispensed study medication and will begin treatment with LCM oral solution 
4mg/kg/day or matching PBO for 4 days. Subjects wi ll then be titrated at 4-day intervals as 
recommended in Table 7‒1. The current 4-day titration step a pproach has been selected as it is 
generally accepted that frequent seizures require a rapid titration of AEDs.
Dosing flexibility during the Titration Period ba sed on tolerability is allowed in SP0967. After 
completion of Day 4, investigators will assess whether a subject would tolerate a further dose increase or whether a subject should hold the dose for a longer duration. In addition to holds, 
subjects may have the study medication titrated  to a higher dose or back titrated by 
LCM 1mg/kg/day or 2mg/kg/day (or matching PBO) steps. If study medication is titrated to a higher dose, the subject should remain on the higher dose for ≥4 days unless a back titration step 
based on tolerability is required.
If study medication is back titrated, the back  titrated dose must never be lower than LCM 
4mg/kg/day (or matching PBO) and must be maintained for ≥3 days (in order to reach steady 
state) before a subsequent dose increase. After study medication is back titrated, if a subject 
returns to a higher dose previously admi nistered, the dose must be maintained for ≥3 days before 
subsequent titration to a higher dose. There is no limit to the number of titration steps or dose 
holds allowed and all are at the investigator’s discretion; however, subjects must achieve at least 
the minimum target dose (LCM 8mg/kg/day or matching PBO) for the final 3 days of the Titration Period. If it becomes apparent that the s ubject will not be able to reach the minimum 
target dose, then the subjects should be withdrawn  from the Titration Period and enter the Taper 
Period.
No adjustments in dose of study medication will be  permitted after Day 20. Subjects who are not 
able to tolerate the study medication during the Titration Period or who will not be able to 
achieve the target dose by the end of the Titration Period will be withdrawn from the Titration Period and enter the Taper Period. 
Maintenance Period
Subjects who achieve at least the minimum target study medication (LCM 8mg/kg/day or 
matching PBO) dose for the final 3 days of the Titration Period will enter a 7-day blinded 
Maintenance Period on the dose achieved on the final day of the Titration Period 
(LCM 8mg/kg/day to LCM 12mg/kg/day, or matching PBO). No adjustments to study REDACTED doseos
ated toated to
tchingching
n on thn on thCOPYon toon to
ether aether
se foef
This documentachieachie
PerPecannot justmustm
e to toto tobe used. If itIf i
hen then thtot dot do
tbtsupport vioio
higher highe
are at tare at 
oseoseanyincrinc
ouslyousmarketing the bache ba
nd mund mu
reaauthorization a sua s
or a lor a lo
o a higa hig
g PBOPBO
he hige higapplicationoach ach
on of An of 
erabilitrabil
subjeubjandwitwit
ed at ed at 
hhhhany c
h LCh LCextensions ain thein the
tchinchinor variations ion on 
M orM orthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 21 of 144medication dose will be allowed during the Maintenance Period. Subjects who complete the 
Maintenance Period may be eligible to partic ipate in the open-label extension study (EP0034). 
Transition Period
A 12-day blinded Transition Period will be re quired for eligible subjects who complete the 
Maintenance Period and who plan to enter EP0034. For subjects randomized to LCM, the 
Maintenance Period dose will be maintained durin g the Transition Period. Subjects randomized 
to PBO will be transitioned in a double-blind fashion as described in Table 7‒2.
Taper Period
A blinded Taper Period (8 to 16 days, depending on dose level achieved) will be required for 
subjects who discontinue study medication pre maturely and for subjects who complete the 
Maintenance Period but will not be entering EP0034. Study medication will be tapered as 
described in Table 7-3 .
At the discretion of the investigator, AEDs may be added or adjusted and VNS adjustments may 
be made once the subject enters the Taper Period. 
Safety Follow-Up Period
There will be a 30-day Safety Follow-Up Pe riod for subjects not entering the open-label 
extension study (EP0034). The Safety Follow-Up Period will include a Safety Follow-Up Clinic 
Visit 14 days (±2 days) after the final dose of study medication, and a Safety Follow-UpTelephone Contact 30 days (-1/+3 days) after the final dose of study medication.
Unscheduled visits can be conducted at  the discretion of the investigator.
Detailed schedules of study procedures are provided in Section 5.2,and study schematic 
diagrams are included in Section 5.3.
5.1.1 Study duration per subject
For each subject, the maximum total study duration can be up to 93 days (not withstanding visit 
windows), including the 30-day Safety Follow- Up Period. Each subject’s particip ation in the 
study begins with a 7-day Baseline Period (no administration of study medication). Each 
subject’s maximum total duration of study medic ation administration in SP0967 can be up to 55 
days. This includes a 20-day Titration Period, a 7-day Maintenance Period, a 12-day Transition 
Period (for subjects who plan to enter the open-label extension study [EP0034]) and/or up to a 16-day Taper Period (for subjects who will not be entering EP0034). 
The end of the study is defined as the date of the last visit of the last subject in the study.
5.1.2 Planned number of subjects and sites
A total of approximately 244 subjects (122 subjects  per treatment arm) are planned to be 
randomized. Approximately 50% of the 244 randomized subjects should be <2 years of age. Of 
these (n=122), every attempt will be made to enroll a minimum target of 20% (n=25) of subjects in each of the 3 age categories: ≥1 month to <6 months, ≥6 months to <1 year, and ≥1 year to <2 
years.REDACTEDthe the 
he dische disc
es are es are
33COPYubub
erioderiod
dy medy me
fifi
This document A totto
randrand
tthcannot otaltalbef the ft h eusedcts ts 
PeriodPeriodto a 2
sw hwhsupportyB a s eBase
tal duraal du
2020-ddanytottot
ay Saay Sa
limarketing e pp
er subr sub
tal stalauthorizationedicedic
inal donal do
cretioncretio
provirovapplication s not e not e
will inwill i
atitand ndndany d VNVNextensionsquireduired
mpletemplete
e tapetapeor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 22 of 144Every attempt will be made to enroll subjects in the following age categories as detailed below:
x ≥1 month to <6 months of age ( ≥25 subjects)
x ≥6 months to <1 year of age ( ≥25 subjects)
x ≥1 year to <2 years of age ( ≥25 subjects)
x ≥2 years to <4 years of age ( ≥20 subjects)
Approximately 140 sites are planned in order to rec ruit the required subjects; additional sites will 
be added if deemed necessary. 
5.1.3 Anticipated regions and countries
The study will be conducted in North America,  Europe, Asia Pacific, and Latin America with
possible extension to other countries and regions. A target of approximately 30% of the 
randomized subjects should consist of subjects originating from sites in North America and Europe.
5.2 Schedule of study assessments
A tabular schedule of study procedures for the Base line and Treatment Periods is presented in 
Table 5‒1.A tabular schedule of study procedures for the Transition Period is presented in 
Table 5‒2.A tabular schedule of study procedures for th e Taper and Safety Follow-Up Periods is 
presented in Table 5‒3.COPYtht
for thefor th
This document cannot be used to support any marketing authorization application reatmeeatm
Transitiransit
e TapeTapand anyorth orthextensions AmerAmer
30% o0% o
hAhAor variations es wils wilthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 23 of 144Table 5‒1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
Informed consent X
DemographicscX
Inclusion/exclusion criteria X X X
Medical history X
Seizure history/count X
Concomitant medications XdX X X X X X X X X X X X X X
Concomitant AEDs XeX X X X X X X X X X X X X X
VNS assessmentfX X X X X X
Physical examination (complete) X X
Physical examination (brief) X X X X
Vital signs (including BP and 
pulse rate)gX X X X X X X
Body weight X X X X X X
Height X X
Head circumference X X
Neurological examination 
(complete)X X
Neurological examination (brief) X X X X
ECG (12-lead)hX XqX XREDACTED XX
DD
XTEACDAAAR
ARRRER
COPY 
YOPCCThis 
document 
tcannotef)f)
ot totnnc
be b
used eX
eeedse
to osupport 
rtttppsuss
any a
marketing 
ngngngngngkeam
authorization 
io
XX
tioiooio
X
rizhout
application 
ontioooli
olililicppliap
and an
any242anaaaa
extensionstenanenan
(7(7ene
or o
variations 
onva
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 24 of 144Table 5‒1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
Video-EEGiX X X X X X X X
Rescue medicationjX X X X X X X X
Clinical chemistry/hematology X X X
LCM plasma concentration X X
Clinical GIC X
Caregiver’s GIC X
Contact IXRS X X X X X X
Randomization Xk
Dispense study medication XkX X X X
Return study medication X X X X
Dosing instructionslX X X
AE reporting X X X X X X X X X X X X X X X
Withdrawal criteria X X X X X X X X X X X X X X
Healthcare resource use X X
Bayley-III scalesmX
BRIEF-PnXREDACTED 
DDTEACXXkkDAAAR
ARRRER
COPY 
YOPCCThis 
document 
cannot 
be be
used sesesesese
to tosupport X
t
XXoruuuupsu
any Xanya
marketing 
gXXkk
ggg ngkeamaaaa
authorization 
iotioiooiorizhouth
application 
on
XXtioooli
olililicppliap
and an
any242anaaaa
extensionstenanenan
(7(7ene
or o
variations 
onva
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 25 of 144Table 5‒1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
PedsQLoX X
Achenbach CBCLpX
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; BRIE F-P=Behavior Rating Inventory of Executive Function-Preschool Version; 
CBCL=Childhood Behavior Checklist; ECG=electrocardiogram; EEG=elec troencephalogram; ET=Early Termination; GIC=Global Impressi on of 
Change; IXRS=interactive voice/web response syst em; LCM=lacosamide; PedsQL=Pediatric Quality of L ife Inventory; T=Telephone Contact; 
UV=Unscheduled Visit; V=Visit; VNS=vagus nerve stimulation.
aIf an Unscheduled Visit is needed, then the as sessments noted will be performed. Additional asse ssments may be performed at the investigator’s 
discretion.
bThe Day -3 and Day 24 assessments should be condu cted prior to the start of video-EEG monitoring . A maximum of 7 days may be added to the 
period between Visit 1 and 2 in the event that additional time is needed to access inpatient facilities to perform the video-EE G. 
cDemographics: date o f birth, age group category, age in months and years, race, ethnicity, and gender. In countries where recording of complete 
date of birth is not permitted, only permitted data will be collected.
dThe concomitant medications recording will include any current medication intake as well as any medications taken ≤30 days prior to Visit 1.
eThe concomitant AED recording will include any current medication intake as well as any previous AED taken prior to Visit 1.
fThe VNS setting will be assessed as applicable.
gOrthostatic assessments of BP and pulse rate will be assesse d where it is feasible according to investigator judgment.
hA 12-lead ECG (2 interpretable recordings) will be performed prio r to any blood draws and vital signs assessment and, if possi ble, with the subject 
in the supine position for 5 minutes preceding the ECG recordin g. The second recording will be conducted approximately 20 to 30 minutes after 
the first recording. Electrocardiograms will be reviewed locally by the investigator, subinv estigator, or qualified designated reader and at a central 
ECG laboratory. The investigator may consult with the cardiologist  at the central ECG laboratory to confirm the presence of a clinically significant 
ECG abnormality; however, it remains the responsibility of the inve stigator to decide whether an ECG finding is of clinical sig nificance on the 
basis of the complete clinical picture and whether this find ing influences the subject’s participation in the study.
iThe video-EEG (up to 72 hours of continuous recording with every attempt to obtain at least 48 ho urs of interpretable recording) will be conducted 
in an inpatient setting. Upon completion of the End-of-Baseline video- EEG (Visits 2 and 3), the investigator will assess the electrographic seizure 
count and confirm the selection criteria have been met. If the subject meets all selection criteria, including the requisite nu mber of seizures based 
on the video-EEG data, the subject may be randomized at Visit 3.  Assessment of video-EEG seizure  count will be performed locall y by the 
investigator, subinvestigator, or qualified designated reader for the purpose of both assessment of eligibility and study analy ses. The 
End-of-Maintenance Period video-EEG will be done at Visit 6. Su bjects who discontinue on or be fore Day 20 will not require a vi deo-EEG.medmed
tart of art of 
ded to ded to 
and yeaand ye
ed.ed.
COPYalal
=Pedi=Ped
d. Ad. AThis 
document eriori
cannotn critcri
subjecubjec
ator, ortor, or
odod
bepletiopletio
iterite
used r
nd whewhe
ntinuontinuo
tolt 
respoespo
support rforfo
ECG recCG re
eviewedviewe
with twith t
anyssed wsed w
ormedrme
marketing ars,rs
edicatioedicat
ication iation
h
authorization dditiondition
videovideo
access ccess
s, rac rac
application 
onentory ontory
m; ET=m; ET=
atric Qutric Q
tiooo
and an
any242anaaaa
extensionstenanenan
(7(7ene
or o
variations 
onva
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 26 of 144Table 5‒1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
jAdditional assessment for changes in VNS or rescue medication tak en within 24 hours prior to and until the end of the video-EEG  monitoring.
kRandomization and initial dispensing of study medication will oc cur at Visit 3 and after the completion of the video- EEG and confirmation that the 
subject has met selection criteria. 
lDosing instructions will be provided to the caregiver(s) duri ng the telephone contacts. At a minimum, AEs and tolerability shou ld be discu ssed 
with the caregiver(s) in order to determine  the next dose for the subject. See Section 7.2.1 for additional details on dosing options. 
mInvestigators must make every attempt to administer the Bayley  Scales of Infant and Toddler Development, Third Edition, for subjects who are 
<18 months of age who originate in English-speaking coun tries. The investigators may utilize trained pediatric psyc hologists or other appropriately 
skilled individuals to administer the scale. 
nThe BRIEF -P will be used only for subjects who are ≥2 years of age at Visits 3. BRIEF -P will be used only in countries where a translated version 
is available.
oThe version of the PedsQL used at Visit 3 should be consistent with the subjec t’s age at Visit 3 and should be  maintained for each subject f or the 
duration of the study. The PedsQL will be used only in countries where a translated version is available. 
pThe Achenbach CBCL/1½- 5 will be completed by the parent(s)/legal re presentative(s)/caregiver(s) of subjects ≥18 months of age at Visit 3. The 
Achenbach CBCL will be administered only in countries where a translated version is available.
qECG at Visit 3 will be performed at the discretion of the investigator.
REDACTEDts 3. Bts 3. B
the subhe sub
where awhere 
/legal /legal 
tt
COPYd Todd To
rs mayrs maThis 
document 
cannot 
be 
used 
to support 
any 
marketingrepresrepre
ranslateanslat
gator.gator.
authorization y utiluti
RIEFRIEF
bject’s ect’s 
transtrans
application on
imum, Amum,
r additioaddit
dler Devler De
ilize lize
andthe ethe e
n of thof th
any242anendaaa
extensionstenanenan
(7(7ene
or o
variations 
onva
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 27 of 144Table 5‒2: Schedule of study assessments (Transition Period)
Assessments Transition Period (12 days)
Visit TV1 TT1 TV2a
Study Day 32 36 40
Concomitant medications X X Xb
Concomitant AEDs X X Xb
VNS assessmentcX Xb
Physical examination (brief) X
Physical examination (complete) Xb
Vital signs (including BP and pulse rate)dX Xb
Body weight X Xb
Neurological examination (brief) X
Neurological examination (complete) Xb
ECG (12-lead)eXb
Clinical chemistry/hematology Xb
Contact IXRS X X
Dosing instructionsfX
Dispense study medication X
Return study medication X X
AE reporting X X Xb
Withdrawal criteria X X X
AE=adverse event; AED=antiepileptic drug; BP=blood pr essure; ECG=electrocardiogram; IXRS=interactive 
voice/web response system; TT=Transition Telephone Contact; TV=Transition Visit; VNS=vagus nerve 
stimulation
aTransition Visit 2 will also serve as Visit 1 for EP0034.
bThe designated procedures will serve as the point of  data for both TV2 in SP0967 and Visit 1 for EP0034.
cVagus nerve stimulation setting will be assessed as applicable.
dOrthostatic assessments of BP and pulse rate will be assess ed if it is feasible according to investigator judgment.
eA 12-lead ECG (2 interpretable recordings) will be performe d prior to any blood draws and vital signs assessment 
and, if possible, with the subject in the supine positio n for 5 minutes preceding the ECG recording. The second 
recording will be conducted approximately 20 to 30 minutes after the first recording. 
fDosing instructions will be provided to the care giver(s) during the telephone contacts. See Section 7.2.3 for 
additional details on dosing options.REDACTED ED
CT
EDRCOPY Y
COCOCOCOCO
This document cannotng wing wi
ing insng ins
ditionditionbeCG
sible, sible,used latiati
ssmentsment
G (2 i (2 ito dur
ion sion support =TT
o serve serv
res wies wanyic druc dr
Transranymarketing ting
rk
mauthorization n
at
orihoooo
auapplication nnnnonat
pand daany ny extensions s
sio
textextetexteor XXbbvariations nnnonat
vathereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 28 of 144Table 5‒3: Schedule of study assessments (Taper and Safety Follow-Up 
Periods)
Assessments Taper Period (8 to 16 days) Safety Follow-Up Period (30 days)a
Visit T4bTaper VisitcSafety Follow-Up
Clinic Visit
Days in Study: 
FSM+14 (±2)Safety Follow-Up
Telephone Contact
Days in Study: 
FSM+30 (-1/+3)
Study Day 32d
36/40/44c,d 50/54/58d66/70/74/93d
Concomitant medications X X X X
Concomitant AEDs X X X X
VNS assessmenteX X
Physical examination (brief) X
Physical examination (complete) X
Vital signs (including BP and 
pulse rate)fX X
Body weight X X
Neurological examination (brief) X
Neurological examination 
(complete)X
ECG (12 -lead)gXhXh
Clinical chemistry/hematology XhXh
Contact IXRS X
Dosing instructionsiX
Return study medication X
AE reporting X X X X
Withdrawal criteria X X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; ECG=electrocardiogram; FSM=Final Study 
Medication; IXRS=interactive voice/web response  system; T=Telephone Contact; VNS=vagus nerve 
stimulation
aThe Safety Follow-Up Clinic Visit will be scheduled  14 days (±2 days) after the final dose of study 
medication. The Safety Follow-Up Telephone Contact will occur 30 days (-1/+3 days) after the fi nal dose of 
study medication.
bA telephone contact (T4) will be conducted at the end of the first taper step of the Taper Period.
cEach subject will have only 1 Taper Visit. The Taper Vi sit will be scheduled at the end of the Taper Period 
(Day 36, 40, or 44), depending on dose level achieved (see Table 7-3 ).
dThe study day numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
Period. The study day numbers provided do not apply to subjects who enter the Taper Period at other times. 
Day 66, 70, or 74 result from the administration of final study medication during the Taper Period whereas 
Day 93 would result from a subject progressing to the end of the Transition Peri od, but then not entering 
EP0034 and instead entering the Transition Period followed by the Taper Period.
eVNS setting will be assessed as applicable.
fOrthostatic assessments of BP and pulse rate will be asse ssed where it is feasible according to investigator REDACTED D
ACACACACAC
REDCOPY XXOPC
This documentEEacac
(D(D
ddcannottion. on. 
y medimedi
telepheleph
hbeFolloFoll
TTusedAEDE
RS=intS=inttoD=aD=aosupport rtrtrtrtortppsany y marketing ngeti
arauthorization ntio
thoaapplication XX
lic
apand daany yanaaaextensions XXs
XXsio
teor ovariations riaarrrthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 29 of 144Table 5‒3: Schedule of study assessments (Taper and Safety Follow-Up 
Periods)
Assessments Taper Period (8 to 16 days) Safety Follow-Up Period (30 days)a
Visit T4bTaper VisitcSafety Follow-Up
Clinic Visit
Days in Study: 
FSM+14 (±2)Safety Follow-Up
Telephone Contact
Days in Study: 
FSM+30 (-1/+3)
Study Day 32d
36/40/44c,d 50/54/58d66/70/74/93d
judgment.
gA 12-lead ECG (2 interpretable recordings) will be pe rformed prior to any blood draws and vital signs 
assessment and, if possible, with the subject in  the supine position for 5 minutes preceding the ECG 
recording. The recordings should be ma de approximately 20 to 30 minutes apart.
hThe assessment will be required for subjects with a clinically significant abnormal value (clinical chemistry or 
hematology) or reading (ECG) at the previous clinic visit. For non- clinically significant abnormalities, repeat 
of these assessments is at the discretion of the investigator. 
iDosing instructions will be provided  to the caregiver(s). See Section 7.2.3 for additional details on dosing 
options.
5.3 Schematic diagram
An overall schematic diagram for subjects entering EP0034 is provided in Figure 5‒1. An overall 
schematic diagram for subjects not entering EP0034 is provided in Figure 5‒2.
REDACTED COPY g EP00g EP0
034 i034 i
This document cannot be used to support any marketing authorization0
is prois proapplication dd
34 is 34 is and ditionitioanye (clie (c
nt abnnt abnextensions l signssigns
e ECGe ECGs
linlinsor ovariations riaarrrthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 30 of 144Figure 5 ‒1: Subjects entering EP0034 open-label extension study
PBO=placebo; T=Telephone Contact; TT=Transition Telephone Contact; TV=Transition Visit; V=Visit
RED
EDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTEEDD 
COP
YYY This 
document 
cannot 
be 
used 
to supportTelepelep
any phonpho
marketing 
a
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaauuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuutttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhooooooooooooooooooooooooooooooooooooooooooriizzaation 
apppplllication 
aaaannnnd 
aaaaaaannnnnnyyy 
exte
nsssssssssssssiiioooooooooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnsssssssssssssssssssssssss or 
orvariations 
on
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 31 of 144Figure 5 ‒2: Subjects not entering EP0034 open-label extension study
aSubjects progressing to the end of the Transition Period, but then not entering EP 0034 and instead entering the Transition Peri od followed by the Taper Period 
would complete the Safety Follow-Up Period at Day 93.
PBO=placebo; T=Telephone Contact; V=Visit
REEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
CCCCCCCCCCCCCCCCCCCCOOOPPPY This 
document 
cannot 
be 
used 
to support 
any 
markeen not enn not e
keting 
auuuuuuuuuuuuuuuuuuuuttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhoooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiizzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiioooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooon 
applica
ttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
and 
any 
ext
eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeennnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnssssssssssssssssssssssssssssssssssssiiiooonsss r
or 
variations 
on
v
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 32 of 1445.4 Rationale for study design and selection of dose
Epilepsy is a condition for which an improved benefit/risk ratio for medicinal products remains a 
challenge; this is especially true for pediatri c patients. Based on the demonstrated efficacy and 
safety of LCM as adjunctive treatment in subjects aged ≥16 years of age, and the experience with 
other AEDs in pediatric subjects, it is likely th at LCM will be an efficacious and safe treatment 
in the pediatric population with uncontrolled partial-onset seizures.
SP0967 is a Phase 3, multicenter, double-bli nd, randomized, PBO-controlled, parallel-group 
study to evaluate the efficacy and safety of LCM as adjunctive therapy in subjects ≥1 month to 
<4 years of age with epilepsy who have uncontrolled partial-onset seizures. 
Based on the currently available LCM pediatric PK , safety, and tolerability data from SP847 and 
SP1047, as well as on information available in the medical literature, the recommendations for 
SP0967 are as follows:
x Subjects must weigh ≥4kg to <30kg a t Visit 1.
x Feeding tube administration is permitted for subjects who are unable to swallow the oral 
solution.
x Titration should occur over a 20-day period; with LCM dose increased by 2mg/kg/day every 
4 days until the target dose (LCM 8mg/kg/day to 12mg/kg/day, or matching PBO) is achieved. All subjects will start on a dose of LCM 4mg/kg/day or matching PBO at the start of the Titration Period.
x During the Titration Period, step-back titrati on by LCM 1mg/kg/day or LCM 2mg/kg/day 
will be permitted to allow subjects with reduced tolerability to remain in the study depending 
on tolerability (ie, based on investigator judgment and legal representative[s]/caregiver[s] 
feedback). If study medication is back titr ated, the dose must never be lower than 
LCM 4mg/kg/day ( or matching PBO) and must be maintained for ≥3 days (in order to reach 
steady state) before subsequent titration to a higher dose.
x During the Titration Period, subjects may also have the dose of study medication held steady 
or titrated to a higher dose. If study medication is titrated to a higher dose, the subject must remain on that dose for ≥4days unless a step-back titration based on tolerability is required.
x The LCM dose should remain fixed over the Maintenance Period.
Based on US FDA and EMA requirements, 2 (co-) pr imary efficacy variables have been defined 
for this study based on electrographic partial-onset seizures with or without clinical correlate depending upon subject age. The primary efficacy variable will be the change in ADF of 
electrographic partial- onset seizures (US) or proportion of subjects experiencing ≥50% reduction 
in their ADF of electrographic partial-onset seizures (EU) as measured on the End-of-Maintenance Period video-EEG compared to th e End-of-Baseline Period video-EEG. At the 
request of FDA, a contingent primary efficacy variable has also been defined based on the 
percentage of subjects who discontinue early from the study prior to completing the End-of-Maintenance Period video-EEG. Contingent upon >10%  of subjects discontinuing early from the 
study, the primary efficacy parameter for the US will become identical to the primary efficacy 
parameter for the EU.REDACTED o
ack tiack ti
cts wicts wi
vestivestiCOPY th Lth 
ay to 1y to 1
f LCf LC
This documentlec
in thin th
MMcannotstudstud
ndingnding
ctrogctrogbeUS FUS 
udyudyuseddose ose 
FDFDto dosupportPerioerio
her doer do
ose fose foanyquenquen
dmarketing ith
igator gator
is backs bac
ing PBng P
nttauthorization12
CM 4mCM 4m
itratioratio
h redh redapplication re ue u
CM dosM do
2mg/kmg/kand unabunaany extensions ta froma fro
commommor momvariations roup oup 
montontthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 33 of 144The endpoint not designated as primary will st ill be summarized as a secondary efficacy 
parameter.
6 SELECTION AND WITHDRAWAL OF SUBJECTS
6.1 Inclusion criteria
To be eligible to participate in this stud y, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Inde pendent Ethics Committee (IEC) approved 
written Informed Consent form is signed and date by the parent(s) or legal representative(s)/caregiver(s) (in accordance with local regulation). 
2. Subject’s parent(s) or legal representative(s)/caregiver(s) is considered reliable and capable 
of adhering to the protocol visit schedule or med ication intake according to the judgment of 
the investigator.
3. Subject is male or female from ≥1 month (ie, 4 weeks after full term [37 weeks gestational 
age]) to <4 years of age. For preterm infants <1 year old, the corrected gestational age 
should be used when determining eligibility. The generally accepted definition of corrected 
gestational age, which is calculated by subtracting the number of weeks born before 37 weeks of gestation from the chronological age, will be used for this study. 
4. Subject has a diagnosis of epilepsy with partial-onset seizures. The resu lts of ≥1 prior EEG 
and ≥1 magnetic resonance imaging/computerized tomography scan should be consistent 
with this diagnosis.
5. Subject weighs ≥4kg to <30kg at Visit 1.
7. Subject has experienced ≥2 partial -onset seizures with or without secondary generalization 
during each consecutive 7-day period during the 2 weeks prior to Visit 1.
8a. Subject has ≥2 partial -onset seizures with or without secondary generalization during the 
End-of-Baseline video-EEG. Electrographic seizures are defined as recognizable ictalpatterns on an EEG involving ≥2 contiguous electrodes. The seizures are initiated as a 
unilateral or strongly asymmetric abnormal  epileptiform discharge lasting a total of 
>10 seconds.
9. Subject is on a stable (concurrently or sequentially) dosage regimen of 1 to 3 AEDs. The 
dosage regimen of concomitant AED therapy must be kept constant for a period of 
≥2weeks prior to Visit 1. A stable daily dosage regimen of a concomitant benzodiazepine 
(BZD) will be considered as a concomitant AED. 
10. Vagus nerve stimulation is allowed and will  not be counted as a concomitant AED. The 
VNS device must have been implanted for ≥6 months prior to Visit 1; device settings must 
be kept stable for ≥2 weeks prior to Visit 1 and kept stable during the Baseline, Treatment,
and Transition Periods. Use of the VNS device magnet is allowed.
11. Subject is an acceptable candidate for venipuncture.
6.2 Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria are met:REDACTEDompuomp
at Visiat Vis
artiaartiaCOPYageag
partialartial
putput
This document cannotBZDBZD
VaVabeweekweek
))used on on 
regimregimto aasupport invoinvo
ngly asgly aanyEEGEEG
olvolmarketingalal--onson
y perioperio
et seizt seiauthorization onson
terizederize
sit 1.it 1.applicationlly acly ac
numbnumb
will bewill b
nsetsetand l tete
e corrcorrany erm ermextensions eliableliabl
ing tong toor variations ed ed thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 34 of 1441a. Subject has been previously randomized in this study (re-screening for screen-failed 
subjects is only allowed with prior consultation and permission of the medical monitor).
2. Subject has participated in another study of an  investigational medicinal product (IMP) or a 
medical device during the 2 months immediately prior to Visit 1 or is currently participating in another study of an IMP or a medical device.
3. Subject has any medical or psychiatric condition that, in the opinion of the investigator, 
could jeopardize or would compromise the subject’s ability to participate in this study.
4a. Subject has been previously treated with LCM and the LCM treatment was stopped due to 
lack of efficacy or adverse event(s).
5. Subject has a known hypersensitivity to any component of the study medication.
6. Subject has a medical condition that could be expected, in the opinion of the investigator, 
to interfere with study medication absorption, distribution, metabolism, or excretion.
7. Subject has experienced febrile seizures exclusively. The occurrence of febrile seizures in 
addition to partial-onset seizures is not exclusionary.
8a. Subject is on a ketogenic diet that has either changed within the 4 weeks prior to Visit 1 or 
is expected to change during the study.
9a. Subject has creatinine clearance <30mL/minute.
10. Subject has a clinically relevant ECG abnormality, in the opinion of the investigator (eg, 
second or third degree heart block at rest or a corrected QT interval [QTc] ≥450ms). 
11. Subject has a hemodynamically significant congenital heart disease. 
12. Subject has an arrhythmic heart condition requiring medical therapy. 
13. Subject has a known history of severe anaphylactic reaction secondary to medication intake 
or serious blood dyscrasias. 
14. Subject has nonepileptic events that could be confused with seizures. Subjects may be 
included if epileptic events can be clearly di stinguished and the frequency meets the study 
inclusion criteria. 
15a. Subject has a current diagnosis of Lennox-Gastaut syndrome, epilepsia partialis continua, 
primary generalized epilepsy, Dravet Syndrome, or seizures that are not of partial-onset origin. 
16a. Subject has a history of generalized convulsive status epilepticus ≤2 months prior to 
Screening (Visit 1). 
19. Subject has been treated with felbamate and has experienced any serious toxicity issues 
(defined as liver failure, aplastic anemia) with this treatment. Subjects treated with 
felbamate for <12 months are excluded. Subjects treated with felbamate for ≥12 months 
prior to Visit 1 and who have not experienced serious toxicity issues are eligible.
20. Subject has an acute or subacutely progressive central nervous system disease. Subject has 
epilepsy secondary to a progressing cerebral disease or any other progressively neurodegenerative disease (malignant brain tumor or Rasmussen Syndrome).REDACTED G abnoG abno
k at resat re
ly signly sig
ttCOPY minutminut
This document 19.19.cannot g
SubjeSubj
ScScbe y
in. in. usedas a s a 
y gengento r
cusupporteptepticic
ptic evtic ev
ia. ia. any ias. ias.
cemarketing gnifni
rt condcond
ry of sey of authorization e..
ormalrmal
st or ast or a
ificficapplication withinwithiandcurrenurrenanyolismolismextensions edicatidicat
n of n of opedpedvariations or, r, 
udy.dy.
dddthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 35 of 14421a. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
22. Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotrans ferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin ( ≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject 
has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagn osed Gilbert’s syndrome (ie, direct bilirubin <35%).
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total 
bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the electronic Case Report form (eCRF).
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
screening, repeat the tests, if possible, prior to  dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
must be discussed with the Medical Monitor.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be 
repeated once for confirmation.
6.3 Withdrawal criteria
Parent(s)/legal representative(s) are free to wi thdraw the subject from the study at any time, 
without prejudice to their continued care. The following criteria for subject withdrawal from 
SP0967 are outlined below. Additional disconti nuation criteria for potential drug-induced liver 
injury (PDILI) are presented in Section 6.3.1 .
Subjects must be withdrawn from the study if any of the following events occur:
1. Subject experiences intolerable AEs, including clinically relevant abnormal laboratory 
findings that, in the opinion of the investigator, preclude further participation in the study. 
Subjects who are unable to tolerate study medication will be withdrawn from the study as 
follows:
x Subjects unable to achieve or maintain target dose for the final 3 days of the Titration Period
2. The sponsor or a regulatory agency requests withdrawal of the subject.
3. Subject has QTc interval of ≥500ms that is confirmed by a cardiologist over -read on any 
ECG.
4. Subject develops a second or third degree atrioventricular (AV) block. 
5. Subject is unwilling or unable to continue, or the parent(s)/legal 
representative(s)/caregiver(s) is unwilling or unable to allow the subject to continue in the 
study.
6. Investigator's decision that withdrawal from further participation would be in the subject’s 
best interest.
7. Subject experiences generalized convulsive status epilepticus.REDACTEDcontincontin
6.3.1.3.1
he studhe stu
AACOPY raw thraw t
followollow
This documentrrcannotbjectect
SubjeSubj
reprebe tdtduseds QTQTto r a ra rsupport achievachiev
regureganytoltomarketing ud
AEs, incEs, inc
f the invthe in
oleraolerauthorizationwing wing
nuationnuatio
dy if y if application e subje suband excluexcluany extensions n limitlimit
s no fno f
incluncluor atavariations o 
ationtionthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 36 of 144Subjects may be withdrawn from the study if any of the following events occur:
1. Subject has any clinically relevant change in medical or psychiatric condition and in the 
opinion of the investigator, the condition warrants discontinuation from the study.
2. Subject requires a medication that is not permitted by the protocol.
3.Subject’s legal representative(s)/caregiver(s) (in accordance with local regulation) is 
noncompliant with study procedures or medication, in the opinion of the investigator. 
5. Subject uses BZDs within 24 hours prior to or during video-EEG for any reason other than a
stable daily dosage regimen as a concomitant AED. The Medical Monitor should be 
contacted if withdrawal is being considere d. Use of a stable daily dosage regimen of a 
concomitant BZD (ie, 1 of the Baseline concom itant AED[s]) should be maintained for the
video-EEG procedures.
Investigators should attempt to obtain information for subjects who withdraw. For subjects 
considered as lost to follow up, the investigator should make an effort (at least 1 phone call and 1 written message to the parent[s] or legal repres entative[s]/caregiver[s]), and document his/her 
effort (date and summary of the phone call a nd copy of the written message in the source 
documents), to complete the final evaluation. All results of these evaluations and observations, together with a narrative description of the reason( s) for removing the subject, must be recorded 
in the source documents. The eCRF must document the primary reason for withdrawal.
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.
Subjects withdrawn from the study will proceed  to the blinded Taper Period described in 
Section 7.2.4 and the assessments described in Table 5‒3will be performed.
Subjects who are withdrawn from the study will not be replaced.6.3.1 Potential drug-induced liver in jury IMP discontinuation criteria
Subjects with potential drug-induced liver injury mu st be assessed to determine if IMP must be 
discontinued. In addition, all concomitant medications and herbal supplements that are not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis sympto ms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to  continue on IMP at the discretion of the 
investigator. REDACTEDonitoonito
will prwill p
descrdescCOPY(s) fo(s) fo
ment tment 
This documentThe The cannotALTALT
AAbe s w
LTLTusedria bia 
withwithto ab eab esupport ugg--
on, all cn, all
shouldshouldany gg--i
induindmarketingribedribed
the stuthe st
indindauthorizationthe phe 
r, wher, wh
oceedoceeapplication ve
ritten mitten 
f these ft h e s e
r removremo
primpriandort (ort (
er[s]r[s]anythdrathdra
(at(atextensions ld bdb
gimen imen 
maintamaintaor be bevariations her ther ththereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 37 of 144x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN , total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 11.6.1 . If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are comp lete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source doc uments. The eCRF must document the primary 
reason for IMP discontinuation.
7 STUDY TREATMENTS
7.1 Description of investigational medicinal products
Investigational medicinal product will be provided as LCM oral solution (LCM 10mg/mL) and 
matching PBO. The LCM 10mg/mL oral solution and matching PBO oral solution are colorless 
to pale yellow in appearance. Both oral solutions will be packaged in amber polyethylene terephthalate (PET) bottles. 
Study medication will be measured and administered via a dosing syringe. If a subject is unable 
to swallow the oral solution, administrati on by feeding tube will be permitted. 
It should be noted, in cases of incomplete doses (eg, subject spits out all or a portion of the 
syrup), missed doses, or administration of an erroneous volume of syrup, study medication 
should not be readministered.
7.2 Treatment(s) to be administered
At Visit 3, subjects will be randomized in a double-blind manner to 1 of 2 parallel treatment 
arms: LCM or PBO in a 1:1 ratio. Randomization will occur after completion of the End-of-
Baseline video-EEG and after confirmation that the subject has met selection criteria. 
Randomization will be stratifie d by age category ( ≥1 month to <6 months of age, ≥6 months to 
<1 year of age, ≥1 year to <2 years of age, and ≥2 years to <4 years of age).
At the end of Visit 3, subjects should take the first dose of study medication while in the clinic. 
At each subsequent clinic visit, subjects shoul d take study medication (and any concomitant 
AEDs) at the regular time(s). Study medication wi ll be administered orally bid (at approximately 
12-hour intervals in the morning and in the evening).
SP0967 will target Maintenance Period doses of LCM 8mg/kg/day to 12mg/kg/day or matching 
PBO.
7.2.1 Titration Period
Subjects will be dispensed study medication and will begin treatment with LCM oral solution at 
a dose of LCM 4mg/kg/day or matching PBO. Table 7‒1provides the recommended LCM (or 
matching PBO) dosing schedule during the Titration Period for subjects to reach the target doses 
for the Maintenance Period.REDACTEDnis
n by fn by f
ete doete d
tion otion oCOPY sterestere
This documentSP0P0
PBPBcannotat that th
our inur in
096096beubseqse
thetheused Visit Visit 
equequtoyeayesupport :1 r1 r
d afterd afte
be strae stra
aranyndomndom
ratioratimarketing of a
o be ao be 
miauthorization ed viaed via
feedineedin
oses (ses (
an ean eapplicationl solsol
ing PBng PB
packagackagandproro
olutlutany oduoduextensionswal al 
ent thent theor (if(ifvariations uationation
studystudythereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 38 of 144Table 7‒1:Recommended dosing schedule for LCM (or matching PBO) during 
the Titration Period
Target LCM (or matching PBO) doses for the Titration Period
Day 1 to Day 4 Day 5 to Day 8 Day 9 to Day 12 Day 13 to Day 16 Day 17 to Day 20
4mg/kg/day 6mg/kg/day 8mg/kg/day 10mg/kg/day 12mg/kg/day
LCM=lacosamide; PBO=placebo
Dosing flexibility during the Titration Period based on tolerability is allowed in SP0967. After 
completion of Day 4, investigators will assess whether a subject would tolerate a further dose 
increase or whether a subject should hold the dose for a longer duration. In addition to holds, 
subjects may have the study medication titrated to a higher dose or back titrated by LCM 
1mg/kg/day or 2mg/kg/day (or matching PBO) steps. If study medication is titrated to a higher 
dose, the subject should remain on the higher dose for ≥4 days unless a back -titration step based 
on tolerability is required. 
If study medication is back titrated, the back  titrated dose must never be lower than LCM 
4mg/kg/day (or matching PBO) and be maintained for ≥3 days before a subsequent dose 
increase. After study medication is back titrated, if a subject returns to a higher dose previously 
administered, the dose must be maintained for ≥3 days (in order to reach steady state) before 
subsequent titration to a higher dose. After st udy medication is back titrated, if a subject 
subsequently receives a higher dose not previously administered, that dose should be maintained for ≥4 days unless tolerability concerns require a back titration. 
There is no limit to the number of titration steps or dose holds allowed and all are at the 
investigator’s discretion; however, subjects must achieve at least the minimum target dose of 
study medication (LCM 8mg/kg/day or matching PBO) for the final 3 days of the Titration 
Period. If it becomes apparent that the subject will not be able to reach the minimum target dose, then the subject should be withdrawn from the Titration Period and enter the Taper Period.
No adjustments in dose of study medication will be  permitted after Day 20. Subjects who are not 
able to tolerate the study medication at an earlier time point during the Titration Period or who are not able to tolerate the reduced dose at the end of the Titration Period will be withdrawn from 
the study and enter the blinded Taper Period. Subjects who withdraw during the Transition 
Period will also enter the blinded Taper Period. 
7.2.2 Maintenance Period
Subjects who achieve at least the minimum target dose of study medication (LCM 8mg/kg/day 
or matching PBO) for the final 3 days of the Titration Period will enter the 7-day blinded 
Maintenance Period on the dose achieved at the end of  the Titration Period and will continue to 
receive this dose for the duration of the Maintena nce Period. No adjustments to study medication 
dose will be allowed during the Maintenance Period. 
Subjects who complete the Maintenance Period will  be offered the opportunity to enroll in an 
open-label extension study (EP 0034). Eligible subjects who choose to enroll in EP0034 will 
proceed to a blinded 12-day Transition Period. REDACTEDviousviou
requireequire
trationratio
subjsubjCOPYss
days days
dy mey m
l
This documentMaiMai
rrececcannotcts whts wh
matchmatch
nttbe useder
so ento ent
MMtor ther thsupportf stustu
dy medy me
te e the the 
ebanyhdradr
udyudymarketingjects jects 
y or may or m
at the st the
rawnrawauthorizationedicaedica
ly admy adm
re a baa ba
stepstepapplicationneveev
ays befoys be
ect retuct ret
(in ord(in or
atiand ververanybackbacextensionsfurthurth
ition ttion t
ated byted b
is titrs titr
kor67.67
herhervariations ayys
ati
7AAthereof. th
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 39 of 1447.2.3 Transition Period
During the Transition Period, subjects randomized to PBO will be transitioned in a double-blind 
manner from PBO to LCM 8mg/kg/day over a 12-day period. Transition dosing will be 
administered according to Table 7‒2. Subjects randomized to LCM will remain on their 
Maintenance Period dose during the Transition Period.
Table 7‒2:Transition Period LCM dosing schedule for subjects randomized to 
PBO
Maintenance Period LCM doses for the Transition Period
Day 28 to Day 31 Day 32 to Day 35 Day 36 to 39
PBO 4mg/kg/day 6mg/kg/day 8mg/kg/day
LCM=lacosamide; PBO=placebo
At Visit 1 of EP0034, all subjects will transition to a dose of LCM 10mg/kg/day. The SP0967 
final Transition Visit is the same as Visit 1 of EP0034.
7.2.4 Taper Period
Subjects who are not eligible for or who choose not to enter EP0034, or subjects who do not 
complete the Maintenance Period, will proceed to a blinded Taper Period of 8 to 16 days during 
which treatment with study medication will be withdrawn. The taper steps will be based on the 
dose of LCM (or matching PBO) achieved du ring the Maintenance Period according to 
Table 7-3. A slower taper is permitted if medically ne cessary. In case of an emergency, a faster 
taper is permitted after discussion with the Medical Monitor, whenever possible. 
Subjects who are withdrawn during either the Titration Period or the Transition Period will also 
proceed to the Taper Period, and study medication w ill be tapered starting at the respective dose 
achieved during the Titration Period or the Transition Period. At the discretion of the investigator, AEDs may be added or adjusted and VNS adjustments may be made once the 
subject enters the Taper Period. 
Table 7-3: Dosing of LCM (or matching PBO) during the Taper Period
LCM (or matching 
PBO) dose achievedLCM (or matching PBO) doses for the Taper Period 
Day 28 to Day 31 Day 32 to Day 35 Day 36 to Day 39 Day 40 to Day 43
11 or 12mg/kg/day 9mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
9 or 10mg/kg/day 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day
7 or 8mg/kg/day 6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day
5 or 6mg/kg/day 4mg/kg/day 2mg/kg/day 2mg/kg/day NA
4mg/kg/day 2mg/kg/day 2mg/kg/day NA NA
LCM=lacosamide; NA=not applicable; PBO=placebo
Note: The study day numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
Period. The study day numbers provided do not apply to  subjects who enter the Taper Period at other times.
Subjects who enter the Taper Period will return for the Taper Visit at the end of the Taper 
Period. REDACTEDe 
durindurin
f medif medi
th theth the
g eitg eitCOPY t to to
o a blo a bl
withwith
This document5 or 6or 6
4m4men
umuuucanno8mg/kgmg/knotg/kg/kg
no
6m6mcabe g/dg
g/dg/dbeused veded
daydayusto totttsupport eriorio
g of Lg of L
suanydded ded
od. od.marketingther thther th
udy meudy m
riod orriod o
dodauthorizationlin
hdrawhdraw
ng theg the
dicallyically
 MedMedapplication nter EPter EP
nded nded and0m0many mg/kmg/extensions Day 3Day 3ns
88ns
exor rvariations d to d to 
vthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 40 of 144Taper of LCM may not be required for some subjects who are on the lowest dose of study 
medication or who need to discontinue study medication abruptly, depending on the treatment 
option selected by the investigator in consultation with the medical monitor.
7.3 Packaging
Lacosamide and matching PBO are manufacture d, packaged, and labeled according to Good 
Manufacturing Practice (GMP) guidelines and applicable laws or regulations. The IMP is 
suitably packaged in such a way as to protect the IMP from deterioration during transport and storage.
Lacosamide 10mg/mL oral solution and matching PBO will be packaged in amber PET bottles, 
and will be measured and administered via a dosing syringe.
7.4 Labeling
Clinical drug supplies will be labeled in accorda nce with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any locally required statements. If necessary, labels will be translated into the local language.
7.5 Handling and storage requirements
The investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by the inve stigator is to be kept in a secured area with 
limited access according to the stora ge conditions ment ioned on the label.
Appropriate storage conditions must be ensured either by controlling the temperature or by 
completion of a temperature log in accordance with local requirements on a regular basis, 
showing minimum and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.
The investigator (or d esignee) will instruct the subject‘s legal representative(s)/caregiver(s) (in 
accordance with local regulation) to store the IMP following the instructions on the label.
7.6 Drug accountability
A Drug Accountability form will be used to record IMP dispensing and return information on a by-subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
The investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned.
The investigator may assign some of the investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
The investigator must ensure that the IMP is used only in accordance with the protocol.REDACTEDitionition
ensurensure
ccordacorda
tempetempeCOPYhe safhe sa
invesinve
nsns
This document TheThecannot te, e, 
uppliepplie
desigdesibe ost, st, 
or ror rusedabab
sis andis an
, dadatobilitbilitsupporgulatiulat
g accoaccany) wil) wi
tiontiomarketingeratueratu
e is notis no
ManualManua
lauthorizationstigatiga
 mentmen
red eitred eit
ance wnce w
turturapplication d ind in
s
e and pand 
atoratoandand Gnd G
intontoanynternaterna
GMGextensionser PEr PEor variations rt and t andthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 41 of 144Periodically, and/or after completion of the clinical  phase of the study, all used (including empty 
containers/partially used), unused, damaged, and/or expired IMP must be reconciled and either 
destroyed at the site accordi ng to local laws, regulations, and UCB SOPs or returned to UCB’s 
designee. Investigational medicinal product intended for the study cannot be used for any other purpose than that described in this protocol.
7.7 Procedures for monitoring subject compliance
At each visit after IMP is dispensed, subjects must return all used, unused, IMP and empty IMP containers. Drug accountability must be done in  the presence of the subject’s parent(s)/legal 
representative(s)/caregiver(s) in order to obtain explanations regarding discrepancies in 
compliance with the dosing regimen. Drug accountability must be recorded on the Drug 
Accountability form.
If a subject is found to be persistently noncompl iant (defined as <75% or >125% compliant with 
the dosage schedule), the sponsor, in conjunction with  the investigator, will make a decision as to 
whether the subject should be withdrawn from the study.
7.8 Concomitant medications/treatments
7.8.1 Permitted and prohibited concomitant treatments (medications and 
therapies)
Subjects must have been maintained on a stable dosage regimen of 1 to 3 marketed AEDs for 
≥2weeks prior to Visit 1. 
Vagus nerve stimulation is allowed and will not  be counted as concomitant AED use. The VNS 
device must have been implanted for ≥6 months p rior to Visit 1, kept at a stable setting for 
≥2weeks prior to Visit 1, and kept stable during the Baseline, Treatment, and Transition Periods. 
Use of the VNS device magnet is allowed.
For subjects who enter the Taper Period, AEDs may be added or adjusted and VNS adjustments 
may be made at the discretion of the investigator.
The following concomitant medications are prohibited during the study:
x Clozapine
x Monoamine oxidase-A inhibitors 
x Barbiturates (except as AEDs)
x Cannabidiols (not approved or indicated for epilepsy by local health authority)
Neuroleptics (except for clozapine) are allowed during the study but the investigator should 
make every effort to keep the dose stable.
Subjects who have been treated with felbamate an d have experienced any serious toxicity issues 
are excluded from the study. Any subject who is currently treated with felbamate, and has 
received felbamate for a period of less than 12 months, is excluded from the study. Subjects 
treated with felbamate for ≥12 months prior to Visit 1 and w ho have not experienced serious 
toxicity issues are eligible.REDACTED d will will 
r ≥6 mr ≥6 m
stabstabCOPY e dose dos
This documentmakmak
SScannotnnabnnab
urolepurole
kkbe uratat
bidbidusedoxioxi
ates testo xidxidsupporttant mant manyn of tn of marketingm
ble duble du
llowedlowe
r PeriPerauthorizationsage rsage r
not bnot b
monthonthapplication nt treant treand any , will  willextensionsies ies i
the Drhe Dr
>125125or )/le/l
ininvariations pty IMy IM
legaegathereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 42 of 144The following medications are not allowed unless used as described: 
x Amphetamines: stable use only. 
A stable daily dosage regimen of concomitant BZDs  will be considered as a concomitant AED. 
Such use is permitted throughout the study and should be maintained for the video-EEG 
procedures. Use of BZDs as rescue medications (ie,  not as part of a stable daily dosing regimen) 
is permitted. However, use of BZDs for any reason other than a stable daily dosage regimen as concomitant AED within 24 hours prior to or dur ing the video-EEG is not permitted and may 
lead to the subject being withdrawn from the study ( May Withdrawal Criterion 5; Section 6.3).
Therapy that becomes necessary (in the investigator’s opinion) during the course of the study 
must not be refused to a subject, even if described above as a therapy that is expressly not 
permitted. In cases where this oc curs but withdrawal criteria have not been met, the advisability 
of the subject’s continuation in the study must be discussed between the Medical Monitor and 
the investigator. Other medications are permitted according to current clinical standards (eg, 
topical anesthetic).
7.8.2 Rescue medication
Use of BZDs as rescue medications (ie, not as part of a daily regimen) is permitted. However, 
use of BZDs for rescue within 24 hours prior to or during video-EEG recording is not permitted.
7.9 Blinding
Subjects, investigators, and all site personnel are blinded to study medication.
Lacosamide and PBO oral solutions are colorless to pale yellow solutions packaged in amber 
PET bottles. The blind is maintained as the accompanying packaging is identical in appearance 
so that neither the investigator/investigator’s designee nor the subject is able to tell whether the subject is receiving LCM or PBO.
An interactive voice/web response system (IXRS) will be used to assign a treatment to subjects 
who meet eligibility criteria at Visit 3, base d on a predetermined randomization schedule. The 
IXRS is used to control all drug distribution and inventory for this study.
The IXRS will be responsible for subsequent i ssue of treatment kits, as appropriate to the visit 
schedule.
7.9.1 Procedures for maintaining and breaking the treatment blind
7.9.1.1 Maintenance of study treatment blind
All subject treatment details will be allocated and maintained by the IXRS.
7.9.1.2 Breaking the treatment blind in an emergency situation
In the event of an emergency, it will be possi ble to determine to treatment arm and dose the 
subject has been allocated by contacting the IXRS. All sites will be provided with details of how 
to contact the system for code breaking at the start of the study. The Medical Monitor or equivalent should be consulted prior to unblinding, whenever possible.
The Clinical Project Manager will be informed immediately via the IXRS when a code is broken, 
but will remain blinded to specific treatmen t information. Any unblinding of the IMP performed 
by the investigator must be recorded in the source documents and on the Study Termination REDACTED nel arnel ar
re colre col
ed as ted as t
stistCOPYduridur
This document 7.9..9.
InIncannot ubjecubjec
11be used ProPrto supporta 
all druall dr
sponsiponsianyonsens
at Viat Vimarketingthe he 
igator’gator’
se syseauthorization re bline blin
lorlessorles
ea cacapplication ily regily reg
ng videg vidand any MM
cliniccliniextensionsof thof th
xpresspress
met, tmet, t
Medicedior tioiovariations n) n) 
n as as 
d may may 
on on66thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 43 of 144eCRF page. Subjects whose treatment is unbli nded will be discontinued from the study and 
tapered off of LCM as noted in Table 7-3.
7.10 Randomization and numbering of subjects
An IXRS will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined randomization schedule provided by UCB or its designee. 
To enroll a subject (Visit 1), the investigator wi ll contact the IXRS and provide brief details 
about the subject to be enrolled. Each subject will  receive a 5-digit number assigned at Screening 
which serves as the subject identifier throughout the study. The subject number will be required 
in all communication between the investigator/inve stigator's designee and the IXRS regarding a 
particular subject. Subject numbers and ki t numbers will be tracked via the IXRS. 
To randomize a subject (Visit 3), the investigator (or designee) will contact the IXRS and 
provide brief details about the subject to be rando mized. The IXRS will allocate kit numbers to 
the subject based on the subject number during the course of the study.
Randomization wil l be stratified by age category ( ≥1 month to <6 months of age, ≥6 months to 
<1 year of age, ≥1 year to <2 years of age, and ≥2 years to <4 years of age).
8 STUDY PROCEDURES BY VISIT 
Detailed tabular schedules of study procedures are provided in Section 5.2. The subject should 
take concomitant AEDs at the usual time(s) on the morning of each clinic visit.
At all visits and telephone contacts, subjects will be instructed to call the investigator if any 
intolerable and/or serious AEs (SAEs) occur before the next visit or contact. After subjects begin 
study medication, if any AEs necessitate a subj ect’s withdrawal from the study, the subject 
should come in for a clinic visit as soon as possible after the occurrence of the AE. 
Planned clinic visits should be scheduled as indicated in Section 5.2with a window of ±2 days 
relative to Visit 3 (Baseline Period), with the ex ception of the Safety Follow-Up Clinic Visit, 
which should be scheduled 14 days (±2 days) af ter the final dose of study medication, and the 
Safety Follow-Up Telephone Contact, which shoul d be scheduled 30 days (-1/+3 days) after the 
final dose of study medication.
8.1 Baseline Period: Visit 1 (Day -7) to Visit 2 (Day -3 to Day -1)
At Visit 1 (Day -7), subjects who meet the sele ction criteria will begin a 7-day Baseline Period 
(Day -7 to Day -1). Visit 1 may occur over more than 1 day; however, all results of Visit 1 
assessments should be available before Visit 3. In the event that additional time is needed to 
access inpatient facilities to perform the video- EEG, a maximum of 7 days may be added to the 
period between Visit 1 and 2. During the Baseline  Period, study visits are scheduled on Days -7,
-3, -2, and -1.
8.1.1 Baseline Period: Visit 1 (Day -7) 
At Visit 1, subjects will be evaluated for their suitability for enrollment. It is acceptable for this 
visit to be conducted on more than 1 day; howev er, all results of Visit 1 assessments should be 
available prior to randomization. Prior to the conduct of any study-related procedures, a 
complete explanation (both verbal and written) of the nature and purpose of the study will be 
given to the subject’s parent(s)/legal representative(s) by the investigator (or designee). The REDACTEDon ton t
ects wects w
s) occus) occu
ssitatessitateCOPY VV
are prare p
thethe
This documentperioerio
--3,3,cannotmentent
ess inpss in
iododbe Day Daused Basas
ay ay --77oasesesupport d 11
phone hone
medicatedica
ianyerioderio
4 da4 damarketinge a se a s
oon as on as 
chedulehedu
od)od)authorizationroviovi
e mormor
will bell be
ur befur bef
susuapplication <6 m
4 yearsyears
IT T 
ideideand dy.y.
monmoanyalloalloextensionsRS reRS re
RS. RS. 
ct the t the 
ocorbe ree rvariations ls ls 
ScreeScreethereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 44 of 144parent(s)/legal representative(s) of the subject is  required to sign and date the IRB/IEC-approved 
informed consent if he/she decides to participate in the study.
The subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria, signature of an informed consent prior to any study-related procedures or evaluations, and the results of the following pretreatment a ssessments (for further details of the assessments 
and the required procedures and methods, refer to Section 9, Section 10,and Section 11of this 
protocol):
x Informed consent
x Demographics (date of birth [where permitted], age group category, age in months and years, 
race, ethnicity, and gender)
x Inclusion/exclusion criteria
x Medical history
x Seizure history/count
x Concomitant medications (including any c urrent medication intake as well as any 
medications taken ≤30 days prior to Visit 1)
x Concomitant AEDs (including any current med ication intake as well as any previous AED 
taken prior to Visit 1)
x VNS assessment (if applicable)
x Physical examination (complete)
x Vital signs (including BP and pulse rate, incl uding orthostatic assessments where feasible 
according to investigator judgment)
x Body weight
x Height
x Head circumference
x Neurological examination (complete)
x 12-lead ECG (2 interpretable recordings [approximately 20 to 30 minutes apart] to be 
performed prior to any blood draws and vital signs assessment and, if possible, with the 
subject in a supine position for 5 minutes preceding the ECG recording)
x Blood sample for clinical chemistry/hematology
x Contact IXRS
x AE reporting
8.1.2 Baseline Period: Visit 2 (Day -3 to Day -1) 
From Visit 2 (Day -3 to Day -1) to Visit 3 (Day 1), an End-of-Baseline video-EEG (up to 72 
hours of continuous recording with every attempt to obtain at least 48 hours of interpretable 
recording) will be performed. The Day -3 assess ments should be conducted prior to the start of 
video-EEG monitoring. The video-EEG will be conducted in an inpatient setting. UponREDACTED pulsepulseCOPY medicatedica
This documentxCCcannotect ect 
BloodBloobemeded
ti nti nused CG (2CG (2
dp rdptoexamxamsupport ee
minmiany marketingse rate,e rate
ment)ent)authorization atiapplication ion inton in
ion inon inand any extensionsonthsonthsor variations is s thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 45 of 144completion of the End-of-Baseline video-EEG (Vis its 2 and 3), the investigator will assess the 
electrographic seizure count and confirm the sele ction criteria have been met. If the subject 
meets all selection criteria, including the requisite number of seizures based on the End-of-
Baseline video-EEG data, the subject may be ra ndomized at Visit 3. Assessment of the video-
EEG seizure count will also be performed locally by the investigator, subinvestigator, or 
qualified designated reader for the purpose of stud y analyses; however, completion of this review 
is not required prior to randomization.
During Visit 2, the following assessments will be performed:
x Inclusion/exclusion criteria (Day -3 only)
x Concomitant medications 
x Concomitant AEDs 
x VNS assessment (Day -3 only and only if applicable)
x Physical examination (brief) (Day -3 only)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment; Day -3 only)
x Body weight (Day -3 only)
x Neurological examination (brief) (Day -3 only)
x Video-EEG 
x Rescue medication assessment
x AE reporting 
x Review withdrawal criteria 
8.2 Titration Period: Visit 3 (Day 1) to Telephone Contact 3 (Day 20)
Beginning with Visit 3 at Day 1 and continuing up to Telephone Contact 3 at Day 20, telephone 
contacts and clinic visits will be conducted during the Titration Period.
Subjects will be randomized into a treatment arm and study medication will be dispensed. The 
subject will take the first dose of study medication in the clinic. The subject will be instructed to 
call the investigator if any intolerable and/or SAEs occur. If any change in the study medication 
is required, the subject should come in for a clinic visit as soon as possible.
During the Titration Period, visits are scheduled  on Days 1, 9, and 17, and telephone contacts are 
scheduled on Days 5, 13, and 20.
8.2.1 Titration Period: Visit 3 (Day 1)
Randomization and initial dispensing of study me dication will occur at Visit 3 and after the 
completion of the video-EEG and confirmation that the subject has met selection criteria.
During Visit 3, the following assessments will be performed:
x Inclusion/exclusion criteriaREDACTED3 on3 onCOPY nlynly
This documentscheche
8.8.cannot red,ed,
ring thng th
heduedubevestiest
d, thd, thused ranra
ake theke the
tigatigaoandondosupport at Dayt Day
isits wisits wanyerioderiomarketing authorization y))application smentssmenand any extensions or variations iew ew thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 46 of 144x Concomitant medications
x Concomitant AEDs
x 12-lead ECG will be at the discretion of the investigator. The ECG (2 interpretable 
recordings [approximately 20 to 30 minutes apart] to be performed, if possible, with the subject in a supine position for 5 minutes preceding ECG recording) 
x Video-EEG (End-of-Baseline video-EEG)
x Rescue medication assessment
x Contact IXRS
x Randomization
x Dispense study medication and administer first dose of study medication before the 
conclusion of visit
x AE reporting
x Review withdrawal criteria
x Healthcare resource use
x Investigators must make every attempt to administer the Bayley-III scales (for subjects who 
are <18 months of age who originate in English-speaking countries) 
x BRIEF-P score 
x PedsQL score 
x Achenbach CBCL (the CBCL/1½-5 will be completed by parent[s]/legal 
representative[s]/caregiver[s] of subjects ≥18 months of age at Visit 3)
8.2.2 Titration Period: Telephone Cont act 1 (Day 5), Telephone Contact 2 
(Day 13), and Telephone Contact 3 (Day 20)
During the Titration Period telephone contacts  (Telephone Contact 1, Telephone Contact 2, and 
Telephone Contact 3), the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x AE reporting
x Review withdrawal criteria
x Dosing instructions
At Telephone Contact 3, in addition to the procedures noted, the investigator or designee will 
confirm that the subject has tolerated study medication. After Day 20, the dose must remain stable.
8.2.3 Titration Period: Visit 4 (Day 9)
At Visit 4, the following assessments will be performed:REDACTEDEnglEng
½½COPY dminidmini
lisli
This document xxcannotE reporepo
RevRevbe mitmitusednt mt m
tanttantto 3
medsupport anan
eriod triod 
), the), theanyiod:iod
nd Td Tmarketing ½-5 wi5 w
of subjf sub
d: Td:authorizationisterster
shh--spespeapplication rt hrt hand any ioioextensions on bon bor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 47 of 144x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (brief)
x Vital signs (BP and pulse rate, including orthostatic assessments where feasible according to 
investigator judgment)
x Body weight
x Neurological examination (brief)
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reporting
x Review withdrawal criteria
8.2.4 Titration Period: Visit 5 (Day 17)
During Visit 5, the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x Physical examination (brief)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment)
x Body weight
x Neurological examination (brief)
x 12-lead ECG (2 interpretable recordings [approximately 20 to 30 minutes apart] to be 
performed prior to any blood draws and vital signs assessment and, if possible, with the 
subject in a supine position for 5 minutes preceding ECG recording)
x Blood sample for clinical chemistry/hematology
x Blood sample for determination of LCM plasma concentration 
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reporting
x Review withdrawal criteriaREDACTEDill bill bCOPY 17)17)
be pbe
This document xxcannotood sod s
BlooBloobe in in used (2(
d priorprior
nasasto2 in2 insupport minatiminat
tany marketing e, inclue, inclauthorization perforperforapplication and any extensions or variations ng to ng tothereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 48 of 1448.3 Maintenance Period: Visit 6/Early Termination (Day 24 to 
Day 27)
Subjects completing the Titration Period will en ter the Maintenance Peri od and continue on the 
final dose of LCM achieved during the Titration Period. Dose reduction or escalation during the 
Maintenance Period is not permitted. Subjects who are withdrawn will enter the Taper Period 
(see Section 7.2.4 ). Subjects who complete the Maintenance Period may be eligible to participate 
in the open-label extension study (EP0034).
During the Maintenance Period, study visits are scheduled on Days 24 to 27. The subject should 
take concomitant AEDs and study medication at the usual time(s) on the morning of each clinic 
visit.
8.3.1 Maintenance Period: Visit 6/Early Termination (Day 24, Day 25, and 
Day 26)
The Day 24 assessments should be conducted prior to the start of the End-of Maintenance Period 
video-EEG monitoring (up to 72 hours of continuous recording with every attempt to obtain at 
least 48 hours of interpretable recording). Asse ssment of video-EEG seizure count will be 
performed locally by the investigator, subinvestigator, or qualified designated reader for the 
purpose of the study analyses. The following assessments will be performed on Day 24 for all 
subjects:
x Concomitant medications 
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (brief)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment)
x Neurological examination (brief)
x Video-EEG 
x Rescue medication assessment
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reporting
x Review withdrawal criteria
The following assessments will be performed on Day 25 and Day 26 during the video-EEG:
x Concomitant medications 
x Concomitant AEDs
x Rescue medication assessmentREDACTED COPYsmem
This documentxxAAcannotpensens
ReturRetube nsenseused caca
XRSXRStoationatiosupportationtionany n(marketing e, incle, incauthorization application-EEGEE
ualifiedualifie
ts will bs willand EE
ith evth ev
Gany Endndextensionsof eof e
y24, D24, Dorectec
eaceacvariations ipate ipate 
ct shct shthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 49 of 144x AE reporting
x Review withdrawal criteria
8.3.2 Maintenance Period: Visit 6/Early Termination (Day 27)
On the final day of the Maintenance Period, the fo llowing assessments will be performed after 
the completion of the End of Maintenance Period video-EEG:
x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (complete)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment)
x Body weight
x Height
x Head circumference
x Neurological examination (complete)
x 12-lead ECG (2 interpretable recordings [approximately 20 to 30 minutes apart] to be 
performed prior to any blood draws and vital signs assessment and, if possible, with the 
subject in a supine position for 5 minutes preceding ECG recording)
x Blood sample for clinical chemistry/hematology
x Blood sample for determination of LCM plasma concentration 
x Clinical Global Impression of Change
x Caregiver’s Global Impressions of Change
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reporting
x Rescue medication assessment
x Review withdrawal criteria
x Healthcare resource use
x PedsQL (same version used at Visit 3)REDACTED gs [apgs [ap
s and vand
5 minuminu
stsCOPY 
This document xxcannotE reporepo
RescRescbe stustuusedudy udy 
udyudyto msupport Impresmpreanyon of on ofmarketing ut
try/hemry/hem
ion of on ofauthorization pproxprox
vital svital 
tes pes papplication and anyere fereextensions fefeor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 50 of 1448.4 Transition Period: Transition Visit 1 (Day 32) to Transition 
Visit 2 (Day 40)
Eligible subjects who choose to enter EP0034 will enter a 12-day Transition Period upon 
completion of the Maintenance Period.
During the Transition Period, subjects assigned to PBO will be transitioned in a double-blind 
manner from PBO to LCM 8mg/kg/day over a 12-day period according to the schedule shown in 
Table 7‒2. Subjects assigned to LCM 8mg/kg/day to 12mg/kg/day will remain at the dose 
achieved during the Maintenance Period. At the entry visit of EP0034, all subjects will transition to a dose of LCM 10mg/kg/day.
During the Transition Period, study visits will be scheduled on Days 32 and 40, and a telephone 
contact will be conducted on Day 36.
8.4.1 Transition Period: Transition Visit 1 (Day 32) 
During Transition Visit 1, the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (brief)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment)
x Body weight
x Neurological examination (brief)
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reporting
x Review withdrawal criteria
8.4.2 Transition Period: Transition Telephone Contact 1 (Day 36)
During Transition Telephone Contact 1, the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x AE reporting
x Review withdrawal criteria
x Dosing instructionsREDACTED ding oing oCOPY 
This documentxCC
xxcannot ing Trng T
CCbe used g
withdrwithdto supportcationatio
dicationcatioany onmarketing ief)ef)authorization orthosorthosapplication andrmedmedany extensions 0, and, andor ltrtvariations own inwn in
se e 
trantranthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 51 of 1448.4.3 Transition Period: Transition Visit 2 (Day 40)
Transition Visit 2 will also serve as Visit 1 for EP0034.
During Transition Visit 2, the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (complete)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment)
x Body weight
x Neurological examination (complete)
x 12-lead ECG (2 interpretable recordings [approximately 20 to 30 minutes apart] to be 
performed prior to any blood draws and vital signs assessment and, if possible, with the 
subject in a supine position for 5 minutes preceding ECG recording)
x Blood sample for clinical chemistry/hematology
x Contact IXRS
x Return study medication
x AE reporting
x Review withdrawal criteria
8.5 Taper Period: Telephone Contact 4 (Day 32) and Taper Visit 
(Day 36, Day 40, or Day 44)
A blinded Taper Period (8 to 16 days, depending on the dose level achieved) will be required for 
subjects who discontinue study medication prem aturely and for subjects who complete the 
Maintenance Period but will not enroll in EP0034. Study medication will be tapered as described 
inTable 7-3 .
During the Taper Period, a telephone contact will  be conducted on Day 32 and a Taper Visit will
be scheduled at the end of the Taper Peri od, on Day 36, 40, or 44. Note that the study day 
numbers provided are for subjects who complete the Maintenance Period and enter the Taper 
Period; the study day numbers provided do not apply to subjects who enter the Taper Period at 
other times.
8.5.1 Taper Period: Telephone Contact 4 (Day 32)
During Telephone Contact 4, the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x AE reportingREDACTED COPY dinn
logylogy
This documentotheothe
88cannot duleule
bers prers p
riod; iod;be TaTa
ledledused aperaperto od bod bsupport (8 to (8 to 
inue stnue s
butbuanyay 40ay 4marketing TeleTelauthorization application to 3to 3
ssment smen
ECG reCG rand 3030any extensions sible aible aor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 52 of 144x Review withdrawal criteria
8.5.2 Taper Period: Taper Visit (Day 36, Day 40, or Day 44)
A Taper Visit will be scheduled at the end of  the Taper Period (Day 36, 40, or 44), depending on 
dose level achieved.
During the Taper Visit, the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (brief)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment)
x Body weight
x Neurological examination (brief)
x 12-lead ECG will be required for subjects with a clinically significant abnormal reading at 
the previous clinic visit. For non-clinically significant abnormalities, repeat of this assessment is at the discretion of the inve stigator. The ECGs (2 interpretable recordings 
[approximately 20 to 30 minutes apart] is to be  performed prior to any blood draws and vital 
signs assessment and, if possible, with the subject in a supine position for 5 minutes 
preceding ECG recording)
x Blood sample for clinical chemistry/hematology collection will be required for subjects with 
a clinically significant abnormal value at the previous clinic visit. For non-clinically significant abnormalities, repeat of these assessm ents are at the discretion of the investigator.
x Contact IXRS
x Dosing instructions
x Return study medication
x AE reporting
x Review withdrawal criteria
8.6 Safety Follow-Up Period
There will be a 30-day Safety Follow-Up Period for all subjects who will not be entering 
EP0034.
8.6.1 Safety Follow-Up Period: Safety Follow-Up Clinic Visit (Day 50, 
Day 54, or Day 58)
The Safety Follow-Up Clinic Visit will occur 14  days (±2 days) after the final dose of study 
medication and will include the following assessments:
x Concomitant medicationsREDACTEDestigestig
t] is to] is to
with thith t
stsCOPYh a clh a c
signifisignif
igatga
This document Thehe
EP0EP0cannot ererebew wiw wused ingngto medmedsupport s
dicadicany ppmarketing try/hemry/hem
mal valual val
peat oeat authorizationficancan
tor. Tor. T
o be pbe p
he sube subapplication nicallyicall
ant ant aand anyere fereextensions ef efeor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 53 of 144x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (complete)
x Vital signs (BP and pulse rate, including orthosta tic assessments where feasible according to 
investigator judgment)
x Body weight
x Neurological examination (complete)
x 12-lead ECG will be required for subjects with a clinically significant abnormal reading at 
the previous clinic visit. For non-clinically significant abnormalities, repeat of this 
assessment is at the discretion of the investigator.  
x Blood sample for clinical chemistry/hematology collection will be required for subjects with 
a clinically significant abnormal value at the previous clinic visit. For non-clinically 
significant abnormalities, repeat of these assessm ents are at the discretion of the investigator.
x AE reporting
8.6.2 Safety Follow-Up Period: Safety Follow-Up Telephone Contact 
(Day 66, Day 70, Day 74, or Day 93)
The Safety Follow-Up Telephone Contact will occ ur 30 days (-1/+3 days) after the final dose of 
study medication and will include the following assessments:
x Concomitant medications
x Concomitant AEDs
x AE reporting
8.7 Unscheduled Visit
Unscheduled visits can be conducted at the disc retion of the investigator (eg, due to an AE). 
During the Unscheduled Visit, the following assessments will be performed:
x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment)
x Body weight
x AE reporting
x Review withdrawal criteria
In addition to the required assessments listed a bove, additional assessments may be performed at 
theinvestigator’s discretion.REDACTEDwill owill o
ollowinlowinCOPYety Fety F
Day 9Day 
This documentxxcannot S asas
Vital Vital 
invinvbe asseasseused mm
tant Aant Atomedmedsupport be conbe con
uled Viled Vanyed Ved Vmarketing authorization93)93)
occur 3ccur 3
ing asng asapplicationthe he
ollowollow
))andsit. it. FF
ed ied iany requirequ
orextensions rmal remal r
eat of eat ofor variations o thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 54 of 1449 ASSESSMENT OF EFFICACY
9.1 Primary and secondary efficacy variables
The primary and secondary efficacy variables are based on the ADF of partial-onset seizures as 
measured on video-EEG (up to 72 hours of continuous recording with every attempt to obtain at least 48 hours of interpretable recording). 
Partial-onset seizure count will be based on electrographic seizures with or without clinical 
correlate depending upon age as specified below. 
Partial-onset seizure frequency for infants aged ≥1 month to ≤6 months will be based on 
electrographic seizures. Partial-onset seizure frequency for children aged >6 months to <4 years 
will be based on electrographic seizures with an accompanying clinical correlate.
Electrographic seizures are defined as recognizable ictal patterns on an EEG involving 
≥2contiguous electrodes. The seizures are initia ted as a unilateral or strongly asymmetric 
abnormal epileptiform discharge la sting a total of >10 seconds. 
The video-EEG recordings will be evaluated for seizure counts locally by the investigator, 
subinvestigator, or qualified designated reader. 
Calculation of the Baseline Period ADF of electrographic partial-onset seizures and the 
Maintenance Period ADF of electrographic partial- onset seizures will be based on results from a 
video-EEG during each period. Subjects are expec ted to have at least 48 hours of interpretable 
video-EEG during each period. For subjects who drop out during the End-of-Maintenance Period 
video-EEG, the number of hours from the start of the End-of-Maintenance Period video-EEG to 
the time of withdrawal (in hours) will be considered  for analysis. Subjects who discontinue on or 
before Day 20 will not require a video-EEG.
9.2 Other efficacy assessments
9.2.1 Global Impression of Change
The Clinic al and Caregiver’s Global Impression of Change  will be administered according to the 
tabular schedules of study procedures (Section 5.2).
The Clinical Global Impression of Change is a 7-point categorical rating scale in which the 
investigator assesses the subject’s change from  Baseline in clinical status, including an 
evaluation of seizure frequency and intensity, the occurrence of AEs, and subject’s f unctional 
status.
The Caregiver’s Global Impression of Change is a 7 -point categorical rati ng scale in which the 
caregiver(s) assesses the subject’s change from  Baseline in clinical status, including an 
evaluation of seizure frequency and intensity, the oc currence of AEs, and subject’s functional 
status.
9.2.2 PedsQL
The PedsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric populations, including those with acute or chronic health conditions (Varni et al, 2001). The PedsQL will be administered only in countri es where a translated version is available. The REDACTEDexpexp
cts whcts wh
the sthe s
ill be ill be 
deodeoCOPYgraphgrap
tialtial--ono
pecpec
This documentevaleval
ststcannot Caregiareg
egiveegivbe usedsesseesse
fs e i z useizutoal Imal I
essupporter’s Ger’s 
udy prudy p
Impmanyessiss
GlGmarketing co
-EEGEEG
assesasse
ioniouthorizationnsetset
cted toted t
ho droho dro
taart ofrt of
onsionsiapplications locas loc
hic partic par
ts ets eand llany EGE
tronglrongextensionssed oed 
onths tnths 
elate.elate.
EG inG inor ononvariations al l thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 55 of 144version of the PedsQL used at Visit 3 (Baseline) should be maintained for the duration of the 
study in accordance with the tabular sc hedules of study procedures (Section 5.2).
The PedsQL Measurement Model consists of de velopmentally appropriate forms for pediatric 
subjects ≥1 month to ≤12 months, ≥13 months to <24 months, ≥2 years to ≤4 years, ≥5 years to 
≤7 years, ≥8 years to ≤12 years, and ≥13 years to ≤18 years of age. Parent proxy report of child 
health- related quality of life (HRQoL) is measured for pediatric subjects ≤4 years of age.
The multidimensional PedsQL generic core scales encompass the essential core domains for 
pediatric HRQoL measurement: Physical Func tioning, Emotional Functioning, Social 
Functioning, and School Functioning. The PedsQL  assessment is retrospective to the prior 
4 weeks, and individual items are scored using a 5-point Likert scale (never, almost never, 
sometimes, often, or almost always). A total heal th summary score ranging between 0 and 100 is 
calculated from the sum of the raw scores, with higher scores indicating higher HRQoL.
9.2.3 Healthcare resource use
For healthcare resource use, the following will  be evaluated: concomitant medications and 
AEDs, medical procedures, and healthcare provider consultations including hospitalizations not foreseen by the protocol.
10 ASSESSMENT OF PHARMACOKINETIC AND 
PHARMACODYNAMIC VARIABLES
Blood samples for the deter mination of LCM plasma concentrations will be collected according 
to the tabular schedules of study procedures (see Section 5.2). In each case, the time the subject 
took the most recent dose of study medication a nd the time of blood sampling must be recorded. 
Actual sampling times will be recorded in the eCRF to the minute.
Details of plasma sample collection and processi ng, sample labeling, and shipment will be 
provided in the laboratory manual.
11 ASSESSMENT OF SAFETY
11.1 Adverse events
11.1.1 Definition of adverse event
An AE is any untoward medical occurrence in  a patient or clinical investigation subject 
administered a pharmaceutical product that does no t necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or  not related to the medicinal (investigational) 
product.
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the Informed Consent form), including any pretreatment and posttreatment periods 
required by the protocol, must be reported in the eCRF even if no investigational product was 
taken but specific study procedures were conducted. This includes all AEs not present prior to the initial visit and all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the investigational product is being studied 
should be recorded as AEs only if their nature  changes considerably or their frequency or CM plaCM pl
dures (ures 
medicatmedica
rdedrdedCOPYMAMACC
VARVAR
This documentprodrod
InIncannotm
mal lamal la
dicinadicina
dudbed 
ment.mentuseduntowntow
a pha phto insupport se eve ev
nitioitioany MENTENmarketingd in thd in th
n and pand 
al.al.authorizationRIIABAB
lasma asma 
(see S(see S
tion aion a
hhapplicationons inons i
OKINOKI
BLBLand omitaomitaany extensionshe pe p
most nost n
etweeetwee
igher gher or priprivariations for for thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 56 of 144intensity increases in a clinically significant manner as compared to the clinical profile known to 
the investigator from the subject’s history or the Baseline Period.
11.1.1.1 Signs and symptoms of depression
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of 
depression. The investigator should be aware of common warning signs that might be a signal for risk of depression. For common signs and symptoms of depression in children, reference should 
be made to the current version of the Diagnostic and Statistical Manual of Mental Disorders. 
Each subject’s parent(s)/legal representative(s)/caregiver(s) (in accordance with local regulation) should also be advised accordingly and effort shou ld be made at clinic visits to specifically 
assess potential depression.
11.1.2 Procedures for reporting and recording adverse events
The subject’s parent(s) and/or legal representativ e(s)/caregiver(s) will be given the opportunity 
to report AEs spontaneously. A general prompt will also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about the subject’s health (since your last visit)?”
In addition, the investigator should review any self-assessment procedures (eg, diary cards) 
employed in the study.
11.1.3 Description of adverse events
When recording an AE, the investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents s hould be consistent. Any discrepancies between the subject’s own words 
on his/her own records and the corresponding medical terminology should be clarified in the 
source documentation.
Details for completion of the Adverse Event eCRF (including judgment of relationship to study 
medication) are described in the eCRF Completion Guidelines.
11.1.4 Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, th e investigator determines 
that it is no longer clinically significant, or the subject is lost to follow up. 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
investigator must provide a justification. The follow up will usually be continued for 30 days 
after the subject has discontinued his/her IMP.
11.1.5 Rule for repetition of an adverse event
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:
x The outcome date of the first AE that is not re lated to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”
x The AE verbatim term being the same for the fi rst and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first oneREDACTED venven
shouldshould
than rethan r
onsisteonsiste
resprespCOPY asss
ntsnts
This documentafterfter
1111cannotally silly si
estigaestiga
er trtbe/stab/stabused ger cer 
ngoinngointo oll
clinclisupport up ofup o
loweloweany AdvAdv
the ethe emarketing entnt
pondinpondin
dversverauthorization d use use 
recordecord
t. At. Aapplication health ealth 
sment pment and eaeaanye give gi
ach stch sextensionscifiifi
entsents
iveivor rege
ficaicavariations for for 
ould ould 
ders. ers. 
egulgulthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 57 of 14411.1.6 Suspected transmission of an infectious agent via a medicinal 
product
For the purposes of reporting, any suspected transm ission of an infectious  agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent. 
11.1.7 Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in th e protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE  associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
11.1.8 Safety signal detection
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed  appropriately and as early as possible.
The Study Physician or medically qualified desi gnee/equivalent will cond uct an ongoing review 
of SAEs and perform ongoing SAE reconciliations  in collaboration with the Patient Safety 
representative.
As appropriate for the stage of development a nd accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course of the study.
11.2 Serious adverse events
11.2.1 Definition of serious adverse event
Once it is determined that a subject experi enced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:
x Death
x Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)
x Significant or persistent disability/incapacity
x Congenital anomaly/birth defect (including that occurring in a fetus)
x Important medical event that, based upon appropri ate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of seriousliatioliatio
opmeopm
CB mCB mCOPYpriatpria
signeeigne
This document xxcannot th
LifeLife-tt
a ma mbehreathreaused toAE mAE supportn of n of
d that d that 
muanyversversmarketingmay imay 
r whichr whicauthorizatione/eque/equ
ns in cns in 
nt annt an
iapplicationdetectdetec
clinicallinica
ely andy an
iand any extensionsshoushou
osing sing 
ered Ared A
exceexcor llvariations c or c or thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 58 of 144(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 11.3], allergic bronchospasm requiring intens ive treatment in an emergency room or 
at home, blood dyscrasias that do not result in  inpatient hospitalization, or the development 
of drug dependency or drug abuse.)
x Initial inpatient hospitalization or prolongation of hospitalization
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalizati on. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening a dverse experience, important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing  condition that has not worsened or manifested 
in an unusual or uncharacteristi c manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medi cal history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the se rious criteria. Note that, if the pre-existing 
condition has worsened or manifested in an unusual or uncharacteristic manner, this would then qualify as an AE and, if necessary, the seriousness of the event would need to be determined.)
11.2.2 Procedures for reporting serious adverse events
If an SAE is reported, UCB must be informed wi thin 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE report form) provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Informat ion recorded on this form will be entered into 
the global safety database.
An Investigator SAE report form will be provided to the investigator. The Investigator SAE 
Report form must be completed in English. 
It is important for the investigator, when completing the SAE report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be summarized in the Investigator SAE report form.
The investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of ting sting s
e infore infor
r SAr SACOPYnusuausua
serioserio
This documentexpexpe
AAcannothe inhe in
d in dein de
pededbent as nt asused st bt b
nt fort fortoAE
be cbesupport ny cy c
ase.e.
E reporepoanyddataat
concconmarketingrm
AE repAE re
. The inThe 
SAE RAE R
aaauthorizationusnesn
serioserio
med med applicationand nd
ery or hry or 
criteriariteri
l or unor un
essandportinortin
dl adl aany AA
worswor
ngextensionswowo
riteriaiteria
medicamedic
AE [eE [eor crc
ouloulvariations in n 
critecritethereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 59 of 144the need to inform the investigator of any SAE within this period. Serious AEs that the 
investigator thinks may be associated with the IMP must be reported to UCB regardless of the time between the event and the end of the study.
Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the Investigator’s Brochure.
11.2.3 Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events are provided in Section 11.6.1.4 .
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety database without limitation of time.
11.3 Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.
The following are LCM’s AEs of special interest:
x The following arrhythmias: atrial fibrillation/ flutter, ventricular tachycardia or fibrillation, 
AV block (second-degree Type I and II and third-degree), and marked bradycardia (<45bpm)
x Syncope or loss of consciousness (other than seizure related)
x Serious suspected multiorgan hypersensitivity reactions
Serious suspected multiorgan hypersensitivity cases may be identified and reported to the 
sponsor by the investigator using the following algorithm as agreed with the US FDA
An AE or laboratory value (as defined in th e following text) suggestive of internal organ 
involvement (including but not limited to hepati tis, nephritis, pneumoniti s, carditis, colitis, 
encephalitis, pancreatitis, myositis, arthriti s, or hematologic system involvement) combined 
with at least 1 of the following: fever, rash, lymphadenopathy, or eosinophilia.
Treatment-emergent abnormal laboratory va lue criteria suggestive of internal organ 
involvement or eosinophilia:
◦ Eosinophils % ≥10%
◦ Eosinophils absolute ≥0.5G/L
◦ Neutrophils absolute <1.5G/L
◦ Platelets ≤100G/L
◦ ALT ≥2×ULN
◦ AST ≥2×ULNREDACTED ereseres
rillatiorillatio
and IIand II
ess (oess (oCOPY tete
est:st:
This document cannotolvelve
◦◦bementnt
ememusedpp
st 1 ot 1 otoancancsupport at
ry valuy valu
ludingluding
reanyan an
or usor usmarketingother other
hypersyper
n hypnh yauthorization on/fluon/flu
and tand application ity hasty ha
ess, or ss, oand anyred tred extensionsw up. up. 
er detr det
ththor or or 
Tvariations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 60 of 144x Potential Hy's Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin 
in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of special interest (ie, without waiting for any additional etiologic investigat ions to have been concluded). Follow-up
information should then be reported if an alternative etiology is identified during 
investigation and monitoring of the subject.
11.4 Immediate reporting of adverse events
The following AEs must be reported immediately:
x SAE: AE that the investigator classifies as serious by the above definitions regardless of 
causality
x Suspected transmission of an infect ious agent via a medicinal product
x AE of special interest (see Section 11.3)
11.5 Anticipated serious adverse events
The following list of Anticipated SAEs ( Table 11‒1) is anticipated to occur in the population 
studied in this protocol at some frequency that is independent of drug exposure. 
This list does not change the investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 11.2.2 .
REDACTED COPY ation ation 
This document cannot be used to support any marketing authorization toapplication ipated pated
dent of ent o
o repoo repand any extensionsegardlgardlor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 61 of 144Table 11 ‒1: Anticipated SAEs for the pediatric epilepsy population
MedDRA SOC MedDRA PT
Congenital, familial and genetic disorders Teratogenicity  
General disorders and ad ministration site conditions Sudden unexplained death in epilepsy  
Nervous system disorders Convulsiona 
Incontinence  
Status epilepticus  
Psychiatric disorders Psychotic behaviour  
Abnormal behaviour  
Anxiety  
Sleep disorder  
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SAE=serious adverse event; 
SOC=system organ class 
aConvulsion if consistent with the seizure type known for the subject.
11.6 Laboratory measurements
Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study procedures (Section 5.2). A central laboratory will 
perform the routine analysis of blood specimens. The procedures for handling and shipping these 
specimens will be provided to the sites. In ex ceptional circumstances, local laboratory analysis 
may be performed. The medical monitor should be contacted beforehand to discuss these 
circumstances.REDACTED oceoce
imensimens
In exIn ex
nitor snitor sCOPY gy andy an
eduredur
This document cannot be used to support any marketing authorization d cl
res (Ses (S
s. The. The
xceptiocepti
houldhouldapplication clinicliniandAE=seE=sedany y
iaextensions io
teeor ovariations s
tio
vathereof. tht
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 62 of 144The laboratory tests to be performed are presented in Table 11‒2as follows:
Table 11‒2: Laboratory measurements
Hematology Clinical chemistry
Hematocrit
Hemoglobin
Platelet count
RBC count
WBC count
Differential countCalcium
Phosphorus
Serum electrolytes (sodium, potassium, chloride, 
bicarbonate)
Creatinine
BUN
AST
ALT
Total bilirubin
ALP
GGT
Glucose
Albumin
Total serum protein
Uric acid
Total cholesterol
Triglycerides
ALP= alkaline phosphatase;  ALT=alanine aminotransfera se; AST=aspartate aminotra nsferase; BUN=blood urea 
nitrogen; GGT=gamma glutamyltransferas e; RBC=red blood cell; WBC=white blood cell
Creatinine clearance will be estimated using th e updated Schwartz bedside formula (Schwartz 
and Work, 2009).
11.6.1 Liver function tests and evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 6.3.1 with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 11.3), and, if applicable, also reported as an 
SAE (see Section 11.2).
Evaluation of PDILI consists of the diagnostic te sting and continued monitoring included in 
Table 11‒3(specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 11.6.1.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 11.6.1.4 ).REDACTED TECOPY 
This documentEvalEval
TTcannotc
ed as d as
E (seeE (seebeor
currcurrusedrequequ
rted rtedtoiscosco
isupport functiunct
ontanyestimstimmarketing etie aminoamin
erase; Rase; Rauthorization aapplication andtal bal bany LTLT
iliiextensions or variations chlorichlorithereof. thththth
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 63 of 144The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be de layed waiting for the repeat result.
If tests are done locally for more rapid results,  a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 2 
laboratory tests are significantly different. Data from the local and central laboratory are to be recorded on the applicable eCRF pages.
When IMP is discontinued, all concomitant medi cations and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable alternative.
When IMP is stopped due to PDILI (as described in Section 6.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings.
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
The table below summarizes the approach to investigate PDILI. 
REDACTEDto invo invCOPY drugdrug-
This document cannot be used to support any marketing authorization estigaestigaapplication3.1.1), ),
explaiexpla
inducenduceand IIanyxic to xic toextensions nts thats tha
gator sator 
and cnd cor rerevariations the he 
om thm th
e to et othereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 64 of 144Table 11‒3: Required investigations and follow up of PDILI  
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNb
NA Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with Medical Monitor 
ASAP.Immediate, 
permanent IMP discontinuation.Essential: Must 
have repeat liver chemistry values 
and additional 
testing completed 
ASAP (see 
Section 11.6.1.3) ;
recommended to 
occur at the site 
with HCP.Monitoring of liver chemistry 
values at least twice per week until values normalize, stabilize, 
or return to within Baseline 
values.d≥5xULN NA NA
≥3xULN NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
Baseline) 
and
<5xULN<2xULN No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.Further investigation 
–immediate IMP 
discontinuation not 
required (see 
Section 11.6.1.2 ).Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).REDACTEDia
poraryporar
ermanerman
discodiscoEDR
COPate, te, 
OPY OPThis 
document 
cannot 
be 
used 
to support ontinntinup
any allowallow
nu
marketingFurFuing ingke
authorization y or y or 
nent, IMent, IM
ontinuntinu
application entent
have rehave r
chemche
aplia
and tialtial
nd
any 
extensions FoFoiotetetete
or 
variations ar
thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 65 of 144Table 11‒3: Required investigations and follow up of PDILI  
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥5xULN 
(and ≥2x 
Baseline) <2xULN No Discussion with
Medical Monitor required.Immediate, 
permanent IMP discontinuation.Essential: Every 
attempt must be made to have 
repeat liver 
chemistry values 
and additional 
testing completed within 48 hours 
at the site with 
HCP (see 
Section 11.6.1.3 )Monitoring of liver chemistry 
values at least twice per week until values normalize, stabilize, 
or return to within Baseline 
values.
d
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=a s soon as possible; AST=aspartate aminotransferase; HCP=healthcar e practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right u pper quadrant pain or tenderness; hypersensitivity symptoms in clude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of b iliary obstruction should be discussed with the Medi cal Monitor.
.cDetails provided in Section 11.6.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by the invest igator and UCB responsible physician. Determination of stabili zation is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsi ble physician, as needed.REDACTED ED
COPY This 
document 
cannot 
be 
used eed ed
gist (asist (as
to epap
d bydb y
support indicatndica
ogist isogist i
atoloatolo
anyupperuppe
marketing 
kekekeke soon as oon a
=poten=pote
authorization 
applicationsentient
attempattemp
madma
repli
and tialtial
nd
any 
extensions FoFoiotetetete
or 
variations ar
thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 66 of 14411.6.1.1 Consultation with Medical Monitor and local hepatologist
Potential drug-induced liver injury events require  notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consul ted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 11.6.1.3 ) and SAE report (if applicable).
11.6.1.2 Immediate action: determina tion of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the labor atory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent di scontinuation (see Section 6.3.1 and Table 11‒3for details).
When IMP is discontinued, all concomitant medic ations and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose reduction for medically necessary concomitant me dication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
11.6.1.3 Testing: identification/exclusion of alternative etiology
The measurements and additional information requi red for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table 11‒4(laboratory measurements) and Table 11‒5(additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding eCRF. If the medical history of th e subject indicates a requirement for other 
assessments not included below, these addi tional assessments should be completed and 
submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.REDACTED on reqon req
may hmay 
) and ) and
matmatioioCOPYtotoxiotox
sion sion
This document cannot be used to supporte ste st
also belso bany toretormarketingon coln col
history history
hese adese aauthorization of aof a
quireduired
have bhave 
TableTable
lapplication al sul su
ator shoor sh
nd connd co
c to a sc to a 
tand e11
suppuppanydiatediate
11‒‒33extensions f hepf hepor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 67 of 144The following measurements are to be assessed:
Table 11 ‒4: PDILI laboratory measurements
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Hematocrit
Hemoglobin
Platelet count
RBC count
WBC count
Differential count
Urinalysis Toxicology screen
Chemistry Amylase
Bilirubin (If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % 
direct bilirubin)
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
AST
ALT
ALP
GGT
Albumin
Additional Prothrombin time/INRa
PK sampleREDACTED ED
AC
RECOPY an
Y
CO
This document mmumcannot be used SeruSerud
utoect bect tsupport ubin (Ibin (I
bilbippany reenreenamarketing g 
ke
mauthorization on
iza
thapplicationuantituantit
dies (qdies (ati
ppand daany aextensions io
le, oe, oteor orvariations oniononon
arthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 68 of 144ALP=alkaline phosphatase; ALT=alanine aminotransfe rase; AST=aspartate aminotransferase; CPK=creatine 
phosphokinase; GGT=gamma-glutamyl transferase; HBcAb-IgM=hepatitis B core antibody-IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin  M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RBC=red blood cell; 
RNA=ribonucleic acid; ULN=upper limit of normal; WBC=white blood cell
aMeasured only for subjects with ALT >8xULN, elevati ons in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosin ophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
Table 11 ‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
x History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
x Adverse reactions to drugs
x Allergies
x Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)
x Recent travel 
x Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotra nsferase; PDILI=potential drug-induced liver injury
11.6.1.4 Follow-up evaluation
Potential drug-induced liver injury events requi re follow-up monitoring as described in 
Table 11‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilizati on is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.REDACTEDorderorde
olving olving 
atioatioCOPY rs
This documentote
TablTabl
rerecannot .44
entiaentiabee amie amiusediaia
m/pathm/patd 
utoalist list suppog or liveor livporthypothypo
po
sany tamarketingthe he
on for sn for 
cal sympl sym
or tendor tenketauthorization (eg, Geg, G
el i vel i vapplicationlic stealic steand danyherbherextensions s
rbalbaxtor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 69 of 14411.7 Other safety measurements
11.7.1 Physical examination
Physical examinations will be performed according to the tabular schedule of study procedures 
(Section 5.2) by a medically qualified clinician license d to perform the examination. Subsequent 
to Visit 1, clinically significant physical examination findings should be reported as AEs.
11.7.1.1 Complete physical examination
The complete physical examination will in clude cardiac and respiratory function via 
auscultation, temperature, and review of all body systems.
11.7.1.2 Brief physical examination
The brief physical examination will include review of the following body systems: 
x Cardiovascular
x Pulmonary
x Abdominal (hepato-gastrointestinal)
x Dermatologic
11.7.2 Neurological examination
Neurological examinations will be performed according to the tabular schedule of study 
procedures (Section 5.2)by a medically qualified clinician with documented training in the 
conduct of neurological examinations. If possible, the same clinician should conduct all 
neurological examinations for the same subject during the study. The investigator or 
subinvestigator is responsible for confirming the diagnosis of partial-onset seizures. Subsequent 
to Visit 1, clinically significant neurological examination findings should be reported as AEs.
11.7.2.1 Complete neurological examination
The complete neurological examination will include selected assessment of general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and 
sensation.
11.7.2.2 Brief neurological examination
The brief neurological examination will include selected assessment of general neurological 
status, reflexes, muscle strength, and coordination/cerebellar function.
11.7.3 Vital signs, body weight, and height
Noninvasive BP (systolic and diastolic) and pulse ra te will be measured at clinic visits after at 
least 3 minutes at rest in a supine position, ac cording to the tabular schedule of study procedures 
(Section 5.2). Assessment of orthostatic changes will be as follows: after the 3 minute 
measurement in a supine position, the subject is asked to stand up, and BP and pulse rate are taken 1 minute and 3 minutes after standing up, as feasible.REDACTEDaccoacc
ualifieualifie
If possIf poss
me subme su
nfirnfirCOPY 
This documentNoniNoni
lealeacannoeflexflex
7.33beneuroneuro
xexeusedBriefBrief
olooloto support exax
ness, mness, 
musclemuscany oo
aminaminmarketing ubjebje
rming ming 
ologicalogi
ologilogauthorization rding ding 
ed clind clin
sible, ible, 
ect ectapplication and any extensions stemstemsor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 70 of 144Body weight will be determined without shoes and wearing light clothing, and height will be 
measured without shoes. Body weight and height will be assessed according to the tabular schedule of study procedures (Section 5.2).
11.7.4 12-lead ECG
Standard 12-lead ECGs will be performed accordin g to the tabular schedule of study assessments 
(Section 5.2). Care should be taken to assure proper le ad placement and quality ECG recordings. 
Two interpretable recordings will be perform ed prior to any blood draws and vital signs 
assessment and, if possible, with the subject in a supine position for 5 minutes preceding the ECG recording and the subject should be motionless during the recording. The second recording will be conducted approximately 20 to 30 minutes after the first recording. 
11.7.5 Overall ECG interpretation
Electrocardiograms will be reviewed locally by  the investigator, subinvestigator, or qualified 
designated reader and at a central ECG laboratory . If the reading identifies second or third degree 
AV block, a QTc ≥500ms, or another abnormal ECG finding that is assessed by the investigator 
to be clinically significant, then the ECG should be repeated on the same day. If the clinically significant abnormality is confirmed by the repeat ECG, then the subject must be withdrawn 
from the study (see Section 6.3). The investigator may consult with the cardiologist at the central 
ECG laboratory to confirm the presence of a clinically significant ECG abnormality. It remains the responsibility of the investigator to decide whether an ECG finding is of clinical significance 
on the basis of the complete clinical picture and whether this finding influences the subject’s 
participation in the study.
11.7.6 Achenbach CBCL
The Achenbach CBCL is a widely used validated questio nnaire to evaluate a child’s 
competencies and behavioral/emotional problems.  Behavioral problems will be scored by the 
parent(s)/legal representative(s )/caregiver(s). The CBCL/1½-5 checklist for children 18 months 
to 5 years and 11 months of age will be used in this study. The Achenbach CBCL/1½-5 will be 
completed by the parent(s)/legal representative(s)/caregiver(s) of subjects ≥18 months of age at 
Visit 3. The Achenbach CBCL will be administered  only in countries where a translated version 
is available.
The scale will be completed in accordance with the tabular schedules of study procedures 
(Section 5.2)and should be completed by the same pare nt(s)/legal representative(s)/caregiver(s). 
The completion of the Achenbach CBCL will require approximately 45 minutes.
In the CBCL/1½-5 checklist, the occurrence of certain problems and behaviors at the time of 
administering the questionnaire or within the pa st 2 months will be scored on the following 
scale:
x 0=not true (as far as known)
x 1=somewhat or sometimes true
x 2=very true or often true
Eight syndrome scores will be calculated from thes e questions, which will in turn be summarized 
by 2 composite scores. Additionally, for each score on the question, syndrome, and total level, REDACTEDwh
and wand w
sedseCOPYy coy c
cally sally s
hethehethe
This document caleal
xxcannotCBCLBCL
ministeniste
e:e:beetionetioused comco
and shnd sh
nonoto ompompsupport/legaeg
CBCLCBCLanyge wilge wi
gal rgalmarketing d validd valid
onal pronal p
aregivaregi
llauthorizationsigg
er an Eer an 
whethehetheapplicationthe sathe sa
the subthe su
nsult wisult w
gnificnificandifiefie
assesassesanytigatoigat
es sees sextensionsnd red reog theg thvariations ts 
ngs. ngs. 
hethereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 71 of 144categorizations based on a normative sample will  be used to evaluate normal, borderline, or 
clinically relevant behavior.
Baseline assessment of the Achenbach CBCL will be performed at Visit 3; however, due to the 
short study duration of SP0967, the next assessment will be collected in subjects entering into the EP0034 study. Thus, the analysis of these data will be conducted in EP0034.
11.7.7 BRIEF-P
The BRIEF- P is a validated tool that will be used for the evaluation of subjects ≥2 years of age 
and will be administered according to the ta bular schedules of study procedures (Section 5.2).
The BRIEF-P will be administered only in count ries where a translated version is available.
The BRIEF- P includes rating forms used by parents to assess subjects’ executive functioning 
within the context of the sub ject’s everyday environment. It requires that the parent must have 
had recent and extensive contact with the child over the past 6 months. Executive functions 
broadly encompass a set of cognitive skills that are responsible for the planning, initiation, 
sequencing, and monitoring of co mplex goal directed behavior. 
The BRIEF-P rating form consists of items that measure various aspects of executive 
functioning: Inhibit, Shift, Emotional Control, Working Memory, and Plan/Organize. The 
clinical scales form 3 broad overlapping indexes: Inhibitory Self-Control (Inhibit and Emotional Control), Flexibility (Shift and Emotional Control), and Emergent Metacognition (Working Memory and Plan/Organize) and 1 composite score (Global Executive Composite).
The BRIEF-P includes validity scales to measure  negativity and inconsistency of responses.
Baseline assessment of the BRIEF-P will be pe rformed at Visit 3; however, due to the short 
study duration of SP0967, the next assessment will be collected in subjects entering into the 
EP0034 study. Thus, the analysis of these data will be conducted in EP0034.
11.7.8 Bayley Scales of Infant and Toddler Development, Third Edition
The Bayley-III scales are recognized internationally as one of the most comprehensive 
developmental assessment instruments (Sattler and Hoge, 2006) used to examine the major 
facets of a young child’s development (Bayley, 2006). The Bayley -III scales are a standardized, 
individually administered, adaptive assessment that measures the developmental functioning of 
infants and young pediatric subjects from 1 month to 42 months of age (Bayley, 2006). The 
Bayley-III scales measure cognitive, language, motor, social-emotional, and adaptive development and are a revision of the predecessor,  the Bayley Scales of Infant Development, 
Second Edition (Bayley, 1993). The Bayley-III scales are a technically sound instrument, with 
strong internal consistency, as well as test-retest  stability. The Bayley-III scales are validated 
only in English. 
The scales are validated as a tool for assessm ent of neurological development in young pediatric 
subjects and are therefore cons idered appropriate for SP0967.
The Bayley-III scales are an individually ad ministered, adaptive assessment that presents 
pediatric subjects with situations and tasks desi gned to produce an observable set of behavioral 
responses. They consist of a cognitive scale, a language composite scale with receptive and 
expressive language subscales, and a motor composit e scale with fine and gross motor subscales scorsco
measurmeasur
will bewill b
assesassesCOPYgg
hibitohibit
ol), andl), an
oreore
This document The The
suscannot EditEdit
g interinter
y in Ey in Ebent ant a
itioitioused g pp
les mees me
andandtoste
pedipedisupportt instrinst
’s deves dev
ered, ered, any gnizegniz
rumarketingssmensmen
hese dahese d
f Infaf Infaauthorizationnd Emd Em
 (Glob(Glo
re negre neg
e perfperfapplication us aspes asp
mory, amory, 
ory Selry Se
memeandplaplaanyxecutecu
anniannextensions on
vailabvailab
ve funve fun
parenpare
iorn5.25.variations f agefa g ethereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 72 of 144to be completed by the investigator or designee. It also has a social emotional scale, comprising 
social-emotional competence, and sensory processi ng, and an adaptive behavior scale, which 
assesses the attainment of skills necessary for the development of independence, to be completed 
by the child’s parent(s)/legal representative(s)/caregiver(s). 
The completion of the Bayley-III scales will  require approximately 50 minutes for pediatric 
subjects who are 12 months old or younger and 90 minutes for pediatric subjects aged 12 months 
to 18 months. 
Investigators must make every attempt to adminis ter the scale according to  the tabular schedules 
of study procedures (Section 5.2). If needed, the investigators may utilize trained pediatric 
psychologists or other appropriately skilled individuals to administer the scale. 
Due to the short study duration of SP0967, the next assessment will be collected in subjects 
entering into the EP0034 study. Thus, the analysis of these data will be conducted in EP0034.
12 STUDY MANAGEMENT AND ADMINISTRATION
12.1 Adherence to protocol
The investigator should not deviate from the protocol. However, the investigator should take any
measure necessary in deviation from or not define d by the protocol in order to protect clinical
study subjects from any immediate hazard to their health and safety. In this case, this action
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or
sponsor. After implementation of such measure, the investigator must notify the Clinical Project 
Manager (CPM) of the sponsor within 24 hours and follow any local regulatory requirements .
12.2 Monitoring
UCB (or designee) will monitor the study to meet the sponsor’s monitoring Standard Operating 
Procedures (SOPs), ICH-GCP guideline, and applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are adequate. Monitoring of the study may be delegated by UCB to a contract research  organization (CRO) or a contract monitor.
The investigator and his/her staff are expected to  cooperate with UCB (or designee) and to be 
available during the monitoring visits to an swer questions sufficiently and to provide any 
missing information. The investigator(s)/instit ution(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).
The investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospital and laboratory records for each study participant). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authority(ies) regulations, and investigator’s obligations are being fulfilled, and resolve any inconsistencies in the study records.
12.2.1 Definition of source data
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some perman ent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments REDACTED ifi
ure, thure, t
4 hours hour
ttCOPYby thby t
healthhea
icaticati
This documentof thf th
reqreq
fcannotstiti
pondiondi
nitorinnitorin
hehbe igatoigatousedfor sfor ston. Tn. T
stustusupporther staer sta
monitorionitor
The Theanyct resect resmarketing udy udy to to
deline, aline,
closuclosauthorization th a
ion ofon of
he invhe inv
rs and s and application ver, thever, th
protocproto
and andandRATATanynducdu
ATIOTIextensionsdiatriiatr
ted ined in
ucteucteochedchevariations hs hs 
dudthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 73 of 144(such as removable self-stick notes). Photocopies  and/or printouts of eCRFs are not considered 
acceptable source documents. 
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other pr intouts, completed scales, or quality of life 
questionnaires, for example. Source documents shoul d be kept in a secure, limited access area.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once prin ted, these copies should be signed and dated 
by the investigator and become a permanent part of the subject’s source documents. The 
investigator will facilitate the process for enabling the monitor to compare the content of the printout and the data stored in the computer to ensure all data are consistent.
Electronic data records, such as Holter monitor re cords or electroencephalogram records, must 
be saved and stored as instructed by UCB (or designee).
12.2.2 Source data verification
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to  being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], x-ray films, laboratory notes). All data reported on the eCRF should be supported by source documents, unless otherwise specified in Section 12.2.1 .
12.3 Data handling
12.3.1 Case Report form completion
This study is performed using remote data capture (RDC). The investigator is responsible for 
prompt reporting of accurate, complete, and legi ble data in the eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the investigator’s review and approv al (by means of a 
password/electronic signature) will be reapproved by the investigator.
The investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF.
Detailed instructions will be provided in the eCRF Completion Guidelines.
12.3.2 Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system  (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to ch eck for discrepancies and to ensure consistency of 
the data. Case Report form data are entered into the clinical database using independent, 
double-data entry, with the exception of comment fi elds, which are verified by a second person.
In the event that the study is performed using RDC, the data are entered into the eCRFs once and 
are subsequently verified.REDACTED ionion
compcomp
edeCOPYm autom aut
on the n the
1212
This documentasas
databdatab
wwcannot e Ree Rebenstrunstruused shoho
toouldoulsupport he invee inv
ignaturgnatu
dany eCeCmarketing p
data capata ca
lete, anete, a
CRFCRFauthorizationeCReCR
2.2.12.1
etioetioapplication data odata 
ate, comate, co
mated mated
RFRFand anyogragrextensions The The 
ntent otent o
ramamond dnd dvariations or r 
dadthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 74 of 144An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. Regular backups of the electronic data will be performed.
12.3.3 Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Sub ject Screening and Enrollment 
Log.
The investigator will keep a Subject Identifica tion Code list. This list remains with the 
investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the stud y must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
12.4 Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or in complete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
investigators/institutions and the regulatory aut hority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the termination or suspension by the sponsor or by th e investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, ar rangements will be made for the return of all 
unused study medication and other material in accordance with UCB procedures for the study.
12.5 Archiving and data retention
The investigator will maintain adequate records for the study, including eCRFs, medical records, laboratory results, Informed Consent documents, drug  dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained by the investigator until at least 2 years after the last 
approval of a marketing application in an IC H region and until there are no pending or 
contemplated marketing applications in an ICH re gion, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the investigational product. These documents 
should be retained for a longer period, however, if required by the applicable regulatory 
requirement(s) or by an agreement with UCB (Committee for Proprietary Medicinal Products 
[CPMP]/ICH/135/95, 2002 [Section 4.9.5]). The investigator will contact UCB for authorization prior to the destruction of any study records or in the event of accidental loss or destruction of 
any study records. The investigator will also notify UCB should he/she relocate or move the 
study- related files to a location other than that sp ecified in the sponsor’s trial master file.
12.6 Audit and inspection
The investigator will permit study-related audits  mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.REDACTEDthortho
ion, inion, in
o be inbe in
nsor ornsor o
). In ). In COPY uanua
ed, UCed, U
orityorit
This documentCPMCPM
prioprio
acannotbe rebe re
uiremeirem
MPMbeconticontusedmarketrke
markmarktomentment
tisupported Cod Co
gardinardi
ts aany n adeqadeqmarketingadditaddit
materialateria
datadataauthorizationCB CB 
ty(ies)y(ies)
n accoacco
nformnform
by thby thapplicationncludincludi
ng, nong, no
y.y.
B (or(orand ntinutinuany extensions ’s meds med
ect’s ect’s or variations nt thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 75 of 144The main purposes of an audit or inspection are to confirm that the rights and well-being of the 
subjects enrolled have been protected, that enroll ed subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority  is announced, the investigator will immediately 
inform UCB (or designee).
12.7 Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
investigator, institution, institution staff, or de signees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompl iance may result in the termination of the
site’s involvement in the study.
13 STATISTICS
A description of statistical methods is presented be low and will be described in more detail in the 
Statistical Analysis Plan (SAP).
13.1 Definition of analysis sets
The Safety Set (SS) will include all randomized subjects who took at least 1 dose of study medication. This is the primary analysis set for the safety variables.
The primary analysis set for the efficacy data w ill be the Full Analysis Set (FAS), which will 
include all subjects in the SS.
The secondary analysis set for the efficacy da ta will be the Per-Protocol Set (PPS), which 
includes all subjects in the FAS who did not have important protocol deviations related to efficacy.
The Pharmacokinetic Per-Protocol Set (PK-PPS) will consist of all subjects having provided at 
least 1 measurable postdose plasma sample (with re corded sampling time) on at least 1 visit with 
documented study medication intake times.
13.1.1 Analysis of the primary efficacy variable
Analyses of the primary efficacy variables are based on the ADF of electrographic partial-onset 
seizures. 
Partial-onset seizure count will be based on el ectrographic seizures. Electrographic seizures are 
defined as recognizable ictal patterns on an EEG involving ≥2 contiguous electrodes. The 
seizures are initiated as a unilateral or strongl y asymmetric abnormal epileptiform discharge 
lasting a total of >10 seconds. The video-EEG rec ordings will be evaluated for seizure counts 
locally by the investigator, subinvestigator, or qualified designated reader. Subjects whodiscontinue on or before Day 20 will not require a video-EEG.ss
mized mized 
s set fo set fo
cacy dcacy dCOPY w a
This documentdefindefin
seiseicannot s. . 
tialial--obeof theof thused yy
AnaAnatomedmedsuppor--ort ProtPro
stdosestdos
dicianywhwhmarketing data data
 efficaeffica
ho dhoauthorization subjesubje
or the r the 
awwapplication will bewill band  thtanyead ad
he terhe terextensions ts by ts by t
dt otoor iatavariations ce e 
atelytelythereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 76 of 144Partial- onset seizure frequency for infants aged ≥1 month to ≤6 months will be based on 
electrographic seizures. Partial-onset seizure frequency for children aged >6 months to <4 years will be based on electrographic seizures with an accompanying clinical correlate.
Calculation of the Baseline Period ADF of electrographic partial-onset seizures and the 
Maintenance Period ADF of electrographic partial-ons et seizures will be based on results from a
video-EEG (up to 72 hours of continuous recording with every attempt to obtain at least 48 hours 
of interpretable recording) during each period. Subjec ts are expected to have at least 48 hours of 
interpretable video-EEG during each period. For subjects who drop out during the 
End-of-Maintenance Period video-EEG, the number of hours from the start of the 
End-of-Maintenance Period video-EEG to the time of withdrawal (in hours) will be considered for analysis. 
The ADF of electrographic partial-onset seizures w ill be calculated as (number of partial-onset 
seizures recorded on the video-EEG divided by the number of interpretable hours recorded) multiplied by 24.
13.1.1.1 Analysis of the primary efficacy variable for the US
Contingent upon ≤10% of subjects discon tinuing early from the study, the primary efficacy 
parameter for the US is the change in ADF of electrographic partial-onset seizures during the Maintenance Period compared to the end of the Baseline Period. Seizure ADF will be analyzed 
using analysis of covariance with terms for treatment, age category (4 age stratification 
categories, pooled as appropriate), and center (pro perly pooled), on log-transformed seizure ADF 
using the transformation of ln (X+1), where X is the seizure ADF. Log-transformed Baseline 
seizure ADF will be used as a covariate. The seizure ADF between LCM and PBO will be 
compared using least squares means (LSMs). The percent reduction over PBO will be estimated 
as 100 x (1 –exp [LSM Treatment {TRT} - LSMPBO]). The analysis of this efficacy variable 
will consist of all subjects in the FAS who have  at least 48 hours of interpretable recordings 
during both the End-of-Baseline Period video-EEG and the End-of-Maintenance Period video-EEG.
The following additional sensitivity analyses on this primary efficacy variable will be conducted 
in order to assess the effect of early discontinuati ons, protocol deviations, and operational bias on 
this primary endpoint:
x Repeat the primary analysis using the PPS.
x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video-EEG  will be replaced using the Baseline 
observation-carried-forward approach. This will be applied for all subjects who discontinued 
early from the study.
x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video-EEG will be replaced by the overall mean ADF 
of partial-onset seizures from the End-of-Maintenance Period video- EEG from the subject’s 
respective treatment arm. This will be applied for all subjects who discontinued early from the study.REDACTEDtm
r (pror (pro
ere X ire X i
e. Thee. The
(LSM(LSM
TRTRCOPYgrapgra
aselineseline
mentment
This document xxcannotm thethe
bservserv
earlearlbethe the 
eEeEusedprimaprima
prto int:nt:supportsensitsensit
effect offect any marketing Ms). Ms).
RT} RT} -
AS whoS wh
Perioderioauthorizatione P
, age , age 
operly perly
is the is the
e seizuseiz
TTapplicationor thr th
he studhe stu
hic partc par
PerioPerioand heheanyle hole hoextensions e conse cons
ber ofer ofor variations urs urs 
urs of rs of thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 77 of 144x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video-EEG will be replaced using multiple imputation 
by treatment arm and age group ( ≥1 month to <6 months of age, ≥6 months to <1 year of age, 
≥1 year to <2 years of age, and ≥2 years to <4 years of age) using monotone regression. This 
will be applied for all subjects who discontinued early from the study.
x Repeat the primary analysis using the FAS for all subjects who have at least 24 hours of 
interpretable recordings during both the End-of-Baseline Period video-EEG and the End-of-Maintenance Period video-EEG.
Contingent upon >10% of subjects discontinuing early from the study, the primary efficacy 
parameter for the US is identical to the primary ef ficacy parameter for the EU, described below. 
The endpoint not designated as primary will still be summarized as a secondary efficacy 
parameter.
13.1.1.2 Analysis of the primary efficacy variable for the EU
The primary efficacy parameter for the EU is the proportion of responders during the 
Maintenance Period. Subjects with a 50% or more reduction in seizure ADF will be categorized 
as responders; this classification requires at least 48 hours of interpretable recordings during both 
the End-of-Baseline Period video-EEG and the End-of-Maintenance Period video-EEG. The 
proportion of responders between LCM and PBO will be analyzed using logistic regression with 
age category (4 age stratification categories, pool ed as appropriate) and center (properly pooled) 
as factors. Subjects who withdraw or drop out before the first 48 hours of the End-of-Maintenance Period video-EEG with reasons related  to lack of efficacy will be considered non 
responders; all other subjects will be missing for this analysis. The number and percentage of 
subjects with a 50% or more reduction in seizure ADF will be presented by treatment group. 
The following additional sensitivity analyses on this primary efficacy variable will be conducted 
in order to assess the effect of early discontinuati ons, protocol deviations, and operational bias on 
this primary endpoint:
x Repeat the primary analysis using the PPS.
x Repeat the primary analysis using the FAS, ex cept subjects who discontinued from the study 
prior to performance of the End-of-Maintenan ce Period video-EEG with reasons related to 
lack of efficacy will be considered non responders, and subjects who discontinued from the study early for any other reason will be considered responders.
x Repeat the primary analysis using the FAS, except all subjects who discontinued from the 
study early will be considered non responders.
x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video-EEG will be replaced using multiple imputation 
by treatment arm and age group ( ≥1 month to <6 months of age, ≥6 months to <1 year of age, 
≥1 year to <2 years of age, and ≥2 years to <4 years of age) using mon otone regression. This 
will be applied for all subjects who discontinued from the study early, and the imputed End-of-Maintenance Period ADF of partial-onset seiz ures will be used to determine whether a 
subject is a responder.REDACTED ool
ut befut bef
sons resons r
missingmissin
on inon inCOPY ofof--fM
will bwill 
led aed a
This document ffcannot at at 
udy eady ea
RepRepbe the the usedacy wcy w
y for y for tomancman
wiwsupportalysislysi
y analyanal
nce oceany sumarketingn seizn seiz
analyseanalys
ly discy disauthorization be a
as apps app
fore thore th
relatedelated
g for tg for applicationpo
seizureeizur
interprinterp
intenanten
analanaand  EE
onderndeany EUEUextensionsefficafica
escribescribe
ry effiy effior variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 78 of 144x Repeat the primary analysis using the FAS for all subjects who have at least 24 hours of 
interpretable recordings during both the end of  Baseline Period video-EEG and the end of 
Maintenance Period video-EEG.
13.1.2 Analysis of secondary efficacy variables
The percent change in ADF of electrographic partial-onset seizures is calculated as the seizure 
ADF during the End-of-Maintenance Period video-EEG minus the seizure ADF during the End-of-Baseline Period video-EEG divided by the seizure ADF at Baseline and then multiplied 
by 100. Descriptive statistics for ADF of electrographic partial-onset seizures and its absolute 
and percentage change from Baseline w ill be summarized by treatment group.
For subjects who complete the Maintenance Period, the number and percentage of subjects who 
achie ved “seizure -free” status from all seizure types, and from partial -onset seizure types only 
during the Maintenance Period will be ta bulated and presented by treatment group.
The number and percentage of subjects experiencing a ≥25% to <50%, 50 to 75%, or > 75% 
reduction in ADF of partial-onset seizures will also be presented by treatment group, as will the 
number and percentage experiencing no change, and the number and percentage experiencing an increase ≥25%.
13.1.3 Other efficacy analyses
The number and percentage of subjects with each Clinical Global Impression of Change, 
Caregiver’s Global Impression of  Change, and the PedsQL heal th summary score will be 
summarized by treatment group.
Descriptive statistics will be presented by tr eatment group for the number of medical resources 
used during the study, healthcare provider consul tations not related to study, procedures, hospital 
stays, and length of hospital stays.
13.2 Planned safety and other analyses
Descriptive statistics will be used to provide an overview of the safety and PK results.
13.2.1 Safety analyses
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®) and tabulated by system organ class (SOC) and preferred term (PT). 
Treatment-emergent AEs will be defined as those events that start on or after the date of first 
study medication administration and within 30 days following the date of final study medication 
administration, or whose severity worsens within  this time frame. The incidence of TEAEs will 
be presented by SOC and PT. Serious AEs a nd TEAEs leading to withdrawal will also be 
tabulated and listed.
Other variables assessing safety are ECG, measurements of laboratory parameters (hematology 
and clinical chemistry) and vital signs (body weight, height and BMI), and physical and neurological examination findings.
Measurement and change from Baseline in vital signs (BP and pulse rate), body weight, 
laboratory parameters (hematology and clinical chemistry), and 12-lead ECG measurements will 
be summarized using descriptive statistics. Wh en analyzing categorical data, the number and nd thend th
d by trd by t
ovideovideCOPY h Clinh Cli
This document OtheOth
anancannot ratiati
esentesente
ulatedlatebecatioati
tiontionused tabta
ergentrgent
ioniontob
abulbulsupport nalysnaly
e code codany used tosed tmarketingder coner co
y andandauthorizationinical nical
e PedsPeds
eatmeatmapplicationy
r and pr and 
Gand%, 5050
treatreatanynt grt g
0 to0t oextensions of subf sub
eizureizure
grogroorsoluoluvariations plied plied
utethereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 79 of 144percentage of subjects in each category will be presented by treatment group. In addition, shift 
tables may be used to evaluate the number and percentage of subjects having a different postbaseline status when compared to their baseline status.
Laboratory, ECG, and vital signs data outside of th e respective reference ranges will be listed 
and highlighted.
Baseline assessment of the Bayley-III sca les, Achenbach CBCL, and BRIEF-P will be 
performed; however, due to the short study duration of SP0967, the next assessment will be collected in subjects entering into the EP0034 study  and analysis of these data will be conducted 
in EP0034.
13.2.2 Pharmacokinetics and pharmacodynamics
13.2.2.1 Descriptive statistics of LCM and AED plasma concentrations
The results of LCM plasma concentrations will be summarized using descriptive statistics: 
arithmetic mean, standard deviation, median, rang e, geometric mean, and geometric coefficient 
of variation.
13.2.2.2 Population pharmacokinetics
A population exposure-response model (PK/pharmacodynamics) between LCM plasma 
concentration and seizure counts will be de veloped using NONMEM. The methods will be 
described in the DAP (Data Analysis Plan) and th e results will be reported in a modeling report. 
13.3 Handling of protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on either primary efficacy outcome or key safety outcomes for an individual 
subject. The criteria for identifying important prot ocol deviations and the classification of 
important protocol deviations will be defined within the project Data Cleaning Plan. To the 
extent feasible the rules for identifying protocol de viations will be defined without review of the 
data and without consideration of the frequency of occurrence of such deviations. Whenever 
possible, criteria for identifying important protocol deviations will be implemented 
algorithmically to ensure consistency in the classification of important protocol deviations across 
all subjects.
Important protocol deviations will be reviewed as part of the blinded data cleaning meetings 
prior to database lock to confirm exclusion from analysis sets.
13.4 Handling of dropouts or missing data
Subjects who prematurely discontinue the study will be evaluated based on the data collected at each visit attended.
As described in Section 13.1.1 , subjects are expected to have at least 48 hours of interpretable 
video-EEG during each period. For subjects who drop out during the End-of-Maintenance Period 
video-EEG, the number of hours from the start of the End-of-Maintenance Period video-EEG to the time of withdrawal (in hours) will be considered  for analysis. Subjects who discontinue prior 
to the End-of-Maintenance Period video-EEG will not  be included in the analyses (ie, data will 
not be carried forward from the End-of-Baseline Period video-EEG).d thd th
deviadevia
iationsiations
y effiy effiCOPYcodycody
ed usined usi
he rhe r
This document achch
As Ascannot ects wects w
h vihv ibe usedcol dol d
ase loase loto ddsupportifyingfying
re cone conany tifytif
n of thn of t
gmarketingicacyicacy
mportanmporta
be defibe de
fyingfyinauthorizationng Ng N
resultsesults
ationation
s fromfromapplication namics)amics
NONOand and and any cripticript
geextensions entrantraoondundvariations be 
ucthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 80 of 144The impact of missing data on the assessment of primary efficacy will be evaluated with 
sensitivity analyses with further details to be included in the SAP. 
No imputation of missing values associated with an individual date or visit is planned for the 
primary safety analysis, with the exception of partial date information for  AEs and concomitant 
medications in order to determine whether they are treatment emergent. 
13.5 Planned interim analysis and data monitoring
No formal interim analysis for determination of efficacy is planned for this study. To ensure 
subject safety, interim reviews of safety data will be performed using an Independent Data 
Monitoring Committee (IDMC). Serious adverse events and other significant events are 
monitored and will be triaged by  the Medical Monitor and UCB Patient Safety in real time. After 
this triage, events will be passed on to the IDMC  as appropriate. In addi tion, 3 interim reviews of 
safety data by the IDMC are planned when 25%, 50%, and 75% of subjects have been 
randomized and at study completion. The objecti ve, procedures, and timing of IDMC safety 
assessments to evaluate risk and benefit for s ubjects in SP0967 will be described in an IDMC 
Charter.
A blinded sample size re-estimation will be performed when 50% of subjects have been 
randomized, completed the study, and have data av ailable for analysis to check the validity of 
these assumptions using interim data from the study. The sample size re-estimation with equal 
allocation in each arm will be performed us ing the related residual variance combined with
Guenther adjustment (Friede and Kieser, 2011). An assessment of the observed dropout rate will 
also be made as part of this analysis, and the potential dropout rate of 14% used for calculation 
of the initial sample size (see Section 13.6) will be modified based on the observed rate. 
Additionally, an assessment of the observed di fference of End-of-Baseline Period video-EEG 
interpretation rate will be made; the anticip ated rate of 5% will be modified based on the 
observed rate (see Section 13.6).
The final sample size will be modified accordi ng to the sample size re-estimate and also the 
anticipated dropout rate and anticipated rate of difference of interpretation of the End-of-
Baseline Period video-EEG; however, an upper bound will be applied to reach a maximum 
sample size based on practical and logistical cons iderations. The initial sample size re-estimate 
using Guenther adjustment will not be adju sted above 109 subjects per treatment arm, the 
original estimated overall study drop-out rate will not  be adjusted above 24%, and the difference 
of End-of-Baseline Period video-EEG interpret ation rate will not be adjusted above 10%.
13.6 Determination of sample size
Assuming an effect size of 0.402, in which the effe ct size was calculated using a PBO-subtracted 
difference of -0.249 and a common standard dev iation of 0.62 on the log-transformed data, the 
difference of -0.249 on the log-transformed data is  equivalent to approximately 22% reduction 
over PBO after exponentiation. With this effect si ze, power of 80%, and a 2-sided test at the 
5% level of significance, a sample of 99 subject s in each treatment arm will be needed.
Assuming a responder rate of 20% and 40% for the PBO and LCM groups, respectively, a 
2-sided continuity corrected Chi-square test at a significance level of 5% will provide 
approximately 83% power with 99 subjects in the PBO group and 99 subjects in the LCM group.REDACTED th
11). A11). A
the pothe p
3.63.6))
bservbservCOPYlabllab
dy. Thy. T
he ree re
This document ffff
diffediffe
ovovcannot uming ming
ferenerenbe useded ovd ov
selineelinetoustmustm
vesupport d ana
EG; hoG; ho
practicractic
menmeanyodifodi
nticipnticipmarketingved ded d
nticipaticip
fiefieauthorization he 
elated lated 
An assn ass
otentiaotenti
will bwill b
didiapplication 50% o50% o
for anafor an
samsamandmim
be debe deanys has h
ng ofng oextensions DaDa
ts are s are 
n realn real
3 inte3 inte
havavor urur
ata atavariations re rethereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 81 of 144Subjects are randomized into the study based on the initial interpretation of the video-EEG to 
meet study entry requirements. However, the subsequent detailed assessment of seizure types 
and counts needed for the efficacy analyses could lead to a discrepancy in seizure counts (ie, a 
subject initially thought to be eligible is later found to have fewer than the required number of partial-onset seizures during the End-of-Basel ine Period video-EEG). To account for an 
anticipated difference of interpretation of the End- of-Baseline Period video-EEG of 5% as well 
as the potential subject dropout rate of approxim ately 14%, the planned number of subjects to 
enroll is 122 subjects per treatment arm.
A blinded sample size re-estimation will be performed when 50% of subjects have been 
randomized, completed the study, and have data av ailable for analysis to check the validity of 
these assumptions as described in Section 13.5.
14 ETHICS AND REGULATORY REQUIREMENTS
14.1 Informed consent
Informed consent must be obtained and documented in accordance with local regulations, 
ICH-GCP requirements, and the ethical principles th at have their origin in the principles of the 
Declaration of Helsinki.
Prior to obtaining informed consent, information s hould be given in a language and at a level of 
complexity understandable to the subject ’s legal representative(s) in both oral and written form 
by the investigator (or designee). Subject’s legal representative(s) will have the opportunity to 
discuss the study and its alternatives with the investigator.
Prior to participation in the study, the Informed Consent form should be signed and personally 
dated by the subject’s legal representative(s), and by the person who conducted the informed 
consent discussion (investigator or designee). The s ubject’s legal representative(s) must receive a 
copy of the signed and dated Informed Consent form. As part of the consent process, each 
subject’s legal representative(s) must consent to direct access to the subject’s medical records for 
study-related monitoring, auditing, IRB/IEC review, and regulatory inspection.
If the Informed Consent form is amended during the study, the investigator (or the sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent form by the IRB/IEC and use of the amended form.
All studies conducted at centers in the US must in clude the use of a Health Insurance Portability 
and Accountability Act Authorization form.
The subject’s legal representative(s) may withdraw his/her consent to participate in the study at 
any time. A subject is considered as enrolled in the study when his/her legal representative(s) has 
signed the Informed Consent form. An eCRF must  not be started, nor may any study specific 
procedure be performed for a given subject, without having obtained written consent from his/her legal representative(s) in order to participate in the study.
14.2 Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), the subject or legal 
representative(s) will be provided with a subject identification card in the language of the 
subject. The investigator will fill in the subj ect identifying information and medical emergency REDACTEDgal rgal r
the invhe inv
InformInform
ntativetativeCOPYhould hould
reprerepre
This document gngn
proceproc
hihiannojectect
ime. Ame. A
ned ted tbe tab
’s’susednducteducte
bilitbilittoConCosupport form iorm i
w all aw all 
onseonsany mm
iting, ting,marketinge(s), e(s),
signee)igne
med Coed C
must cust authorizationesentaesent
epresenpresen
vestigestig
med Cmed C
aapplication e w
ir origir orig
be givee giv
atiand with with any extensions en n 
 validvalid
SSor variations o  thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 82 of 144contact information. The investigator will instruct the subject’s parent(s)/legal 
representative(s)/caregiver(s) to keep the card with him/her at all times.
14.3 Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical princ iples that have their origin in the Declaration 
of Helsinki.
The investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or  applicable country-specific regulations will 
be responsible for the initial and continuing review  and approval of the clinical study. Prior to 
initiation of the study, the investigator/UCB will forward copies of the protocol, Informed 
Consent form, Investigator’s Brochure, investigator’s curriculum vitae (if ap plicable), 
advertisement (if applicab le), and all other subject-related documents to be used for the study to 
the IRB/IEC for its review and approval.
Before initiating a study, the investigator w ill have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate appa rent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the investigator to obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC requirements for continui ng review of approved studies, the investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropri ate to the degree of subject risk involved, but no less than 
once per year. The investigator should provide a final report to the IRB/IEC following study completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the investigator or the sponsor, as specified by 
the applicable regulatory requirements in e ach concerned country. Where applicable, 
investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC notification.
14.4 Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.REDACTED es in ts in t
iminaimina
oved poved pCOPYB/IECB/IE
n subjesubje
This documentnotifotif
1414cannotopop
plicablicab
estigastiga
ficfibe and
priatpriatsedpresenresen
d alld allto supportmitit
s appr appr
vestigatestigaanymenmen
ting tingmarketing protoroto
vestigavestig
ntsntsauthorizationects ects 
the stuthe st
ate appte ap
ococapplicationdated fdated 
C all chall c
orand o bo bany apapplp
be usbe usextensions plielie
gulatigulati
study.tudy
col, Inol, In
plicplior es wes wvariations ion on thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 83 of 144The investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities  will be allowed to review that portion of the 
subject’s primary medical records that directly co ncerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
14.5 Protocol amendments
Protocol changes may affect the legal and ethi cal status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.
15 FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled  according to local requirements.
Finance, insurance, and publication rights are addressed in the investigator and/or CRO 
agreements, as applicable.
REDACTED COPYsed sed
This document cannot be used to support any marketing authorization application A
ments.ents
n the inthe iand ATIOTIOanyred)redextensions mary ary 
e protoprot
d) pd) porthethevariations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 84 of 14416 REFERENCES
Aicardi J. Syndromic classification in the management of childhood epilepsy. J Child Neurol. 
1994;9(Suppl 2):14-18.
Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, et al. Gabapentin as 
add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study: Gabapentin Ped iatric Study Group. Epilepsia. 1999;40:1147-54.
Bayley N. Bayley Scales of Infant and Toddler Development. 3rd ed. San Antonio: Pearson 
Education Inc; 2006.
Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio: The Psychological 
Corporation; 1993.
Bourgeois BF, Goodkin HP. Efficacy of antiepileptic drugs in adults vs children: does one size 
fit all? Neurology. 2012;79;1420-1.
CHMP/EWP/566/98 Guideline on clinical investigation of medicinal products in the treatment of 
epileptic disorders (EMA) Rev 2, 20 Jan 2010.
Clinical Global Impression of Change, the Caregi ver Global Impression of Change, quality of 
life assessments (Pediatric Quality of Life Inventory [PedsQL™] ).
http://www.pedsql.org/PedsQL-CostStructure.pdf and http://plaza.umin.ac.jp/qol-research/. 
Accessed on 10 July 2014. 
Cognitive function assessments (Behavior Rating Inventory of Executive Function
®
[BRIEF®]/BRIEF®Preschool Version [BRIEF®P].
http://www4.parinc.com/ Products/PermsLicensing.aspx?id=6 and 
http://www4.parinc.com/produ cts/PermsLicensing.aspx?id=8. Accessed 10 July 2014. 
Commission on Classification and Terminology of the International League Against Epilepsy. 
Proposal for revised classification of epilep sies and epileptic syndromes. Epilepsia. 
1989;30:389-99.
CPMP/ICH/135/95 Note for guidance on G ood Clinical Practice (EMEA) Jul 2002.
Dichek B. Epilepsy: an ancient ailment that still eludes a cure. Scrip Magazine. 1999;Feb:9-11.
Duchowny M, Pellock JM, Graf WD, Billard C, Gilm an J, Casale E, et al. A placebo-controlled 
trial of lamotrigine add-on therapy for partial s eizures in children: Lamictal Pediatric Partial 
Seizure Study Group. Neurology. 1999;53:1724-31.
Elterman RD, Glauser TA, Wylie E, Reife R, Wu SC, Pledger G. A double-blind, randomized 
trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology. 1999;52:1338-44.
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Huma n Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
Friede T, Kieser M. Blinded sa mple size recalculation for clinic al trials with normal data and 
baseline adjusted analysis. Pharm Stat. 2011;10:8-13.REDACTED r RatinRatin
[BRIE[BRIE
PermsLPermsL
rmrmCOPYy [Pedy [Pe
f and f and 
This documentStudStud
FoFcannot man Ran R
l of toof tobeudy Gudy usedPelloello
igineigine
Gto a
ckksupport e for gufor g
an ancn ancanyon oon marketingLiceLice
msLicemsLice
d TermiTerm
of eofauthorizationhttphttp
ng Invng Inv
EFF®®PP
cenenapplication l ImpreImpr
dsQL™sQL™
p://pp://pand l proproanyldrldrextensions hologiologi
drenrenor onovariations d, ,
nnthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 85 of 144Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. on behalf of 
the N159b Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66:1654-60.
Glauser TA, Nigro M, Sachdeo R, Pasteris LA, We instein S, Abou-Khalil B, et al. Adjunctive 
therapy with oxcarbazepine in children with par tial seizures: the Oxcarbazepine Pediatric Study 
Group. Neurology. 2000;54:2237-44.
Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother. 
2007;7:179-193.
Herman ST, Pedley TA. New options for the treatment of epilepsy. JAMA. 1998;280:693-4.
Institute of Medicine. Epilepsy across the spectrum: promoting health and understanding. 
Washington, DC: The National Academies Press; 2012.
Pellock JM, Carman WJ, Thyagarajan V, Daniels T, Morris DL, D’Cruz O. Efficacy of 
antiepileptic drugs in adults predicts efficacy  in children: A systematic review. Neurology. 
2012;79;1482-9.
Perucca E. Established antiepileptic drugs. Baillieres Clin Neurol. 1996;5:693-722.
Rheims S, Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset 
seizures. Neuropsychiatr Dis Treat. 2013;9:629-37.
Sander JW. New drugs for epilepsy. Curr Opin Neurol. 1998;11:141-8.
Sattler JM, Hoge RD. Assessment of children: be havioral, social, and clinical foundations. 5th 
ed. La Mesa: Jerome M Sattler; 2006.
Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J 
Am Soc Nephrol. 2009;4:1832-43.
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliabil ity and validity of the Pediatric Quality of Life 
version 4.0 generic core scales in healthy and patient populations. Med Care. 2001; 39:800-12REDACTEDin Nein N
ldren: dren:
ent aent aCOPYotentoten
7..
This document cannot be used to support anys in hes in hmarketing and estnd es
dsQLdsQLauthorization urol. urol. 
behavbehaapplication urol. 19rol. 1
al in l in thtandic revc revany O. EfO. E
vieextensions 80:6980:69
erstanderstanor variations othertherthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 86of 14417 APPENDICES
17.1 AMENDMENT 1
Rationale for the amendment
The primary purposes of this amendment are to implement the contingent primary efficacy 
variable for the US, include sensitivity analyses for the primary endpoint, to clarify the 
enrollment of subjects <2 years of age, and to provide additional detail regarding the sample size 
re-estimation a t the request of FDA.
Modifications and changes 
Global changes
The fol lowing changes were made throughout the protocol:
x Contact details for the Clinical Project Manager have been updated
x The Sponsor Declaration has been updated for electronic signature
x The language of the percentage of subjects <2years of age to be included in the study has 
been clarified 
x The contingent primary efficacy vari able for the US has been defined
x The anticipated SAE table has been updated to include a footnote for convulsion
x Text for adherence to th e protocol has been updated
x Text for healthcare resource use has been updated
x Rescue medication assessment has been added
x Analysis of the primary efficacy variable for the US and EU has been updated 
x The sensitivity analysis has been described
x Sample size re -estimation text has been further detailed
Specific changes
Change #1
SPONSOR DECLARATION
The Clinical Project Manager has changed.
Clinical Project Manager
_____________________________
Date/SignatureREDACTEDated toated t
as beens bee
has bhas bCOPY the USthe U
This document CliClicannotSORSOR
e ClinClinbe #1
RRusedangangto support ation ttionany as bees beemarketingbeen en
s beens bee
cy varcy vaauthorizationS haS ha
o incluo inclu
en updn upd
nunuapplicationaturetur
e to be e to be
as bas band d
rereany extensions or variations le sizee sizethereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 87of 144Clinical Trial Biostatistician
, MA _____________________________
Date/Signature
Study Physician
, MD _____________________________
Date/Signature
Clinical Program Director
, BS _____________________________
Date/Signature
Has been revised and moved to Section 19 : 
19 SPONSOR DECLARATION
Iconfirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
Change #2
STUDY CONTACT INFORMATION
The Clinical Project Manager contact details have been updated.
Name:
Address: UCB BIOSCIENCES Inc. 
8010 Arco Corporate Drive 
Raleigh, NC 27617 UNITED STATES
Phone:
Fax:REDACTED hav
ED
IENCIEN
CorCorACACTCOPY ve bve b
This document cannot be used to suppopport rtt
pporany yanymarketingrporatrporat
C 2761C 276
D STAD STauthorization been upeen up
za
CES InES Ithoapplicationt Goot Goand agreeagreeany extensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 88of 144Has been changed to : 
Name:
Address: UCB BIOSCIENCES GmbH 
Alfred -Nobel-Straße 10 
40789 Monheim 
GERMANY
Phone:
Fax:
Change #3
Section 1 SUMMARY
Reference to the Food and Drug Administration has been clarified that it is for the US and the 
contingent primary efficacy variable has been defined, 5thparagraph.
Based on Food and Drug Administration (FDA ) and European Medicines Agency (EMA) 
requirements, 2 (co -) primary efficacy variables have be en defined for this study based on 
electrographic partial -onset seizures with or without clinical correlate depending upon subject 
age. The primary efficacy variable will be the change in average daily frequency (ADF) of 
electrographic partial -onset seizures (US) or proportion of subjects experiencing ≥50% reduction 
in their ADF of electrographic partial -onset seizures (EU) as measured on the 72 -hour
end-of-Maintenance Period video -electroencephalogram (EEG) compared to the 72 -hour
end-of-Baseline Period video -EEG. Partial -onset seizures will be counted b y a central reader 
evaluating the characteristic ictal patterns of electrographic seizures. 
Has been changed to : 
Based on US Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
requirements, 2 (co -) primary efficacy variables have been defined for this study based on 
electrographic partial -onset seizures with or without clinical correlate depending upon subject 
age. The primary efficacy variable will be the change in average daily frequency (ADF) of 
electrographic partial -onset seizures (US) or proportion of subjects experiencing ≥50% reduction 
in their ADF of electrographic partial -onset seizures (EU) as measured on the 72 -hour
End-of-Maintenance Period video -electroencephalogram (EEG) compared to the 72 -hour
End-of-Baseline Period video -EEG. Partial -onset seizures will be counted by a central reader 
evaluating the characteristic ictal patterns of electrographic seizures. At the request of FDA, a 
contingent primary efficacy variable has also been defined based on the percentage of subject s
who discontinue early from the study prior to completing the End -of-Maintenance Period 
video -EEG. Contingent upon >10% of subjects discontinuing early from the study, the primary 
efficacy parameter for the US will become identical to the primary efficacy parameter for the 
EU. The endpoint not designated as primary will still be summarized as a secondary efficacy 
parameter. 
Change #4
Section 4.1.1 Primary efficacy variableREDACTEDha
propoprop
et seizet seiz
troenctroenc
PartiaPartia
ttCOPYbeebe
ut clinut clin
angeange
This documenwho who 
videvidcannota
ting thing t
tingeningen
ddbent
selinselinusedf electelec
enanenantoialal--oosupportary ery e
nset seiset se
cacy vacy v
onanyAdmiAdm
effieffmarketing al--ono
erns of ns of authorizationnic
e in avin av
ortionortion
zures zures 
cephalephal
onsnsapplicationaph.ph
n Medin Med
definedefin
cal cocal coandhat it at it 
hhany iextensions ns
nsor rvariations vvthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 89 of 144The contingent primary effica cy variable has been defined. 
For the US: 
The primary efficacy variable will be the change in ADF of electrographic partial-onset seizures 
as measured on the 72-hour end-of-Maintenan ce Period video-EEG compared to the 72-hour
end-of-Baseline Period video-EEG. 
Has been changed to:
For the US, the primary efficacy variable will be contingent on the percentage of subjects that 
discontinue from the study after the first dose of study medication but prior to performance of the 72-hour End-of-Maintenance Period vide o-EEG (ie, early discontinuation).
The fol lowing variable will be considered primary for the US given that ≤10% of subjects 
discontinue early from the study:
x The change in ADF of electrographic partial-onset seizures as measured on the 72-hour
End-of-Maintenance Period video-EEG compar ed to the 72-hour End-of-Baseline Period 
video-EEG. 
If >10% of subjects discontinue early from the study, the following contingency endpoint will be 
considered primary for the US (same as the primary efficacy variable for the EU):
The proportion of responders where a responder is  a subject experiencing a 50% or greater 
reduction in their ADF of electrographic partial-onset seizures recorded on the 72-hour
End-of-Maintenance Period video-EEG compared  to the 72-hour end of Baseline Period 
video-EEG.
Change #5
Section 5.1.2 Planned number of subjects and sites
The language of the percentage of subjects <2 years of age to be included in the study has been 
clarified, 1
stand 2ndparagraphs.
A total of approximately 244 subjects (122 subjects  per treatment arm) are planned to be 
randomized.
Subjects will be enrolled in the following age categories as detailed below:
x ≥1 month to <6 months of age ( ≥25 subjects)
x ≥6 months to <1 year of age ( ≥25 subjects)
x ≥1 year to <2 years of age ( ≥25 subjects)
x ≥2 years to <4 years of age ( ≥20 subjects)
Approximately 175 sites are planned in order to rec ruit the required subjects; additional sites will 
be added if deemed necessary. A target of approx imately 50% of the randomized subjects should 
consist of subjects <2 years of age. Of these s ubjects (122), a target of 20% will be enrolled in 
each of the 3 age categories <2 years of age.
Has been changed to:REDACTEDialial--ono
omparmparCOPYefficeffi
is a sis a s
This document≥≥
ApApcannot onon
≥1 year1 year
≥2≥2be nths nths used nr
to <6to <6torollerollsupport 244 su244 s
dany ofof
hs.hs.marketing of subof su
f subjfs u bauthorizationsubjeubje
set seet se
red to d to application lowingowin
acy varcy va
tand suru
r EndEndany red oredextensionsmanman
% of su of sors ths th
ncevariations hathathereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 90 of 144A total of approximately 244 subjects (122 subjects  per treatment arm) are planned to be 
randomized. Approximately 50% of the 244 randomized subjects should be <2 years of age. Of 
these (n=122), a minimum target of 20% (n=25) of subjects will be enrolled in each of the 3 age 
categories: ≥1 month to <6 months, ≥6 months to <1 year, and ≥1 year to <2 years.
Subjects will be enrolled in the following age categories as detailed below:
x ≥1 month to <6 months of age ( ≥25 subjects)
x ≥6 months to <1 year of age ( ≥25 subjects)
x ≥1 year to <2 years of age ( ≥25 subjects)
x ≥2 years to <4 years of age ( ≥20 subjects)
Approximately 175 sites are planned in order to rec ruit the required subjects; additional sites will 
be added if deemed necessary. 
Change #6
Section 5.2 Schedule of study assessments
Schedule of study assessments Table 5-1 has  been updated to include rescue medication 
assessment.
REDACTED COPY 
This document cannot be used to support any marketing authorization application o incluo incland any extensions ; addiaddor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 91 of 144Table 5-1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
Informed consent X
DemographicscX
Inclusion/exclusion criteria X X X
Medical history X
Seizure history/count X
Concomitant medications XdX X X X X X X X X X X X X X
Concomitant AEDs XeX X X X X X X X X X X X X X
VNS assessmentfX X X X X X
Physical examination (complete) X X
Physical examination (brief) X X X X
Vital signs (including BP and pulse rate)
gX X X X X X X
Body weight X X X X X X
Height X X
Head circumference X X
Neurological examination (complete) X X
Neurological examination (brief) X X X X
ECG (12-lead)hX X X X
Video-EEGiX X X X X X X XREDACTED XX
D
XXTEACACACACR
ARRRER
COPY 
YPYYCCCThis 
document 
me
cannot f)
otnooca
be be
usedX
d se
to support 
ttppsussss
any aa
marketing 
ggggngketamaaaa
authorization 
ioXX
tioiooio
Xrizhothh
application 
onioononi
olililicppliapp
and an
any 242ananananan
extensionstenanenan
(7(7en
4bex
or o
variations 
onva
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 92 of 144Table 5-1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
Clinical chemistry/hematology X X X
Concomitant AED plasma concentration X X X
LCM plasma concentration X X X
Clinical GIC X
Caregiver’s GIC X
Contact IXRS X X X X X X
Randomization Xj
Dispense study medication XjX X X X
Return study medication X X X X
Dosing instructionskX X X
AE reporting X X X X X X X X X X X X X X X
Withdrawal criteria X X X X X X X X X X X X X X
Healthcare resource use X X X X
Bayley-III scaleslX
BRIEF-PmX X
PedsQLnX X
Achenbach CBCLoX X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; BRIE F-P=Behavior Rating Inventory of Executive Function-Preschool Version; 
CBCL=Childhood Behavior Checklist; ECG=electrocardiogram; EEG=elec troencephalogram; ET=Early Termination; GIC=Global Impression  of REDACTED 
DEDCXXjjXXX
ACACACAC
XXjjEDR
COPY 
YYYYYCOCThis 
documentehavihavi
canantiepntiep
nnot 
ttttot
or
nn
be b
used
d seu
to support XX
ttppsussss
any XXanyyaa
marketing 
ngtinnna
naaarkam
authorization 
n io
XXzahohohohohoa
application 
on
XXatpplippppppp
and an
any 242ananananan
extensionstenanenan
(7(7en
4bex
or o
variations 
onva
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 93 of 144Table 5-1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
Change; IXRS=interactive voice/web response system; LCM=lacosamid e; PedsQL=Pediatric Quality of Life Inventory; T=Telephone Con tact; 
UV=Unscheduled Visit; V=Visit; VNS=vagus nerve stimulation.
aIf an Unscheduled Visit is needed, then th e assessments noted will be performed. Addit ional assessments may be performed at the investigator’s 
discretion.
bThe Day -3 and Day 24 assessments should be conducted prior to the start of video-EEG monitori ng. A maximum of 7 days may be added to the 
period between Visit 1 and 2 in the event that additional time is needed to access inpatient facilities to perform the video-EE G, 
cDemographics: date of birth, age group category, age in months and years, race, ethnicity, and gender. In countries where recording of complete 
date of birth is not permitted, only permitted data will be collected.
dThe concomitant medications recording will include any current medication intake as wel l as any medications taken ≤30 days prior to Visit 1.
eThe concomitant AED recording will include any current medication intake as well as any previous AED taken prior to Visit 1.
fThe VNS setting will be assessed as applicable.
gOrthostatic assessments of BP and pulse rate will be assessed  where it is feasible according to investigator judgment.
hA 12-lead ECG (2 interpretable recordings) will be performed prior to any blood draws and vital signs assessment and, if possib le,with the subject 
in the supine position for 5 minutes preceding the ECG recording.  The second recording will be conducted 20 to 30 minutes after  the first 
recording. Electrocardiograms will be reviewed locally by the investigator, subinvestigator, or qualified designated reader and  at a central ECG 
laboratory. The investigator may consult with the cardiologist at the central ECG laboratory to confirm the presence of a cli nically significant ECG 
abnormality; however, it remains the responsibility of the investigator to decide whether an ECG finding is of clinical significance on the basis of 
the complete clinical picture and whether this finding influences the subject’s participation in the study.
iThe video-EEG (72 hours of continuous recording) will be condu cted in an inpatient setting. Upon completion of the Baseline vid eo-EEG (Visits 2 
and 3), the investigator will assess the electrographic seizure co unt and confirm the selection criteria have been met. If the subject meets all 
selection criteria, including the requisite num ber of seizures based on the video-EEG data, the subject may be randomized at Vi sit 3. All 
video-EEG data recordings will be transmitted to a central reader for the purposes of data analysis. The End-of-Maintenance Per iod video- EEG 
will be done at Visit 6. Subjects who discontinue on or before Day 20 will not require a video-EEG.
jRandomization and initial dispensing of study medication will oc cur at Visit 3 and after the completion of the video- EEG and confirmation that the 
subject has met selection criteria. 
kDosing instructions will be provided to the caregiver(s) duri ng the telephone contacts. At a minimum, AEs and tolerability sh ould be discussed 
with the caregiver(s) in order to determine  the next dose for the subject. See Section 7.2.1 for additional details on dosing options. 
lThe Bayley Scales of Infant and Toddler Development, Third Ed ition, will be completed by subjects who are <18 months of ag e who originate in 
English-speaking countries. 
mThe BRIEF- P will be used only for subjects who are ≥2 years of age at Visits 3 and 6. BRIEF -P will be used only in countries where a translated REDACTEDintakeintak
take astake as
re it is re it is
rior torior to
T
COPYpatienpatie
ethnicithniThis 
documente usedused
cannotto deto det
nt and Tt and 
es. es. 
beded toded to
used contiont
of studf stud
to ted ted t
tinutinu
support will beill b
hic seizhic se
er of r of seise
to a to
anynvenve
fluenceluenc
ec
marketing o any bany 
The seche sec
nvestigavestig
t at the at the
estigesti
authorization ity,y,
as weas we
well awell a
feasibeasib
bb
application mentsment
nitoringitoring
facilitiefacilit
, and and
andLifeife
tt
any 242ane InveI nananan
extensionstenanenan
(7(7en
4bex
or o
variations 
onva
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 94 of 144Table 5-1: Schedule of study assessments (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
version is available.
nThe version of the PedsQL used at Visi t 3 should be consistent with the subject’s age at Vis it 3 and should be maintained for each subject for the 
duration of the study. The PedsQL will be used only in countries where a translated version is available. 
oThe Achenbach CBCL/1½-5 will be comple ted by the parent(s)/legal represen tative(s)/caregiver(s) of subjects ≥18 months of age at Visits 3 and 6. 
The Achenbach CBCL will be administered only in  countries where a translated version is available.
REDACTED 
COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization 
application able. able.
r(s) of sus) of 
ailable.ailable
and ould buld b
any 242anananan
extensionstenanenan
(7(7en
4bex
or o
variations 
onva
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 95 of 144Has been changed to:
Table 5-1: Schedule of study assessments  (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
Informed consent X
DemographicscX
Inclusion/exclusion criteria X X X
Medical history X
Seizure history/count X
Concomitant medications XdX X X X X X X X X X X X X X
Concomitant AEDs XeX X X X X X X X X X X X X X
VNS assessmentfX X X X X X
Physical examination (complete) X X
Physical examination (brief) X X X X
Vital signs (including BP and 
pulse rate)gX X X X X X X
Body weight X X X X X X
Height X X
Head circumference X X
Neurological examination 
(complete)X X
Neurological examination (brief) X X X XREDACTED 
DD
XCTAC
XXDAAAR
ARRRR
COPY 
YYOPCCThis 
document 
tcannot 
ot
(briefbrief
nnc
be XXeused eXX
eeedse
to Xtosupport 
tppsu
any ana
marketing 
ngngngngngkeam
authorization 
ioatioiooo
i
X
oooriho
XXut
application 
ontiooopli
oplipliplipplia
and 2020an
any anaaaa
extensions 
s
Mainteaint
ioe
or o
variations 
on
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 96 of 144Table 5-1: Schedule of study assessments  (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
ECG (12-lead)hX X X X
Video-EEGiX X X X X X X X
Rescue medicationjX X X X X X X X
Clinical chemistry/hematology X X X
Concomitant AED plasma 
concentrationX X X
LCM plasma concentration X X X
Clinical GIC X
Caregiver’s GIC X
Contact IXRS X X X X X X
Randomization Xk
Dispense study medication XkX X X X
Return study medication X X X X
Dosing instructionslX X X
AE reporting X X X X X X X X X X X X X X X
Withdrawal criteria X X X X X X X X X X X X X X
Healthcare resource use X X X X
Bayley-III scalesmX
BRIEF-PnX XREDACTED 
DEDACACACACACEDR
COPY 
YOPCThis 
document
nt cannot 
otototototan
be eused eeeedseu
to XXosupport
rtt tppsussss
any ya
marketing 
ng
XXetiaaaara
authorization 
iozahothohohohoa
application 
ontioooli
olililicppliap
and an
any242anaaaa
extensionstenanenan
(7(7ene
or o
variations 
onva
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 97 of 144Table 5-1: Schedule of study assessments  (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
PedsQLoX X
Achenbach CBCLpX X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; BRIE F-P=Behavior Rating Inventory of Executive Function-Preschool Version; 
CBCL=Childhood Behavior Checklist; ECG=electrocardiogram; EEG=electroencephalogram ; ET=Early Termination; GIC=Global Impression of 
Change; IXRS=interactive voice/web response system; LCM=lacosamid e; PedsQL=Pediatric Quality of Life Inventory; T=Telephone C ontact; 
UV=Unscheduled Visit; V=Visit; VNS=vagus nerve stimulation.
aIf an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments may be performed at t he investigator’s 
discretion.
bThe Day -3 and Day 24 assessments should be condu cted prior to the start of video-EEG monitoring . A maximum of 7 days may be added to the 
period between Visit 1 and 2 in the event that additional time is needed to access in patient facilities to perform the video-EE G. 
cDemographics: date of birth, age group category, age in  months and years, race, ethnicity, and gender. In countries where recording of complete 
date of birth is not permitted, only permitted data will be collected.
dThe concomitant medications recording will include any current medication intake as well as any medications taken ≤30 days prior to Visit 1.
eThe concomitant AED recording will include any current medication intake as well as any previous AED taken prior to Visit 1.
fThe VNS setting will be assessed as applicable.
gOrthostatic assessments of BP and pulse rate will be assesse d where it is feasible according to investigator judgment.
hA 12-lead ECG (2 interpretable recordings) will be performed prior to any blood draws and vital signs assessment and, if possib le,with the subject 
in the supine position for 5 minutes preceding the ECG recording.  The second recording will be conducted 20 to 30 minutes after  the first 
recording. Electrocardiograms will be reviewed locally by the investigator, subinvestigator, or qualified designated reader a nd at a central ECG 
laboratory. The investigator may consul t with the cardiologist at the cent ral ECG laboratory to confirm the presence of a clinically significant ECG 
abnormality; however, it remains the responsibility of the investigator to decide whether an ECG finding is of clinical signifi cance on the basis of 
the complete clinical picture and whether this finding influences the subject’s participation in the study.
iThe video-EEG (72 hours of continuous recording) will be condu cted in an inpatient setting. Upon completion of the Baseline vid eo-EEG (Visits 2
and 3), the investigator will assess the electrographic seizure co unt and confirm the selection criteria have been met. If the subject meets all 
selection criteria, including the requisite number of seizures ba sed on the video-EEG data, the subject may be randomized at Vis it 3. All 
video-EEG data recordings will be transmitted to a central reader for the purposes of data analysis. The end-of-Maintenance Per iod video- EEG 
will be done at Visit 6. Subjects who discontinue on or before Day 20 will not require a video-EEG.
jAdditional assessment for changes in VNS or rescue medication tak en within 24 hours prior to and until the end of the video-EEG  monitoring.REDACTED medmed
tart of art of 
ded to ded to 
and yeaand ye
ed.ed.
COPYala
=Pedi=Ped
d. Ad. AThis 
documentt for for 
cannote requreq
will bewill b
ubjectubject
chh
bes the s the 
quiqui
usedon
er thisr this
ous reus re
toh t
nsibilsibi
support rforfo
ECG recCG re
locally ocall
the carhe car
it
anyssed wsed w
ormedrme
marketing ars,rs
edicatioedicati
ication iation
h
authorization dditiondition
videovideo
accessccess
s, rac rac
application 
onentory ontory
m; ET=m; ET=
atric Qutric Q
tiooo
and an
any242anaaaa
extensionstenanenan
(7(7ene
or o
variations 
onva
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 98 of 144Table 5-1: Schedule of study assessments  (Baseline and Treatment Periods)
Assessment Baseline Period
(7 days)Treatment Period (27 days)
Titration Period
(20 days)Maintenance Period
(7 days)
Visit V1 V2 V3 T1 V4 T2 V5 T3 V6/ET UVa
Study Day -7 -3b-2 -1 1 5 9 13 17 20 24b25 26 27
kRandomization and initial dispensing of study medication will occur at Visit 3 and after the completion of the video-EEG and co nfirmation that the 
subject has met selection criteria. 
lDosing instructions will be provided to the caregiver(s) duri ng the telephone contacts. At a minimum, AEs and tolerability sh ould be discussed 
with the caregiver(s) in order to determine  the next dose for the subject. See Section 7.2.1 for additional details on dosing options. 
mThe Bayley Scales of Infant and Todd ler Development, Third Edition, will be completed by su bjects who are <18 months of age who originate in 
English-speaking countries. 
nThe BRIEF -P will be used only for subjects who are ≥2 years of age at Visits 3 and 6. BRIEF -P will be used only in countr ies where a translated 
version is available.
oThe version of the PedsQL used at Visit 3 should be consistent  with the subject’s age at Visit 3 and should be maintained for each subject for the 
duration of the study. The PedsQL will be used only in countries where a translated version is available. 
pThe Achenbach CBCL/1½- 5 will be completed by the parent(s)/legal re presentative(s)/caregiver(s) of subjects ≥18 months of age at Visits 3 and 6. 
The Achenbach CBCL will be administered only in  countries where a translated version is available.
REDACTEDbject’sbject’
a transa trans
represrepre
re re a traa tr
COPY nd 6. Bd 6. BThis 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization RIE
age atage at
lated vated v
sentativentativ
nslateslate
applicationum, AEum, A
dditionadition
subjectsubject
IEFEF-PP
andof thethe
E
any242anevaaa
extensionstenanenan
(7(7ene
or o
variations 
onva
thereof. pr 201r 201
SPSP
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 99 of 144Change #7
Section 5.4 Rationale for study design and selection of dose 
Text defining the contingent primar y efficacy variable has been added, 4thparagraph.
Based on US FDA and EMA requirements, 2 (co-) pr imary efficacy variables have been defined 
for this study based on electrographic partial-onset seizures with or without clinical correlate 
depending upon subject age. The primary efficacy variable will be the change in ADF of electrographic partial- onset seizures (US) or proportion of subjects experiencing ≥50% re duction 
in their ADF of electrographic partial-onset seizures (EU) as measured on the 72-hour End-of-
Maintenance Period video-EEG compared to the 72-hour End-of-Baseline Period video-EEG. At 
the request of FDA, a contingent primary effica cy variable has also been defined based on the 
percentage of subjects who discontinue early from the study prior to completing the 
End-of-Maintenance Period video-EEG. Continge nt upon >10% of subjects discontinuing early 
from the study, the primary efficacy parameter for the US will become identical to the primary efficacy parameter for the EU.
The endpoint not designated as primary will still be summarized as a secondary efficacy 
parameter
Change #8
Section 8.1.2 Baseline Period: Visit 2 (Day -3 to Day -1)
Rescue medication has been added to the list of assessments.
x Inclusion/exclusion criteria (Day -3 only)
x Concomitant medications 
x Concomitant AEDs 
x VNS assessment (Day -3 only and only if applicable)
x Physical examination (brief) (Day -3 only)
x Vital signs (BP and pulse rate, including orthostatic assessments where feasible according to 
investigator judgment; Day -3 only)
x Body weight (Day -3 only)
x Neurological examination (brief) (Day -3 only)
x Video-EEG (72 hours of continuous recording)
x AE reporting 
x Review withdrawal criteria
Has been changed to:
x Inclusion/exclusion criteria (Day -3 only)
x Concomitant medications 
x Concomitant AEDs REDACTEDof aof a
nly)nly)COPY --3 to3 t
ass
This documentRR
HaHacannot AE repE rep
ReRebe EEGEEGused (D
cal excal exto Day Day supportulse raulse r
ment; Dent; D
3anyef) (Def) (Dmarketing y and onand authorization o DD
sessmsessmapplication s a 
Day Dayand a secseanynticnticextensions eoo--E
ased ased 
g the the 
discondiscon
caor ndd
EEEEvariations uctionction
d-ofofthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 100 of 144x VNS assessment (Day -3 only and only if applicable)
x Physical examination (brief) (Day -3 only)
x Vital signs (BP and pulse rate, including orthos tatic assessments where feasible according to 
investigator judgment; Day -3 only)
x Body weight (Day -3 only)
x Neurological examination (brief) (Day -3 only)
x Video-EEG (72 hours of continuous recording)
x Rescue medication assessment
x AE reporting 
x Review withdrawal criteria 
Change #9
Section 8.2.1 Titration Period: Visit 3 (Day 1)
Rescue medication has been added to the list of assessments .
Randomization and initial dispensing of study me dication will occur at Visit 3 and after the 
completion of the video-EEG a nd confirmation that the subject has met selection criteria.
During Visit 3, the following assessments will be performed:
x Inclusion/exclusion criteria
x Concomitant medications
x Concomitant AEDs
x 12-lead ECG (2 interpretable recordings [20 to 30 minutes apart] to be performed, if possible, 
with the subject in a supine position for 5 minutes preceding ECG recording)
x Video-EEG (end-of-Baseline video-EEG)
x Contact IXRS
x Randomization
x Dispense study medication and administer first dose of study medication before the 
conclusion of visit
x AE reporting
x Review withdrawal criteria
x Healthcare resource use
x Bayley-III scales (for subjects who are <18 months of age who originate in English-speaking 
countries)
x BRIEF-P score 
x PedsQL score REDACTEDl be l beCOPYationatio
at the at th
p
This document xxcannotE reporepo
RevRevbesion onused n
study tudy
oto support selinelianypospos
inenmarketing recordiecord
sitisitauthorization e susu
performerformapplication will ocwill o
ubjecubjeand any extensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 101 of 144x Achenbach CBCL (the CBCL/1½-5 will be completed by parent[s]/legal 
representative[s]/caregiver[s] of subjects ≥18 months of age at Visit 3)
Has been changed to:
Randomization and initial dispensing of study me dication will occur at Visit 3 and after the 
completion of the video-EEG a nd confirmation that the subject has met selection criteria.
During Visit 3, the following assessments will be performed:
x Inclusion/exclusion criteria
x Concomitant medications
x Concomitant AEDs
x 12-lead ECG (2 interpretable recordings [20 to 30 minutes apart] to be performed, if possible, 
with the subject in a supine position for 5 minutes preceding ECG recording)
x Video-EEG (End-of-Baseline video-EEG)
x Rescue medication assessment
x Contact IXRS
x Randomization
x Dispense study medication and administer first dose of study medication before the 
conclusion of visit
x AE reporting
x Review withdrawal criteria
x Healthcare resource use
x Bayley-III scales (for subjects who are <18 months of age who originate in English-speaking 
countries)
x BRIEF-P score 
x PedsQL score 
Achenbach CBCL (the CBCL/1½-5 will be completed by parent[s]/legal 
representative[s]/caregiver[s] of subjects ≥18 months of age at Visit 3)
Change #10
Section 8.3.1 Maintenance Period: Visit 6/Early Termination (Day 24, Day 25 and 
Day 26)
Rescue medication has been added to the list of assessments.
The Day 24 assessments should be conducted prior to the start of video-EEG monitoring. The 
following assessments will be performed on Day 24 for all subjects:
x Concomitant medications 
x Concomitant AEDsREDACTED firfirCOPY rst dst d
This document ayay
ResRescannot ##
tion 8ion 8
y 26y 26be #10#10usedCL (tL (t
[s]/ca[s]/cato ththsupport any ts s marketing whowhauthorization dose oose oapplication and anyordinrdiextensions erformrform
ngor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 102 of 144x VNS assessment (if applicable)
x Physical examination (brief)
x Vital signs (BP and pulse rate, including orthostatic assessments where feasible according to 
investigator judgment)
x Neurological examination (brief)
x Video-EEG (72 hours of continuous recording)
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reporting
x Review withdrawal criteria
The following assessments will be performed on Day 25 and Day 26 during the 72-hour
video-EEG:
x Concomitant medications 
x Concomitant AEDs
x AE reporting
x Review withdrawal criteria
Has been changed to:
The Day 24 assessments should be conducted prior to the start of video-EEG monitoring. The 
following assessments will be performed on Day 24 for all subjects:
x Concomitant medications 
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (brief)
x Vital signs (BP and pulse rate, including orthostatic assessments where feasible according to 
investigator judgment)
x Neurological examination (brief)
x Video-EEG (72 hours of continuous recording)
x Rescue medication assessment
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reportingREDACTED COPY 
This document xxcannot eurolourolo
VidVidbegatorgatoused minin
s (BPs (BPtonatinatisupport if applf appany marketing nductenduct
ormed rmedauthorization application 26 26 and 6duduany extensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 103 of 144x Review withdrawal criteria
The following assessments will be performed on Day 25 and Day 26 during the 72-hour video-
EEG:
x Concomitant medications 
x Concomitant AEDs
x Rescue medication assessment
x AE reporting
x Review withdrawal criteria
Change #11
Section 8.3.2 Maintenance Period: Visit 6/Early Termination (Day 27)
Rescue medication has been added to the list of assessments.
x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (complete)
x Vital signs (BP and pulse rate, including orthostatic assessments where feasible according to 
investigator judgment)
x Body weight
x Height
x Head circumference
x Neurological examination (complete)
x 12-lead ECG (2 interpretable recordings [20 to 30 minutes apart] to be performed prior to 
any blood draws and vital signs assessment and, if possible, with the subject in a supine 
position for 5 minutes preceding ECG recording)
x Blood sample for clinical chemistry/hematology
x Blood sample for determination of conc omitant AED plasma concentration 
x Blood sample for determination of LCM plasma concentration 
x Clinical Global Impression of Change
x Caregiver’s Global Impressions of Change
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reportingREDACTED g orthoorthoCOPY 
This document xxcannot ood saood sa
ClinClinbesampsamusedple fole fo
lltominuminusupport pretabpretab
nd vitad vit
utesuteany(com(commarketing authorization ostaticstaticapplication and any y yextensions 27)27)or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 104 of 144x Review withdrawal criteria
x Healthcare resource use
x BRIEF-P
x PedsQL (same version used at Visit 3)
x Achenbach CBCL (the CBCL/1½-5 will be completed by parent[s]/legal 
representative[s]/caregiver[s] of subjects ≥18 months of age at Visit 6/ET) 
Has been changed to:x Concomitant medications
x Concomitant AEDs
x VNS assessment (if applicable)
x Physical examination (complete)
x Vital signs (BP and pulse rate, including orthostatic assessments where feasible according to 
investigator judgment)
x Body weight
x Height
x Head circumference
x Neurological examination (complete)
x 12-lead ECG (2 interpretable recordings [20 to 30 minutes apart] to be performed prior to 
any blood draws and vital signs assessment and, if possible, with the subject in a supine position for 5 minutes preceding ECG recording)
x Blood sample for clinical chemistry/hematology
x Blood sample for determination of conc omitant AED plasma concentration 
x Blood sample for determination of LCM plasma concentration 
x Clinical Global Impression of Change
x Caregiver’s Global Impressions of Change
x Contact IXRS
x Dispense study medication
x Return study medication
x AE reporting
x Rescue medication assessment
x Review withdrawal criteria
x Healthcare resource useREDACTED )
ordingordin
asseasseCOPY 
This document R
xxcannot ispensspen
RetRetbet IXt IXused s GlobGlob
RtoImpImsupport minmin
eterminterm
mpremprany emem
nationatimarketing gs [gs 
essmenessme
g ECG ECG
mistrmistauthorization [20[20application nts ws and whwhany extensions or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 105 of 144x BRIEF-P
x PedsQL (same version used at Visit 3)
x Achenbach CBCL (the CBCL/1½-5 will be completed by parent[s]/legal 
representative[s]/caregiver[s] of subjects ≥18 months of age at Visit 6/ET) 
Change #12
Section 9.2.3 Healthcare resource use
Healthcare resource use section has been updated, 1stparagraph.
For healthcare resource use, the following will  be evaluated: concomitant medications and 
AEDs, medical procedures, healthcare provid er consultations not related to study, and 
hospitalizations not related to study.
Has been changed to:
For healthcare resource use, the following will  be evaluated: concomitant medications and 
AEDs, medical procedures, and healthcare provider consultations including hospitalizations not 
foreseen by the protocol.
Change #13
Section 11.1.4 Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, th e investigator determines 
that it is no longer clinically significant, or the subject is lost to follow up. 
If an AE is still ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
investigator must provide a justification. The follow up will usually be continued for 30 days 
after the subject has discontinued his/her IMP.
Has been changed to:
An AE should be followed until it has resolved, has a stable sequelae, th e investigator determines 
that it is no longer clinically significant, or the subject is lost to follow up. 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the investigator must provide a justification. The follo w up will usually be continued for 30 days 
after the subject has discontinued his/her IMP.REDACTEDd, had, h
the suthe su
he studhe stud
achieachie
jejeCOPY ventsents
hashas
This document cannotatortor
the suhe subeignigni
rmrmused ng ng
ble levle lev
ificifictog at ga tsupport ed untd un
nicallynicallyany marketingevedved
ect is loct is lo
ation. Ttion. 
his/hehis/hauthorization s a staba sta
ubjectbject
dy fordy for
eddapplication ncandtant ant
cludcludany tm etmextensionsns anns an
y, and and or variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 106 of 144Change #14
Section 11.5 Anticipated serious adverse events
The anticipated SAE table has been updated to include a footnote for convulsion.
Table 11-1: Anticipated SAEs for the pediatric epilepsy population
MedDRA SOC MedDRA PT
Congenital, familial and genetic disorders Teratogenicity  
General disorders and ad ministration site conditions Sudden unexplained death in epilepsy  
Nervous system disorders Convulsion  
Incontinence  
Status epilepticus  
Pregnancy, puerperium and perinatal disorders Abortion spontaneous  
Psychiatric disorders Psychotic behaviour  
Abnormal behaviour  
Anxiety  
Sleep disorder  
Reproductive system and breast disorders Menstrual disorder  
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SAE=serious adverse event; 
SOC=system organ class 
Has been changed to:
Table 11-1: Anticipated SAEs for the pediatric epilepsy population
MedDRA SOC MedDRA PT
Congenital, familial and genetic disorders Teratogenicity  
General disorders and ad ministration site conditions Sudden unexplained death in epilepsy  
Nervous system disorders Convulsiona 
Incontinence  
Status epilepticus  
Pregnancy, puerperium and perinatal disorders Abortion spontaneous  
Psychiatric disorders Psychotic behaviour  
Abnormal behaviour  
Anxiety  
Sleep disorder  
Reproductive system and breast disorders Menstrual disorder  
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SAE=serious adverse event; 
SOC=system organ class 
a  Convulsion if consistent with the s eizure type known for the subject.REDACTEDies; PTies; PD
for forCOPYSleSl
OPOPOPOPOPC
This document umuuucannotc disdisbesorsobeerpp
be used periuperiuseto support tionio
ortanyderser
n sitens inymamarketingr the pthe 
ket
maauthorizationMensMen
tT=prefeT=prefettioapplication havioavio
tio
ep disorp disoplicapand oururdaany yaextensions io
teneor ovariations onati
vathereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 107 of 144Change #15
Section 12.1 Adherence to protocol
Text for adherence to the protocol has been updated.
The investigator should not deviate from the protocol. In medical emergencies, the investigator 
may use his/her medical judgment and may remove  a study participant from immediate hazard 
before notifying UCB (or its representative) and the IRB/IEC in writing regarding the type of emergency and the course of action taken.
Has been changed to:
The investigator should not deviate from the protocol. However, the investigator should take any
measure necessary in deviation from or not define d by the protocol in order to protect clinical
study subjects from any immediate hazard to their health and safety. In this case, this action
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, orsponsor. After implementation of such measure, the investigator must notify the Clinical Project Manager (CPM) of the sponsor within 24 hours and follow any local regulatory requirements .
Change #16
Section 13.1 Definition of analysis sets
Definition of the analysis sets has been clarified, 1
stparagraph.
The primary analysis set for the efficacy data w ill be the Full Analysis Set (FAS), and will 
include all subjects who were randomized, received at least 1 dose of study medication, and had an End-of-Maintenance Period video-EEG.
The secondary analysis set for the efficacy da ta will be the Per Protocol Set (PPS), which 
includes all subjects in the FAS who did not have important protocol deviations related to efficacy.
The Safety Set (SS) will include all randomized subjects who took at least 1 dose of study 
medication. This is the primary analysis set for the safety variables.
The Pharmacokinetic Per Protocol Set (PK-PPS) will consist of all subjects having provided at 
least 1 measurable postdose plasma sample (with rec orded sampling time) on at least 1 visit with 
documented study medication intake times .
Has been changed to:
The Safety Set (SS) will include all randomized subjects who took at least 1 dose of study 
medication. This is the primary analysis set for the safety variables.
The primary analysis set for the efficacy data w ill be the Full Analysis Set (FAS), which will 
include all subjects in the SS.
The secondary analysis set for the efficacy da ta will be the Per-Protocol Set (PPS), which 
includes all subjects in the FAS who did not have important protocol deviations related to 
efficacy.
The Pharmacokinetic Per-Protocol Set (PK-PPS) will consist of all subjects having provided at 
least 1 measurable postdose plasma sample (with re corded sampling time) on at least 1 visit with 
documented study medication intake times.REDACTEDwill will
receivreceiv
EG.G.
fficacyfficacy
didCOPY tparpar
lblb
This documentinclunclu
TTcannottion. ion.
e primprim
ddbeSet Set
TTused hangeange
(tomedmedsupport r Protor Prot
stdosestdose
dicdiany allal
ry anay anamarketingy dada
id not hd not h
ll rall rauthorization ragg
be the e the 
ved atved at
dataataapplication grapgrapand noto
l regureguanyuthouth
tify ttify textensions hould hould 
protectrotect
ase, thase, th
horhoror variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 108 of 144Change #17
Section 13.1.1.1 Analysis of the pr imary efficacy variable for the US
This section has been added.
Contingent upon ≤10% of subjects discontinuing early from the study, the primary efficacy 
parameter for the US is the change in ADF of electrographic partial-onset seizures during the 
Maintenance Period compared to the end of the Baseline Period. Seizure ADF will be analyzed 
using analysis of covariance with terms for treatment and center (properly pooled), on log-
transformed seizure ADF using the transformation of ln (X+1), where X is the seizure ADF. 
Log-transformed Baseline seizure ADF will be used as a covariate. The seizure ADF between 
LCM and PBO will be compared using least squares means (LSMs). The percent reduction over 
PBO will be estimated as 100 x (1 –exp [LSM Treatment {TRT} - LSMPBO]). The analysis of 
this efficacy variable will consist of all subjects in the FAS who have at least 48 hours of 
interpretable recordings during both the End-of-Baseline Period video-EEG and the End-of-Maintenance Period video-EEG.
The following additional sensitivity analyses on this primary efficacy variable will be conducted 
in order to assess the effect of early discontinuati ons, protocol deviations, and operational bias on 
this primary endpoint:
x Repeat the primary analysis using the PPS.
x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video- EEG will be replaced using the Baseline 
observation-carried-forward approach. This will be applied for all subjects who discontinued 
early from the study.
x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video-EEG will be replaced by the overall mean ADF 
of partial-onset seizures from the End-of-Maintenance Period video- EEG from the subject’s 
respective treatment arm. This will be appl ied for all subjects who discontinued early from 
the study.
x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video-EEG will be replaced using multiple imputation 
by treatment arm and age group ( ≥1 month to <6 months of age, ≥6 months to <1 year of age,
≥1 year to <2 years of age, and ≥2 years to <4 years of age) using a Markov chain Monte 
Carlo method assuming a log-normal distribution. This will be applied for all subjects who 
discontinued early from the study.
x Repeat the primary analysis using the FAS for all subjects who have at least 24 hours of 
interpretable recordings during both the En d-of Baseline Period video-EEG and the 
End-of-Maintenance Period video-EEG.
Contingent upon >10% of subjects discontinuing early from the study, the primary efficacy
parameter for the US is identical to the primary ef ficacy parameter for the EU, described below. 
The endpoint not designated as primary will still be summarized as a secondary efficacy 
parameter.REDACTED , ex, ex
deodeo--EE
h. Thih. Thi
gt hgt hCOPY xcexce
This documentincannotontinntin
RepeaRepea
inteintebemetheth
inuinuused armrm
<2 ye<2 ye
hodhodto M
m anmasupport analysanaly
MaintMaintanyThis whis marketing the FAShe FA
erioriod vd
the Enhe E
wauthorization ept mipt mi
EEG wEG w
is wills willapplication acyy
deviatioeviatiand y vay vaanyG anG aextensions betwet
reducteduct
. The The
t 48 h48 h
nddorDFDF
twewvariations d 
F.Fthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 109 of 144Change #18
Section 13.1.1.2 Analysis of the pr imary efficacy variable for the EU
This section has been added.
The primary efficacy parameter for the EU is the proportion of responders during the 
Maintenance Period. Subjects with a 50% or more reduction in seizure ADF will be categorized 
as responders; this classification requires at l east 48 hours of interpretable recordings during both 
the End-of-Baseline Period video-EEG and the End-of-Maintenance Period video-EEG. The 
proportion of responders between LCM and PBO will be analyzed using logistic regression with
center (properly pooled) as a factor. Subjects who withdraw or drop out before the first 48 hours of the End-of-Maintenance Period video-EEG with reasons related to lack of efficacy will be 
considered non responders; all other subjects will be missing for this analysis. The number and 
percentage of subjects with a 50% or more re duction in seizure ADF will be presented by 
treatment group. 
The following additional sensitivity analyses on this primary efficacy variable will be conducted 
in order to assess the effect of early discontinua tions, protocol deviations, and operational bias on 
this primary endpoint:
x Repeat the primary analysis using the PPS.
x Repeat the primary analysis using the FAS, ex cept subjects who discontinued from the study 
prior to performance of the 72-hour End-of-Maintenance Period video-EEG with reasons 
related to lack of efficacy will be considered non responders, and subjects who discontinued 
from the study early for any other reason will be considered responders.
x Repeat the primary analysis using the FAS, except all subjects who discontinued from the 
study early will be considered non responders.
x Repeat the primary analysis using the FAS, except missing ADF of partial-onset seizures 
from the End-of-Maintenance Period video-EEG will be replaced using multiple imputation 
by treatment arm and age group ( ≥1 month to <6 months of age, ≥6 months to <1 year of age, 
≥1 year to <2 years of age, and ≥2 years to <4 years of age) using a Markov chain Monte 
Carlo method assuming a log-normal distribution. This will be applied for all subjects who 
discontinued from the study early, and the imputed End-of-Maintenance Period ADF of 
partial-onset seizures will be used to determine whether a subject is a responder.
x Repeat the primary analysis using the FAS for all subjects who have at least 24 hours of 
interpretable recordings during both the end of  Baseline Period video-EEG and the end of 
Maintenance Period video-EEG.
Change #19
Section 13.2.1 Planned efficacy analyses
This section has been removed.
Subjects evaluable for the EEG-based efficacy en dpoints will consist of all subjects in the FAS 
who have at least 48 hours of interpretable recordi ngs during both the end of Baseline Period 
video-EEG and the end of Ma intenance Period video-EEG.REDACTED f-MM
dered ndered n
ason wson w
g the Fg the 
on ron rCOPY xcept sxcept
MainMai
This document SecSeccannotintennten
angeangbeetabletabused seizeiz
e primprimto m 
izurizursupportf age, age, 
ming a ming a
m the the any e e 
groupgroupmarketing FAFA
responespon
ing theng th
PeriPerauthorizationsubub
ntenantenan
non renon re
will bewill be
AS,ASapplication iati
bjecbjecandy varivari
tionionany iabiextensionsrst 4st 4
acy wacy w
The nuhe nu
presepreseor on on
4848variations both oth 
e e 
nnwwthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 110 of 144Change #20
Section 13.5 Planned interim analysis and data monitoring
The sample size re-estimation has been further detailed, 2ndand 3rdparagraphs.
A blinded sample size re-estimation will be performed when 50% of subjects have been 
randomized, completed the study, and have data av ailable for analysis to check the validity of 
these assumptions using interim data from the study. The sample size re-estimation with equal allocation in each arm will be performed usin g the related residual variance combined with 
Guenther adjustment (Friede and Kieser, 2011). An assessment of the observed dropout rate will 
also be made as part of this analysis, and th e anticipated dropout rate of 14% will be modified 
based on the observed rate. Additionally, an  assessment of the observed difference of 
interpretation rate will be made; the anticipa ted rate of 5% will be modified based on the 
observed rate.
The final sample size will be modified according  to the sample size re-estimate and also the 
anticipated dropout rate and anticipated rate of diff erence of interpretation of the end-of-Baseline 
Period video-EEG; however, an upper bound may be  applied to reach a maximum sample size 
based on practical and logistical considerations.
Has been changed to:
A blinded sample size re-estimation will be performed when 50% of subjects have been 
randomized, completed the study, and have data av ailable for analysis to check the validity of 
these assumptions using interim data from the study. The sample size re-estimation with equal 
allocation in each arm will be performed usin g the related residual variance combined with 
Guenther adjustment (Friede and Kieser, 2011). An assessment of the observed dropout rate will 
also be made as part of this analysis, and the potential dropout rate of 14% used for calculation 
of the initial sample size (see Section 13.6) will be modified based on the observed rate. 
Additionally, an assessment of the observed difference of End-of-Baseline Period EEG 
interpretation rate will be made; the anticipa ted rate of 5% will be modified based on the 
observed rate.
The final sample size will be modified according  to the sample size re-estimate and also the 
anticipated dropout rate and anticipated rate of difference of interpretation of the 
End-of-Baseline Period video-EEG; however, an  upper bound will be applied to reach a 
maximum sample size based on practical and logi stical considerations. The initial sample size 
re-estimate using Guenther adjustment will not be adjusted above 109 subjects per treatment 
arm, the original estimated overall study drop out rate will not be adjusted above 24%, and the 
difference of End-of-Baseline Period EEG interpr etation rate will not be adjusted above 10%.
Change #21
Section 13.6 Determination of sample size
Text for third paragraph has been updated.
Subjects are randomized into the study based on the investigator’s interpretation of the video -
EEG to meet study entry requirements; however, there may be a difference of interpretation of 
the number of seizures counted on the end-of-Baseline Period video-EEG between the central 
reader and the investigator. To account for an anticipated difference of interpretation of the REDACTED ta ata a
he stuhe stu
usingusing
er, 20er, 20
, and , andCOPY rmed wrmed
avaiava
This document SecSeccannotnce oe o
angeangebeiginigin
ffusedle sie si
ing Ging Gtoriodrio
zesupport ll be m be m
ate and e and
dvdany ththmarketingd the pd the 
13.6) w13.6)
observobser
he anhe aauthorization whwh
ailablelable
udy. Thdy. T
g the rthe r
11). A11). Aapplication ach
hen 5henandationation
h a h a anyimatimat
noextensionsmodmod
of of 
sed oned onorraterat
difdifvariations te wte wthereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 111 of 144end-of-Baseline Period video-EEG of 5% as well  as an anticipated subject dropout rate of 
approximately 14%, the planned number of subjects to enroll is 122 subjects per treatment arm.
Has been changed to:
Subjects are randomized into the study based on the investigator’s interpretation of the video -
EEG to meet study entry requirements; however, there may be a difference of interpretation of 
the number of seizures counted on the End-of-Baseline Period video-EEG between the central reader and the investigator. To account for an anticipated difference of interpretation of the 
End-of-Baseline Period video-EEG of 5% as well  as the potential subject dropout rate of 
approximately 14%, the planned number of subjects to enroll is 122 subjects per treatment arm.
Change #22:
The following section has been added for electronic signature:
Section 19 SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
17.2 AMENDMENT 2
Rationale for the amendment
The primary purposes of this substantial amendment are to clarify elements of the study design 
including inclusion and exclusion criteria, withdrawal criteria, permitted and prohibited 
concomitant medication, and study procedures to make the protocol more patient-friendly and 
enhance enrollment. The protocol was also updated according to the new UCB protocol 
template, for example, with the addition of text regarding PDILI.
The following table summarizes each change with the associated rationale. REDACTEDthdrathdra
ures toures to
also upalso up
tion oftion oCOPY ment ament a
This document cannot be used to support any marketing f teft e
changechanauthorizationare toare to
wal crwal cr
to mako mak
pdpdatedated
text extapplication Go
ocandagreegree
ood ood any et oetextensions meorent ant variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 113 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 1 Lacosamide is being evaluated in pediatric subjects 1 month to 17 years of age in 3 studies: SP847 (open label, 
Phase 2, safety, tolerability, and PK study), SP848 (open 
label long term safety study), and SP1047 (PK study for 
subjects prescribed LCM). In SP847 and SP848, subjects 
with uncontrolled partial onset seizures receive LCM oral 
solution at doses up to 12mg/kg/day based on tolerability.Lacosamide is being evaluated in pediatric subjects 1 month to 17 years of age with partial-
onset seizures in completed and ongoing studies. 
The completed pediatric studies include: SP847 
(open
-label, safety, tolerability, and PK study) 
and SP1047 (PK study for subjects prescribed 
LCM). The ongoing pediatric studies include: 
SP848 and EP0034 (open -label, long- term safety 
studies). In SP847 SP848, and EP0034  subjects 
with uncontrolled partial onset seizures have 
received LCM oral solution at doses up to 
12mg/kg/day based on tolerability.Updated text according to pediatric studies that have 
been completed. 
Section 1Section 5.1.2 A total of approximately 244 subjects (122 subjects per treatment arm) are planned to be randomized at approximately 175 sites in North America, Europe, Asia 
Pacific, and Latin America, with possible extension to 
other countries and regions.A total of approximately 244 subjects (122 subjects per treatment arm) are planned to be randomized at approximately 140 sites in North 
America, Europe, Asia Pacific, and Latin 
America, with possible extension to other 
countries and regions.Revised number of sites. REDACTEDADA
DCOPYotal ootal 
subjectsubje
randrand
YYThis 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization ts ps p
domizedomize
AmericAmeric
AmeAme
cocuthththh
applifa p p r o xappro
per trer tr
plicationpartiapartia
oral solural so
y based basedpli
anden--lablab
848, a48, a
l
any ectec
ic studic stud
belb
extensionspartialartia
ng studg stud
lude: Slude: S
and PKnd PK
cts pts p
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 114 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 1Section 
5.1.1x The maximum duration of study medication 
administration in SP0967 is 55 days, and the maximum 
study duration is 93 days (not withstanding visit windows).
x For each subject, the total study duration can be up to 93 
days (not withstanding visit windows), including the 30 
day Safety Follow- Up Period. Each subject’s 
participation in the study begins with a 7- day Baseline 
Period (no administration of study medication). Each 
subject’s total duration of study medication 
administration in SP0967 is up to 55 days. This includes 
a 20-day Titration Period, a 7- day Maintenance Period, 
and a 12- day Transition Period (for  subjects who plan to 
enter the open label extension study [EP0034]) or up to a 
16-day Taper Period (for subjects who will not be 
entering EP0034).x The maximum duration of study medication 
administration in SP0967 is 55 days (this 
includes a 20-day Titration Period, a 7-day 
Maintenance Period, a 12-day Transition 
Period, and/or up to a 16- day Taper Period), 
and the maximum study duration is 93 days (not 
withstanding visit windows).
x For each subject, the maximum total study 
duration can be up to 93 days (not withstanding 
visit windows), including the 30 day Safety Follow-
Up Period. Each subject’s participation 
in the study begins with a 7-day Ba seline Period 
(no administration of study medication). Each 
subject’s maximum total duration of study 
medication administration in SP0967 can be up 
to 55 days. This includes a 20-day Titration 
Period, a 7-day Maintenance Period, a 12- day 
Transition Period (for subjects who plan to 
enter the open label extension study [EP0034]) 
and/or up to a 16- day Taper Period (for subjects 
who will not be entering EP0034).Clarify that the duration of 
study medication 
administration (55 days) 
and total study duration 
(93 days) are maximum 
durations for a subject who 
enters the Transition 
Period end up also going 
through the Taper Period.
Section 2 Epilepsy is the second most prevalent neurological 
disorder in the world. More than 40 million people suffer 
from epilepsy –about 1% of the world’s population 
(Dichek, 1999).Epilepsy is the second most prevalent 
neurological disorder in the world. It is estimated that almost 70 million people suffer from epilepsy 
(Ngugi et al, 2011).Updated introductory text 
with newer reference .REDACTED 
DCOPY the the
(no ad(no ad
subsubThis 
document 
cannot 
be 
used 
to support 
rtanypopupopu
marketing logical ogical
n peoppeo
l
ke
authorizationject’sect’
medicamedica
to 5to 5
PPth
application p to to
, includinclu
Period. Period
dy begiy beg
ministrministr
sm
andmaximmaxim
o9 393
anyationatio
ws).ws).
extensions on on 
his is 
a 77--dayday
ransitioansitio
Taper aper 
on
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 115 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 4.2Table 5
-1
Section 8.1.1Section 8.2.4Section 8.3.2Section 10Section 13.2.2.1
Section 13.2.2.3Collection of blood at V1, V5, and V6 (Day 27) to investigate the effect of LCM on the steady
-state plasma 
concentrations of concomitant
AEDsGlobal change:
x Remove variable. Collection of blood samples at V1, Visit 5, and V6 (Day 27) for analysis of 
concomitant AEDs will not be performed.x No clinically significant 
impact of concomitant 
AEDs on LCM plasma 
concentrations or LCM 
efficacy –as shown by 
PK analyses in adults 
and children. 
x Additional blood 
collected for this analysis 
is unnecessary in this 
vulnerable patient 
population.
Table 5-1
Section 8.1.1Collection of blood sample for analysis of LCM plasma 
concentrations at V1.Removed from V1. x There is no need to 
collect blood to evaluate 
LCM plasma 
concentrations prior to 
subject randomization.
x Collection of blood for 
this analysis pu ts undue 
burden on this vulnerable 
patient population. REDACTED 
DCOPY emovemove
YThis 
document 
cannot 
be 
used 
to support 
any 
marketing ark
authorization th
application d from frompp
and 
any 
extensions sampleample
analysanalys
erformrform
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 116 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Table 5-1Table 5
-2
Table 5 -3
Section 8.1.1Section 8.2.1Section 8.2.4Section 8.3.2
Section 8.4.3
Section 8.5.2
Section 11.7.4A 12-lead ECG (2 interpretable recordings) will be performed at V1, V3, V5, V6 (Day 27), TV2, Taper Visit, 
and Safety Follow
-up Visit (at investigator’s discretion) 
prior to any blood draws and vital signs assessment and, if 
possible, with the subject in the supine position for 5 
minutes preceding the ECG recording. Th e second 
recording will be conducted 20 to 30 minutes after the first 
recording.Global changes:
x Insert “approximately” as follows: The second recording will be conducted approximately 20 
to 30 minutes after the first recording.
x ECG performed at V3 will be at the discretion 
of the investigator.
x ECG at V1 will serve as Baseline for the 
evaluation of change in ECG measurements. 
x The ECG at the Taper Visit and Safety Follow-
up Visit will be required for subjects with a clinically significant abnormal or readin
g at the 
previous clinic visit. For non-clinically significant abnormalities, repeat of this 
assessment is at the discretion of the 
investigator. x Allow some flexibility 
for the timing of the 
second ECG recording.
x ECG is performed at V1, 
which will be at most 7 
days prior to V3. 
Therefore, ECG at V3 is 
unnecessary. 
x No changes in 
concomitant AEDs are 
allowed during the 
Baseline Period. Thus, there is no need to repeat 
the ECG unless 
medically necessary. 
x If the ECG is normal at 
End of Maintenance, there is no need to repeat 
as early as 4 days later at 
the Taper Visit when the 
study drug is being tapered. REDACTED 
DCOPYreviorevio
signisign
asasThis 
document 
cannot 
be 
used 
to support 
any ny
marketing 
authorizationfic
sessmesessm
investinvesth
applicationTaperTape
be requie requ
significagnific
s clinic clini
cant aant a
and s BB
e in ECin EC
any BaselBase
extensions e seconsecon
imatelymatel
rding.ding.
at theat the
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 117 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 1Section 4.1
Section 4.1.1
Section 5.1
Table 5
-1
Section 5.4Section 8.1.2
Section 8.2.1
Section 8.3.1
Section 9.1
Section 13.1.1
Section 13.1.1.2x Video-EEG (72 hours of continuous recording) 
performed at V2, V3, and V6 serves to evaluate both the 
primary and secondary efficacy variables. 
x The ADF of electrographic partial- onset seizures will be 
calculated as (number of partial- onset seizures recorded 
on the 72-hour video- EEG divided by 72 [or number of 
interpretable hours recorded]) multiplied by 24.Global changes:
x Revise duration of video- EEG to be up to 72 
hours of continuous recording with every attempt to obtain at least 48 hours of interpretable recording. 
x Localize definition of video- EEG duration to 
Sections 4.1, 5.1, 8.1.2, 8.3.1, 9.1, and 13.1.1, 
and Table 5-1.
Text revised:
x The ADF of electrographic partial-onset seizures will be calculated as (number of partial-onset seizures recorded on the video-
EEG divided by the number of interpretable 
hours recorded) multiplied by 24.x Clarify duration of 
video- EEG requirements 
with every attempt to 
obtain at least 48 hours 
of interpretable recording. 
x Com pletion of a full 72-
hour EEG is an 
impediment to patient enrollment based on site 
feedback. 
x Seizure data are 
normalized to 24 hours.
x There would be no 
changes to the analyses 
that would affect the 
validity of the data. 
Section 5.1.3 A target of approximately 30% of the randomized subjects should consist of subjects originating from sites in North America and the EU. A target of approximately 30% of the randomized subjects should consist of subjects originating from sites in North America and Europe. Inclusion of non-EU countries into the 30% randomization target.
Table 5-1Table 5
-2
Table 5 -3
Section 8.2.3Section 8.2.4Section 8.4.1Section 8.4.3Section 8.5.2
Section 8.6.1Assessments of healthcare resour ce use on Visit 3, Visit 4, 
Visit 5, Visit 6, TV1, TV2, Taper Visit, and Safety 
Follow -up Visit.Global change:
x Remove assessments for healthcare resource use on Visit 4, Visit 5, TV1, TV2, Taper Visit, 
and Safety Follow-up Visit. Duration of the study is too short to administer the 
questionnaire on multiple 
occasions.D
ed subjed sub
es in Nes in N
DA
COPY izureizu
partiapartia
EEEEThis 
document 
cannot 
be 
used ed
to support 
any 
marketing North North
sit 3, Vit 3, V
d SafetySafe
ket
authorizational
EG divEG div
hours hours thects cts 
hhuththhth
application f electrof elect
will be ill b
onset onset 
id
and 8.8
any -EEGEE
3.1, 93.1
extensions p to 72 to 72
every very 
s of s of 
G
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 118 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Table 5-1Section 8.2.1
Section 11.7.8
Section 13.2.1The Bayley Scales of Infant and Toddler Development, Third Edition is to be completed by subjects who are <18 
months of age who originate in English
-speaking 
countries.Text revised:
x Investigators must make every attempt to administer the Bayley Scales of Infant and Toddler Development, Third Edition, for subjects who are <18 months of age who originate in English-speaking countries. 
x The investigators may utilize trained pediatric 
psychologists or other appropriately skilled individuals to administer the scale.
x Investigators must make every attempt to 
administer Baseline assessment of the Bayley-
III scales; however, due to the short study duration of SP0967, the next asse
ssment will be 
collected in subjects entering into the EP0034 
study and analysis of these data will be 
conducted in EP0034.The administration of Bayley Scales is 
complicated and requires 
trained individuals.  The 
revised wording provides 
additional instructions to 
the investigators.  REDACTED 
CT
DCOPYI scaI sc
duratidurati
colcoThis 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorizationo
llectedllected
study tudy 
conconori
application minin
must mamust m
BaselinBaseli
s; howe; how
n of Sn of S
i
andutilti
er apprr appr
isteste
anyng cong c
lize trize 
extensions t to to 
ant andnt and
tion, foion, f
of age f age
ou
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 119 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 1Section 4.3.2
Table 5
-1
Section 8.3.2Section 11.7.7Section 13.2.1x The BRIEF- P will be used only for subjects who are ≥2 
years of age at V3 and V6.
x The BRIEF P includes rating forms used by parents to 
assess subjects’ executive functioning. Executive 
functions broadly encompass a set of cognitive skills 
that are responsible for the planning, initiation, sequencing, and monitoring of complex goal direc
ted 
behavior. 
x The BRIEF P rating form consists of items that measure 
various aspects of executive functioning: Inhibit, Shift, 
Emotional Control, Working Memory, and 
Plan/Organize. The clinical scales form 3 broad indexes 
(Inhibitory Self-Control, Flexibility, and Emergent Metacognition) and 1 composite score (Global Executive Composite).
x The BRIEF P includes validity scales to measure negativity and inconsistency of responses.x The BRIEF-P will be used only for subjects 
who are ≥2 years of age at V3 and this will 
serve as the baseline fo r assessment in EP0034 
(open-label extension study).
x The Other Safety Variable for change from 
Baseline to end of Maintenance Period in the 
BRIEF- P score for subjects ≥2 years was 
removed.
x The BRIEF P includes rating forms used by 
parents to assess subjects’ executive functioning 
within the context of the subject’s everyday environment. It requires that the parent must 
have had recent and extensive contact with the 
child over the past 6 months. 
x The clinical scales form 3 b road overlapping 
indexes: Inhibitory Self- Control (Inhibit and 
Emotional Control), Flexibility (Shift and 
Emotional Control), and Emergent 
Metacognition (Working Memory and 
Plan/Organize) and 1 composite score (Global 
Executive Composite).
x Baseline assessment of the BRIEF- P will be 
performed at Visit 3; however, due to the study 
duration of SP0967, the next assessment will be 
collected in subjects entering into the EP0034 
study. Thus, the analysis of these data will be conducted in EP0034. x Recall period for BRIEF-
P is 6 months. In a study 
of approximately 1-
month treatment 
duration, the recall 
period at V3 would 
overlap that at V6/ET. 
Therefore, it is not 
possible to reliably 
detect any change from 
Baseline. 
x V3 measures of BRIEF-
P will still serve as 
Basel ine for subjects in 
EP0034. 
x Because the V6 assessment was 
removed, the analysis of 
change from baseline 
will occur in EP0034; 
therefore, the variable 
was removed from SP0967.  REDACTED 
DCOPYnvirovir
have hhave h
chichThis 
document 
cannot 
be 
used 
to support su
any 
marketing 
authorizationh
ild ovild ov
The cThe c
indindth
application cludesude
ess subjss sub
context contex
ment. It ment. I
ad reced rece
and ectec
es rs
any ance ance
ts ≥2 ts ≥
extensions cts ts 
will will 
in EPn EP
changchan
P
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 120 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 1Section 4.3.2
Table 5
-1
Section 8.3.2Section 11.7.6Section 13.2.1x Achenbach CBCL (the CBCL/1½ 5 will be completed 
by parent[s]/legal representative[s]/caregiver[s] of subjects ≥18 months of age at V3 and V6/ET)
x In both questionnaires, the occurrence of certain 
problems and behaviors in the past 6 months will be 
scored on the following scale:
 0=not true (as far as known)
 1=somewhat or sometimes true
 2=very true or often truex Achenbach CBCL (the CBCL/1½ 5 will be 
completed by parent[s]/legal 
representative[s]/caregiver[s] of subjects ≥18 
months of age at V3 and this will serve as the 
baseline for assessment in EP0034 (open- label 
extension study))
x The Other Safety Variable for change from 
Baseline to the end of the Maintenance Period 
in the Achenbach CBCL/1½- 5 for subjects ≥18 
months was removed.
x Baseline assessment of Ach enbach CBCL will 
be performed; however, due to the short study 
duration of SP0967, the next assessment will be collected in subjects entering into the EP0034 
study and analysis of these data will be 
conducted in EP0034.
x In both questionnaires, the occurren ce of certain 
problems and behaviors at the time of 
administering the questionnaire or within the 
past 2  months will be scored on the following 
scale: 
 0=not true (as far as known)
 1=somewhat or sometimes true
 2=very true or often truex Recall period for 
Achenbach CBCL is 2 
months. In a study of 
approximately 1- month 
treatment duration, the 
recall period at V3 
would overlap that at 
V6/ET. Therefore, it is 
not possible to reliably 
detect any change from 
Baseline. 
x V3 measures of 
Achenbach CBCL will 
still ser ve as Baseline for 
subjects in EP0034.
x Because the V6 
assessment was 
removed, the analysis of 
change from baseline 
will occur in EP0034; 
therefore, the variable 
was removed from SP0967. 
Table 5-2
Section 8.4.3Height and head circumference will be measured at TV2. Removed from TV2 Height and head 
circumference are 
measured at V6 (Day 27). 
There is no need to repeat 2 weeks later. 
Table 5-3 No dosing instructions provided to the caregiver at the Taper Visit. At the Taper Visit, dosing instructions will be provided to the caregiver(s). Provide the caregiver with dosing instructions.REDACTED 
DCOPYe perfpe
duratidurati
colcoThis 
document 
cannot 
be be
usedions prns pr
ed ed
to supportwill be ll be 
tany a
marketing 
authorizationo
llectedllected
study tudy 
concon
xxth
application CBCB
moved.moved
sessmensessm
rmed; hmed; 
n of Sn of S
i
andbleble
f the Mthe M
BCLBCL
any e for ce for
extensions be e 
bjects ≥ects ≥
serveerve
0034 (o034 (
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 121 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Table 5-3Section 8.5.2 x Blood sample for clinical chemistry/hematology drawn 
at Taper Visit and Safety Follow-up Visit.
x At the Safety Follow- up Visit, the assessment will be 
required only for subjects with an abnormal value 
(clinical chemistry or hematology) or reading (ECG) at 
the previous clinic visit.x Blood sample for clinical chemistry/hematology 
drawn at Taper Visit and Safety Follow-up Visit.
x For both the Taper Visit and Safety Follow- up 
Visit: blood sample for clinical 
chemistry/hematology collection will be 
required for subjects with a clinically 
significant abnormal value at the previous clinic 
visit. For non-clinically significant 
abnormalities, repeat of these assessments are at 
the discretion of the investigator.If the laboratory values are 
normal at End of 
Maintenance, there is no 
need to repeat as early as 4 
days later at the Taper 
Visit when the study drug 
is being tapered. 
Section 6.1 Inclusion Criterion 6: 
x Subject has uncontrolled partial- onset seizures after an 
adequate course of treatment (in the opinion of the investigator) with ≥2 AEDs (concurrently or 
sequentially).Remove Inclusion Criterion 6 x Inclusion Criterion 9 
targets the population of interest with regard to 
concomitant AEDs. 
x Requiring subjects to fail 2 or more AEDs is an 
impediment for recruiting younger 
subjects.
Section 6.1 Inclusion Criterion 8: 
x Subject has ≥2 partial -onset seizure s with or without 
secondary generalization during the 72- hour Baseline 
video-EEG.Revise Inclusion Criterion 8a: 
x Subject has ≥2 partial -onset seizures with or 
without secondary generalization during the 
End-of-Baseline video-EEG.Duration of End-of-
Baseli ne video- EEG is 
explained elsewhere. 
Section 6.2 Exclusion Criterion 1: 
x Subject has previously participated in this study.Revise Exclusion Criterion 1a: 
x Subject has been previously randomized in this 
study (re-screening for screen- failed subjects is 
only allowed with prior consultation and 
permission of the medical monitor). Clarify that re-screening is 
allowed for screen failed 
subjects who have not been
previously randomized in 
SP0967 (see Exclusion 
Criterion 4a).
Section 6.2 Exclusion Criterion 4: 
x Subject has been previously treated with LCM.Revise Exclusion Criterion 4a: 
x Subject has been previously treated with LCM 
and the LCM treatment was stopped due to lack 
of efficacy or adverse event(s).Clarify exclusion of 
subjects previously treated with LCM  REDACTED 
DCOPY ovevThis 
document 
cannotas bes beca
be rion on
eeneen
us4:4used us
to support icipatedipate
tany 22--houhoa
marketing h or wih or w
ur
ket
authorization th
application nicalca
repeat oepeat
on of theon of th
clusionlusion
ic
andth th
value value
allylly
anyectionectio
a clina cl
extensions atolol
w-up up 
fety Foty Fo
l
or logyogyrvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 122 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 6.2 Exclusion Criterion 8: 
x Subject is on a ketogenic or other specialized diet for the 
treatment of epilepsy. If the subject was on a ketoge nic 
or other specialized diet in the past, they must be off this 
diet for ≥2 months prior to Visit 1.Revise Exclusion Criterion 8a: 
x Subject is on a ketogenic diet that has either 
changed within the 4 weeks prior to Visit 1 or is 
expected to change during the study.x As long as a ketogenic 
diet is stable, the subject 
should be allowed into 
the study. 
x Treatment of ketogenic 
diet eligibility should be 
similar to VNS use 
eligibility (Inclusion 
Criterion 10).
Section 6.2 Exclusion Criterion 9: 
x Subject has an alanine aminotransferase (ALT), 
aspartate aminotransferase (AST ), or total bilirubin level 
≥2 times the upper limit of normal (ULN), or creatinine 
clearance <30mL/minute.Revised Exclusion Criterion 9a: 
x Subject has creatinine clearance <30mL/minute.x Update to UCB protocol 
template text.
x Exclusion of subjects 
with abnormal ALT, 
AST, or bilirubin now 
covered by new 
Exclusion Criterion 22.
Section 6.2 Exclusion Criterion 15: 
x Subject has a current diagnosis of Lennox-Gastaut 
syndrome, epilepsia partialis continua, primary 
generalized epilepsy, or seizur es that are not of partial-
onset origin.Revise Exclusion Criterion 15a: 
x Subject has a current diagnosis of Lennox-
Gastaut syndrome, epilepsia partialis continua, 
primary generalized epilepsy, Dravet 
Syndrome, or seizures that are not of partial -
onset origin.A subject could have 
partial -onset seizures but 
also have generalized 
seizures. LCM can 
exacerbate generalized seizures in subjects with 
Dravet Syndrome in this 
age category.
Section 6.2 Exclusion Criterion 16: 
x Subject has a history of status epilepticus ≤2 months 
prior to Screening (Visit 1).Revise Exclusion Criterion 16a: 
x Subject has a history of generalized convulsive 
status epilepticus ≤2 months prior to Screening 
(Visit 1).x Clarify type of status 
epilepticus history that 
would be excluded
x Generalized convulsive 
status epilepticus has the 
highest associated 
morbidity and mortality; 
therefore, only subjects 
with a history of this 
type of status epilepticus 
will be excluded. REDACTED 
D
astaut astaut
mary mary 
CT
COPY This 
document 
ntcannot 
be 
used 
to support us epileps epil
)..
tany a
marketing of partiaof parti
authorization 
hoRRhhhorth
application n Criten Cri
s creatincreati
n and 
any 
extensions either ither 
 Visit Visit 
udy.dy.
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 123 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 6.2 Exclusion Criterion 17: 
x Subject has been treated with ethosuximide.Remove Exclusion Criterion 17 x Subjects with IGE are 
excluded per Exclusion 
Criterion 15. 
x Ethosuximide is 
generally only used for 
treatment of generalized 
seizures. 
Section 6.2 Exclusion Criterion 18: 
x Subject is currently being treated with vigabatrin or has discontinued use <12 months prior to Visit 1. Subjects who were previously treated with vigabatrin and have 
discontinued use >12 months prior to Visit 1 are eligible.Remove Exclusion Criterion 18. x The risks with vigabatrin 
use are higher with long-term treatment. SP0967 
is only 27 days of LCM 
treatment. 
x This criterion was removed from long-
term, 
open- label extension to 
SP0967 (EP0034).
Section 6.2 Exclusion Criterion 21: 
x Subject has a known sodium channelopathy, such as Brugada syndromeRevise Exclusion Criterion 21a: 
x Subject has a known cardiac sodium 
channelopathy, such as Brugada syndromeClarification of the 
exclusion criterion. REDACTED 
D
such asuch a
CTR
COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing s ting
authorization RRhhhorth
application 
and terionriondany 
extensions 
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 124 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 6.2 NA New Exclusion Criterion 22:
x Subject has >2x upper limit of normal (ULN) of any of the following: alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total 
bilirubin ( ≥1.5xULN total bilirubin if known 
Gilbert’s syndrome). If subject has elevations 
only in total bilirubin that are >ULN and <1.5xULN, fractionate b ilirubin to identify 
possible undiagnosed Gilbert’s syndrome (ie, 
direct bilirubin <35%).
x For randomized subjects with a Baseline result 
>ULN for ALT, AST, ALP, or total bilirubin, a 
Baseline diagnosis and/or the cause of any 
clinically meaningful elevation must be 
understood and recorded in the electronic Case 
Report form (eCRF).
x If subject has >ULN ALT, AST, or ALP that 
does not meet the exclusion limit at screenin g, 
repeat the tests, if possible, prior to dosing to 
ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant 
increase, inclusion of the subject must be discussed with the Medical Monitor.
x Tests that result in ALT, AST, or ALP up to 
25% above the exclusion limit may be repeated 
once for confirmation. Provide more detailed eligibility criteria to align 
with FDA guidance 
regarding PDILI.REDACTED 
DCOPY r rar r
>ULN>ULN
BasBasThis 
document 
cannot 
be 
used 
to support su
any 
marketing 
authorizationselineeline
clinicalinica
undund
RRth
applicationona
nosed nosed
bin <35%n <35
omized mized
for ALfor AL
ed id
andthat athat a
ate bte b
anyilirubiliru
bject hbject 
re
extensions (ULN)ULN
transferansfe
se (ASe (AS
r >UL>UL
ubb
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 125 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 6.3Section 7.2.2
Section 8.3Must Withdrawal Criterion 1:
x Subject experiences intolerab le AEs, including clinically 
relevant abnormal laboratory findings that, in the 
opinion of the investigator, preclude further participation 
in the study. 
x Subjects who are unable to tolerate study medication 
will be withdrawn from the study as follows:
 Subjects unable to achieve or maintain target dose 
for the final 3 days of the Titration Period
 Subjects who require dose reduction during the 
Maintenance Period
Section 7.2.2 and Section 8.3:
x Subjects who require dose reduction during the 
Maintenance Period will be withdrawn from the study 
and enter the blinded Taper Period.Revise must Withdrawal Criterion 1:
x Subject experiences intolerable AEs, including 
clinically relevant abnormal laboratory findings 
that, in th e opinion of the investigator, preclude 
further participation in the study. 
x Subjects who are unable to tolerate study 
medication will be withdrawn from the study as 
follows:
 Subjects unable to achieve or maintain 
target dose for the final 3 days of the Titration Period
x Text removed from Section 7.2.2 and Section 
8.3 x The patient can still 
contribute valuable 
efficacy and safety data 
even if they need a dose 
reduction. 
x This patient will be 
included the Full 
Analysis Set but not 
included in the Per-
Protocol set.
Section 6.3 x Must Withdrawal Criterion 8:
 Subject has liver function test (LFT) results for 
transaminases (AST, ALT, or both) ≥3xULN to 
<5xULN and total bilirubin ≥2xULN, or 
transaminases (AST, ALT, or both) ≥5xULN. In 
such instances, the study medication must be 
immediately discontinued and the subject withdrawn from the study. The LFTs will be repeated as soon as 
possible, and in no case more than 1 week later.
x May Withdrawal Criterion 4:
 Transaminases (AST, ALT, or both) ≥3xULN to 
<5xULN, in t he presence of normal total bilirubin, 
will be repeated within a few days. If the repeat 
testing confirms the abnormality (ie, transaminases 
are ≥3xULN to <5xULN with normal bilirubin), then 
weekly monitoring of LFTs should continue until 
resolved (ie, <3xULN or stable condition). The 
investigator is to decide whether or not to stop the study medication.x Remove must Withdrawal Criterion 8.
x Remove may Withdrawal Criterion 4.x Withdrawal criteria 
related to liver function 
tests now covered in new 
Section 6.3.1.REDACTlts for ts for
ULNULN
CTED 
DCT
COPY ext rext 
8.3 8.3 This 
documentstustunt cannot y momo
lved (ived (
nvestigvestig
tudyudy
beLN toLN t
onitoni
usedd withwith
ms thems the
o<<
to,
sencsenc
i
supportre thane than
4:
ALT, oALT, 
anysubjesubj
e repee repe
marketing to to 
xULN. IULN.
must bmust b
ecte
authorization 
horxxorth
applicationle toe to
for the for th
PeriodPerio
moved froved 
and hdradr
oa coa
anytolertole
awn fawn
extensions ncludincludin
ory finory fin
gator, pgator, 
dy. y. 
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 126 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 6.3 Must Withdrawal Criterion 9:
x Subject requires a change in concomitant AED daily 
dose or a change in VNS setting.Remove must Withdrawal Criterion 9. x The patient can still 
contribute valuable 
efficacy and safety data 
even if they need a 
change in dose or VNS 
setting. 
x This patient will be 
included the Full 
Analysis Set but not 
included in the Per-
Protocol set.
Section 6.3 Must Withdrawal Criterion 10:
x Subject initiates a ketogenic diet.Remove must Withdrawal Criterion 10. x Per Exclusion Criterion 
8, a patient’s ketogenic diet must remain stable. 
x Due to the short duration 
of this study, it is 
unlikely that a subject 
would initiate a ketogenic diet. 
x Should a ketogenic diet 
be initiated in violation 
of the exclusion 
criterion, the patient will be included in the Full 
Analysis Set but not 
included in the Per-
Protocol set.
Section 7.8.1 However, use of BZDs for any reason other than a stable 
daily dosag e regimen as concomitant AED within 24 
hours prior to or during the video -EEG is not permitted 
and may lead to the subject being withdrawn from the study (Withdrawal Criterion 15; Section 6.3).Text revised:
x However, use of BZDs for any reason other 
than a stable daily dosage regimen as 
concomitant AED within 24 hours prior to or 
during the video- EEG is not permitted and may 
lead to the subject being withdrawn from the 
study ( MAY Withdrawal Criterion 5; Section 
6.3).Correct Withdrawal 
Criterion cross reference 
number. REDACTED 
DCOPY ovevThis 
document 
ntcannot rawaw
bethe he 
wal wal 
usedas coas co
uring thing t
susu
toor anr an
on
syrsupport s
any 
marketing 
authorization th
application uststWitWic
and 
any 
extensions 
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 127 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 6.3 x Investigators should attempt to obtain information for 
subjects who withdraw or discontinue. 
x The Case Report form (CRF) must document the primary reason for withdrawal or discontinuation.Text revised: 
x Investigators should attempt to obtain information for subjects who withdraw. 
x The eCRF must document the primary reason for withdrawal.Update to UCB protocol template text.
New Section 
6.3.1NA New Section 6.3.1: Potent ial drug-induced liver 
injury IMP discontinuation criteria
x Subjects with potential drug-induced liver 
injury (PDILI) must be assessed to determine if 
IMP must be discontinued. In addition, all concomitant medications and herbal 
supplements that are not medically necessary 
should also be discontinued. 
x The PDILI criteria below require immediate 
and permanent discontinuation of IMP: 
 Subjects with either of the following:
◦ ALT or AST ≥5xULN
◦ ALT or AST ≥3xULN and coexisting total 
bilirubin ≥2xULN x Update to UCB protocol 
template text.
x Sponsor l anguage for 
monitoring of PDILI 
events was added to 
increase clarity for the 
sites and to align across programs. Addition of 
this language is to align 
with FDA guidance 
regarding monitoring of 
PDILI events and does 
not reflect a change in 
the liver safety signal for 
LCM.REDACTED 
DCOPYuppleuppl
shoulsho
xxThThThis 
document 
cannot 
be 
used 
to support 
any 
marketing 
ket
authorization d
he PDIhe PDI
and pand p
th
application must bust b
discontiiscon
t medict med
ments thants th
also balso b
and tioio
tial drual dru
beb
anyl drul dru
n crin cr
yextensions raw. aw. 
rimarymarye
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 128 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
New Section 6.3.1 (continued) NA New Section 6.3.1: Potent ial drug-induced liver 
injury IMP discontinuation criteria 
(continued)
x The PDILI criterion below requires immediate 
discontinuation of IMP:
 Subjects with ALT or AST ≥3xULN who 
exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis 
symptoms include fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness. 
Hypersensitivity symptoms include fever (without clear alternative cause), rash, or 
eosinophilia (ie, >5%).
 The PDILI criterion below allows for 
subjects to continue on IMP at the discretion 
of the investigator. 
 Subjects with ALT or AST ≥3xULN (and 
≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with 
no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness).(continued)REDACTED 
DCOPYwiw
eosieos
TTThis 
document 
cannot 
be 
used 
to support 
any 
marketing ma
authorization he Pe P
subjesubje
ofoth
applicationude 
uadranuadran
sitivity itivity
ut clear t clea
nophiliaophil
PDID
andso
ensitivnsitiv
e fatifat
anyT ≥3T ≥
ciatedciated
it
extensions d 
res immes im
3x3
oriveriverrrvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 129 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
New Section 6.3.1 (continued) NA New Section 6.3.1: Potent ial drug-induced liver 
injury IMP discontinuation criteria 
(continued)
x Evaluation of PDILI must be initiated as described in Section 8.3.2. If subjects are unable to comply with the applicable 
monitoring schedule, IMP must be discontinued 
immediately.
x Investigators should attempt to obtain information on subjects in the case of IMP 
discontinuation to complete the final evaluation. 
Subjects with PDILI should not be withdrawn 
from the study until investigation and 
monitoring are complete. All results of these 
evaluations and observ ations, as well as the 
reason(s) for IMP discontin uation and subject 
withdrawal (if applicable), must be recorded in 
the source documents. The eCRF must 
document the primary reason for IMP 
discontinuation.(continued)
Section 7.2.4 NA x Text added:
x Taper of LCM may not be required for some 
subjects who are on the lowest dose of study 
medication or who need to discontinue study 
medication abruptly, depending on the 
treatment option selected by the investigator in 
consultation with the medical monitor.x If a subject received 
study medication at a 
dose of 2mg/k g/day and 
discontinued, a taper 
would not be required. 
x In case there is a need to 
immediately switch the 
subject to a different 
AED, the protocol would 
allow immediate 
discontinuation from 
LCM. REDACTED 
DCOPY bjecbj
from tfrom t
monmonThis 
document 
cannot 
tbe b
used 
to support 
any 
marketing 
tin
authorizationnitoriitor
evaluatvalua
reasreas
wwth
application uld ald a
subjectsubje
tion to ction to 
with PDwith P
he studye stud
ingi
and atteatte
anypplicppli
P mustmust
extensions d 
iated aated a
ubjectubjec
ica
oriveriverrrvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 130 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 7.5 x Investigational medicinal product stored by the
investigator is to be kept in a secured area with limited 
access.
x Appropriate storage conditions must be ensured either by controlled room temperature or by completion of a 
temperature log in accordance  with local requirements 
on a regular basis, showing minimum and maximum 
temperatures reached over the time interval.
x In case an out of range temperature is noted, it must be 
immediately communicated in accordance with the pharmacy manual.Text revised:
x Investigational medicinal product stored by the 
invest igator is to be kept in a secured area with 
limited access accord ing to the storage 
conditions mentioned on the label.
x Appropriate storage conditions must be ensured 
either by controlling the temperature or by 
completion of a temperature log in accordance 
with local requirements on a regular basis, 
showing minimum and maximum temperatures 
reached over the time interval.
x In case an out-of- range temperature is noted, it 
must be immediately reported as per instructions contained in the IMP Handling 
Manual.Update to UCB protocol template text.
Section 7.6 x Details of any IMP lost (due to breakage or wastage), 
not used, or returned to the sponsor or designee must 
also be recorded on the appropriate forms. 
x Periodically, and/or after completion of the clinical 
phase of the study, all used (including empty containers) 
and unused IMP containers must be reconciled and 
returned to UCB’s designee, preferably in their original 
package. Text revised:
x Details of any IMP lost, damaged (due to 
breakage or wastage), not used, partially used, disposed of at the study site, or returned to the 
sponsor or designee must also be recorded on 
the appropriate forms.
x Periodically, and/or after completion of the 
clinical phase of the study, all used (including 
empty containers/partially used), unused, 
damaged, and/or expired IMP must be 
reconciled and either destroyed at the site 
according to local laws, regulations, and UCB 
SOPs or returned to UCB’s designee. Update to UCB protocol template text.
Section 7.8.1 Subjects must have been maintained on a stable dosage 
regimen of 1 to 3 marketed AEDs for ≥2 weeks prior to 
Visit 1 (ie, prior to entry into the Baseline Period). Text revised:
x Subjects must have been maintained on a stable dosage regimen of 1 to 3 marketed AEDs for ≥2 
weeks prior to Visit 1 (ie, prior to initiation of 
Baseline video-EEG monitoring) Timing of stable AED 
dosing clarified. REDACTED 
D
e), e), 
must must 
clinicclinic
EDDDDCOPY caseca
must must 
insinsThis 
document 
cannot nn
ber to eo e
usedeen men m
marketearket
entent
to matosupport 
any 
marketing cal cal 
containeontain
iled anded an
n their n thei
authorizationbe
structitructi
ManuaManua
Text Text 
xx
zath
application menmen
mum andum a
r the timthe ti
n outout-o
e immimm
ande tet
peratureratur
ntsnts
anyons mons 
empeemp
extensions ed by thd by t
ed aread area
torage orage
abel.bel.
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 131 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 7.8.1 x The following concomitant medications are prohibited 
during the study:
 Neuroleptics 
 Monoamine oxidase inhibitors 
 Barbiturates (except as AEDs)
 Narcotic analgesics Text revised:
x The following concomitant medications are 
prohibited during the study:
 Clozapine
 Monoamine-A oxidase inhibitors 
 Barbiturates (except as AEDs)
 Cannabidiols (not approved or indicated 
for epilepsy by local health authority)
x Neuroleptics (except for clozapine) are allowed 
during the study but the investigator should 
make every effort to keep the dose stable. 
x Other medications are permitted according to 
current clinical standards (eg, topical 
anesthetic).x Clozapine is the only 
neuroleptic that lowers 
seizure threshold.
x Clarification made to 
note that prohibited 
medication refers to 
MAO-A inhibitors.
x Majority of narcotic 
analgesics do not lower 
seizure threshold and, 
therefore, should not interfere with efficacy 
evaluations. In the rare instance they are used in association with an AE, 
the reason for use would 
be recorded.
x Cannibidiols that are 
approved or indicated 
will count as a 
concomitant AED.
x Revisions in prohibited 
medications to allow use 
of medications to those 
patients who may need 
it.
Section 7.8.1 
(continued)x The following medications are not allowed unless used 
as described: 
 Amphetamines and sedative antihistamines: 
stable use only.Text revised:
x The following medications are not allowed 
unless used as described: 
 Amphetamines: stable use only. x Antihistamines should be 
allowed for treatment of 
URTI. 
x They are not expected to
have an effect on 
efficacy or safety 
evaluations.REDACTED 
DCOPYOther Other
currecurr
ananThis 
document 
cannot n
be 
usednes anes an
only.only.
to supps are nare n
pport pp
any 
marketing 
authorization ent 
nesthetesthetth
application cept fept 
dy but ty but 
y effort ty effort
medicatiedicat
cliniclin
andot at 
y locay loca
fofo
anyas Aas A
approappr
extensions ns are s are 
inhibinhib
AE
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 132 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 7.8.1 Subjects who have been treated with ethosuximide are excluded from the study. Subjects who are currently being 
treated with vigabatrin or have discontinued vigabatrin use 
<12 months prior to Visit 1 are excluded from the study. 
Subjects who were previously treated with vigabatrin and 
have discontinued use >12 months prior to Visit 1 are 
eligible. Concomitant use of either vigabatrin or 
ethosuximide during the course of the study is prohibited.Text removed. Text removed for consistency with changes 
to Exclusion Criteria 17 
and 18. 
New Section 
11.1.6NA New Section 11.1.6: Suspected transmission of 
an infectious agent via a medicinal product
x For the purposes of reporting, any suspected 
transmission of an in fectious agent via a 
medicinal product should be considered as an 
SAE; such cases must be reported immediately, 
recorded in the AE module of the eCRF, and 
followed as any other SAE. Any organism, 
virus, or infectious particle (eg, prio n protein 
transmitting transmissible spongiform 
encephalopathy), pathogenic or nonpathogenic, 
is considered an infectious agent.
x Subsequent Sections 11.1.7 and 11.1.8 
renumbered.Update to UCB protocol 
template text.REDACTED 
DCOPYnsms
medicimedic
SAESA
rrThis 
document 
cannot 
be 
used 
to support 
any 
marketing ma
authorizationE; susu
ecordecorde
follofollo
vivith
applicationS
nt via nt via
oses of ses o
ion of aon of 
nal prodnal pro
uchuch
andSuspeuspend nd
any 
extensions 
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 133 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 11.2.1 (Important medical events may include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias that do not 
result in inpatient hospitalization, or the development of 
drug dependency or drug abuse.)Text revised:
x (Important medica l events may include, but are 
not limited to, potential Hy’s Law [see Section 
11.3], allergic bronchospasm requiring 
intensive treatment in an emergency room or at 
home, blood dyscrasias that do not result in 
inpatient hospitalization, or the development of
drug dependency or drug abuse.)x Update to UCB protocol 
template text.
x Sponsor language for monitoring of PDILI 
events was added to 
increase clarity for the sites and to align across 
programs. Addition of 
this language is to align 
with FDA guidance regard
ing monitoring of 
PDILI events and does 
not reflect a change in 
the liver safety signal for 
LCM.
Section 11.2.3 An SAE should be followed until it has resolved, has a stable sequelae, the investigator determines that it is no longer clinically significant, or the subject is lost to follow 
up. Text revised:An SAE should be followed until it has resolved, has a stable sequelae, the investigator determines 
that it is no longer clinically significant, or the 
subject is lost to follow up. This follow
-up 
requirement applies to AEs, SAEs, and AEs of special interest; further details regarding follow up of PDILI events
are provided in Section 
11.6.1.4.x Update to UCB protocol 
template text.REDACTED 
D
no no 
to folloto foll
EDDDDCOPY This 
document 
cannot 
be 
used 
to support 
any any
marketing 
authow w 
horizatText rText r
AnAn
ation atth
application 
and,,
drug arug a
anydo ndo 
or the or the 
b
extensions e, but , but 
see Secee Se
uiring uiring
gencygency
no
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 134 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 11.3 NA New text:
x Potential Hy’s Law, defined as ≥3xULN ALT 
or AST with coexisting ≥2xULN total bilirubin 
in the absence of ≥2xULN ALP, with no 
alternative explanation for the biochemical 
abnormality, must ALWAYS be reported to 
UCB as an AE of special interest (ie, without 
waiting for any additional etiologic 
investigations to have been concluded). Follow-
up information should then be reported if an 
alternative etiology is identified during investigation and monitoring of the subject.x Update to UCB protocol 
template text.
x Sponsor language for monitoring of PDILI 
events was added to 
increase clarity for the 
sites and to align across 
programs. Addition of 
this language is to al ign 
with FDA guidance 
regarding monitoring of 
PDILI events and does 
not reflect a change in 
the liver safety signal for 
LCM.
Section 11.5 x The following list of Anticipated SAEs has been 
identified, as these events ar e anticipated to occur in the 
populatio n studied in this protocol at some frequency 
that is independent of drug exposure. This original list 
(Table 11 ‒1) will remain in effect for the duration of the 
protocol.
x Pregnancy, puerperium and perinatal disorders: Abortion 
spontaneous
x Reproductive syst em and breast disorders: Menstrual 
disorderText revised:
x The following list of Anticipated SAEs (Table 11‒1) is anticipated to occur in the population 
studied in this protocol at some frequency that 
is independent of drug exposure.
x Removal of pregnancy, puerperium and 
perinatal disorders: Abortion spontaneous 
x Removal of reproductive system and breast 
disorders: Mens trual disorderx Update to UCB protocol 
template text.
x Updated based on patient 
population of this study
Section 14.1 Prior to participation in the study, the written Informed 
Consent form should be signed and personally dated by 
the subject’s legal representative(s), and by the person 
who conducted the informed consent discussion 
(investigator or designee).Text revised:
x Prior to participation in the study, the Informed 
Consent form should be signed and personally 
dated by the subject’s legal representative(s), 
and by the person who conducted the informed 
consent discussion (investigator or designee).Update to UCB protocol
template text.REDACTED 
D
r in thein the
quencyquency
originaorigina
ratira
EDDDDCOPY esesThis 
document 
cannot 
be be
usedformerm
signee)gnee
toentatentat
eddsuppoudy, the dy, the
ned anded an
ivei
ort spo
any ordersrders
marketingl list list
ion of thon of th
orders: rders
authy
t
horizatText rText r
xx
ation atth
applicationav
shouldshould
tiology ology
ion andon an
andional eonal 
ve bee be
anyS beS b
interentere
eti
extensions N ALTN ALT
tal bilial bili
with nwith n
biochbioch
er
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 135 of 144Protocol Section(s) impacted Key components of previous protocol text Key components of revised protocol text Rationale
Section 11.6.1 (formerly Section 
11.7)Section 11.7  Liver function tests
x Refer to Section 6.3 for LFT withdrawal criteria.
x Transaminases (AST, ALT, or both) ≥3×ULN but 
<5×ULN, in the presence of total bilirubin ≥2×ULN, or 
transaminases (AST, ALT, or both) ≥5×ULN will result 
in immediate discontinuation of study medication and 
withdrawal of the subject from the study. The LFTs will 
be repeated as soon as possible, and in no case more 
than 1 week later.
x Transaminases (AST, ALT, or both) ≥3xULN to 
<5xULN, in the presence of normal total bilirubin, will 
be repeated within a few days. If the repeat testing 
confirms the abnormality (ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then 
weekly monitoring of LFTs should continue until 
resolved (ie, <3xULN or stable condition). The 
investigator is to decide whether or not to stop the study 
medication.
x In all cases of transaminases (AST, ALT, or both) 
≥3xULN, testing for hepatitis A, B, and C will be done.
x Referral to a specialist (ie, hepatologist or 
gastroenterologist) is at the di scretion of the investigator. 
This is recommended especially if the transaminase 
abnormalities >3xULN persist after discontinuation of 
the study medication.Section 11.6.1  Liver function tests and 
evaluatio n of PDILI
x Original text removed and replaced with more 
detailed text about the evaluation of PDILI:
 Table 11‒1:Required investigations and 
follow up of PDILI
 Section 11.6.1.1 Consultation with Medical 
Monitor and local hepatologist
 Section 11.6.1.2 Immediate action: 
determination of IMP discontinuation
 Section 11.6.1.3 Testing: 
identification/exclusion of alternative 
etiology
 Table 11‒2: PDILI laboratory measurements
 Table 11‒3: PDILI information to be 
collected
 Section 11.6.1.4 Follow-up evaluation
x Subsequent sections renumbered.x Update to UCB protocol 
template text.
x Sponsor language for 
monitoring of PDILI 
events was added to 
increase clarity for the 
sites and to align across 
programs. Addition of 
this language is to align 
with FDA guidance 
regardin g monitoring of 
PDILI events and does 
not reflect a change in 
the liver safety signal for 
LCM.
Administrative updates x CRF
x Drug Safety
x ICH=International Conference on Harmonisation
x More than 40 million people suffer from epilepsy –about 
1% of the world’s population (Dichek, 1999).Text revised:
x eCRF
x Patient Safety
x ICH=International Council for Harmonisation
x Updated list of abbreviations
x Updated list of references
x It is estimated that almost 70 million people 
suffer from epilepsy (Ngugi et al, 2011).NAREDACTEDe studye study
r both)r both)
illil
D DCOPY dede
etioetio
TThis 
document 
cannot ca
be ld’sds
used onfn
llion peion p
sspopo
to ferefere
support 
o
anytrantran
discondiscon
marketing )
be donbe don
the invthe in
nsans
authy
horizationTableable
TabTab
ccth
application 2 ImIm
n of IMn of IM
1.6.1.3 1.6.1.3
cation/cation
ogyogy
11
anduu
hepatoepat
mmmm
any ltationltation
l
extensions with mwith m
of PDof PD
stigatitigati
or rvariations 
onRatioRatio
onvav
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 136 of 14417.3 AMENDMENT 3
Rationale for the amendment
The primary purpose of this substantial amendment is  to address the high variability in video-
EEG seizure counts between the site and central re ader by removing the central reader. This 
change was proposed by the FDA as part of a Type C meeting written response obtained on 25 January 2018.
Additional changes in Protocol Amendment 3 included the following:
x Update clinical trial biostatistician contact
x Update of the regulatory status of LCM in the US and EU
x Clarify the planned number of subjects per ag e group to reflect UCB’s commitment to make 
every attempt to enroll subjects <2 years of age while recognizing the difficulty of enrolling 
this age group
x Prevent ineligibility of an otherwise eligible subject who has undergone the baseline EEG 
due to the narrow visit window for central laboratory measurements
x Clari fy that “seizure -free” status during the Maintenance Period will be summarized by 
(1) all seizure types and (2) partial-onset seizure types only
x Update hematology and chemistry measurements for the assessment of PDILI events
x Replace Markov chain Monte Carlo multiple imputation method with a more appropriate 
monotone regression method 
x Add age group to the analysis of the primary efficacy variable since randomization is 
stratified by age group
The following table summarizes each change with the associated rationale.REDACTED m
ultiple ultiple 
f the pf the pCOPYe typetype
ments ents 
This document cannot be used to support any marketingprimarim
acch chah chauthorizations for thfor th
e impuimpu
marmarapplicationremenremen
e PerioPerio
s onlyonlyand dergoergoany iffiffextensions mmitmmmitm
fficuficuor variations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 137of 144Appendix Table 2: Summary of changes in SP0967 Amendment 3
Protocol 
Section(s) 
impactedKey components of previous protocol text Key components of revised protocol text Rationale
STUDY 
CONTACT 
INFORMATIONClinical Trial Biostatistician
, MA
UCB BIOSCIENCES Inc. 
8010 Arco Corporate Drive 
Raleigh, NC 27617 
UNITED STATESClinical Trial Biostatistician
UCB BIOSCIENCES Inc. 
8010 Arco Corporate Drive 
Raleigh, NC 27617 
UNITED STATESUpdate clinical trial 
biostatistician contact
Section 1.0
Section 5.1
Table 5 -1
Section 9.1
Section 13.1.1a central reader locally by the investigator, subinvestigator, or 
qualified designated readerAddress the high 
variability in video- EEG 
seizure counts between the site and the central reader; 
clarify who is responsible 
for the assessment of the 
video-EEG seizure count
Section 2.0 Lacosamide has been approved as monotherapy or 
adjunctive therapy in the treatment of partial -onset 
seizures in patients 17 years of  age and older in the US 
(tablets, oral solution, and solution for intravenous [iv] infusion) and as adjunctive therapy in the treatment of 
partial
-onset seizures with or without secondary 
generalization in adult and adolescent (16 to 18 years of 
age) patients with epilepsy  in the EU (tablets, oral 
solution, and solution for iv infusion).In the US, LCM has been approved as 
monotherapy and adjunctive therapy in the 
treatment of partial -onset seizures in patients 
4years of age and older for tablets and oral 
solution, and 17 years of age and older for 
intravenous [iv] infusion. In the EU, LCM has 
been approved as monotherapy and adjunctive therapy in the treatment of partial
-onset seizures 
with or without secondary generalizati on in 
adults, adolescents, and children from 4 years of 
age with epilepsy (tablets, oral solution, and 
solution for iv infusion).Update of the regulatory 
status of LCM in the US 
and EU
Section 4.1.2 x Proportion of subjects who achieved “seizure -free” 
status (yes/no) for subjects who completed at least 48 
hours of interpretable video- EEG recording during the 
End-of-Maintenance Period video-EEGx Proportion of subjects who achieved 
“seizure -free” status (yes/no) from all seizure 
types, and from partial-ons et seizure types 
only for subjects who completed at least 48 
hours of interpretable video- EEG recording 
during the End-of- Maintenance Period video-
EEGClarify that “seizure -free” 
status during the 
Maintenance Period will 
be summarized by (1) all 
seizures t ypes and (2) 
partial -onset seizures onlyREDACTED 
D
r r 
nset nset 
in thein the
AC
COPY fieiThis 
document 
ntcannot MaiMai
be)
terprterpr
ntnt
usedubjectsbjects
 for sfor 
dto tosupport U (U (
sion).on).
any16 to 16 to
tabletab
marketing e US e US 
ous [iv]ous [iv
atment tmen
ndary ndary
1
authorization 
hIhhhoth
application investignvesti
esignatesignat
tiotio
and 
any 
extensions 
ion
or 
variations 
onvavavava
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 138 of 144Appendix Table 2: Summary of changes in SP0967 Amendment 3
Protocol Section(s) 
impactedKey components of previous protocol text Key components of revised protocol text Rationale
Section 5.1 Assessment of video-EEG seizure count for verification of selection criteria will be performed by the investigator, but for the purpose of study analyses will be performed by a central EEG reader. Assessment of video-EEG seizure count will be performed locally by the investigator, subinvestigator, or qualified designated reader for the purpose of both assessment of eligibility and study analyses. Address the high variability in video
-EEG 
seizure counts between the 
site and the central reader; clarify who is responsible 
for the assessment of the 
video-EEG seizure count
Section 5.1.2 Of these (n=122), a minimum target of 20% (n=25) of subjects will be enrolled in each of the 3 age categories: 
≥1 month
to <6 months, ≥6 months to <1 year, and ≥1 
year to <2 years.
Subjects will be enrolled in th e following age categories as 
detailed below:Of these (n=122), every attempt will be made to 
enroll a minimum target of 20% (n=25) of 
subjects in each of the 3 ag e categories: ≥1 month 
to <6 months, ≥6 months to <1 year, and ≥1 year 
to <2 years.Every attempt will be made to enroll subjects in 
the following age categories as detailed below:Clarify the planned 
number of subjects per age 
group to reflect UCB’s 
commitment to make every attempt to enroll subjects 
<2 years of age while 
recognizing the difficulty 
of enrolling this age group
Table 5-1
(footnote i)The video-EEG (up to 72 hours of continuous recording 
with every attempt to obtain at least 48 hours of
interpretable recording) will be conducted in an inpatient setting. Upon completion of the End
-of-Baseline video -
EEG (Visits 2 and 3), the investigator will assess the 
electrographic seizure count and confirm the selection 
criteria have been met. If the subject meets all selection criteria, including the requisite number of seizures based on the video
-EEG data, the subject may be randomized at 
Visit 3. All video EEG data re cordings will be transmitted 
to a central reader for the pu rposes of data analysis. The 
End-of-Maintenance Period video- EEG will be done at 
Visit 6. Subjects who discontinue on or before Day 20 will 
not require a video -EEG.The video-EEG (up to 72 hours of continuous 
recording with every attempt to obtain at least 
48hours of interpretable recording) will be 
conducted in an inpatient setting. Upon 
completion of the End -of-Baseline video- EEG 
(Visits 2 and 3), the investigator will assess the 
electrographic seizure count and confirm the selection criteria have been met. If the subject meets all selection criteria, including the requisite number of seizures based on the video
-EEG data, 
the subject may be randomized at Visit 3. 
Assessment of video -EEG seizure count will be 
performed locally by the investigator, 
subinvestigator, or qualified designated reader for the purpose of both assessment of eligibility and study analyses. The End
-of-Maintenance Period 
video -EEG will be done at Visit 6. Subjects who 
discontinue on or before Day 20 will not require a 
video-EEG.Address the high 
variability in video- EEG 
seizure counts between the site and the central reader; clarify who is responsible 
for the assessment of the 
video
-EEG seizure countREDACordingording
off
an inpan in
ACTED 
DAC
COPYctsct
<6 mo<6 m
to <2 to <2 
EvEvThis 
document 
ntcannot 
be 
useddiscodisco
EEG.EEG
tood vod v
supportbebe
ct mayt may
cordingordin
rposesrposes
idid
anyeets aeets 
r of sr of
marketingpatientpatien
e videovide
ssess theess th
he selehe sel
lll
authorizationyearear
ery attry att
the folhe fohhoThhhoth
application , every every
mum targum tar
each of ach o
nths, ≥ nths, ≥
rs.s
nand 
anynt of nt of
extensions unt wilt wil
tor, or, 
ignategnate
fef
ion
or 
variations 
onvavavava
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 139 of 144Appendix Table 2: Summary of changes in SP0967 Amendment 3
Protocol Section(s) 
impactedKey components of previous protocol text Key components of revised protocol text Rationale
Section 6.1 (IC
8a)Subject has ≥2 partial -onset seizures with or without 
secondary generalization during the E nd-of-Baseline 
video -EEG.Subject has ≥2 partial -onset seizures with or 
without secondar y generalization during the 
End-of-Baseline video-EEG. Electrographic 
seizures are defined as recognizable ictal patterns on an EEG involving ≥2 contiguous electrodes. 
The seizures are initiated as a unilateral or 
strongly asymmetric abnormal epileptiform 
discharge lasting a total of >10 seconds.Provide clarity by including the definition of electrographic seizures
Section 8.1.2 From Visit 2 (Day -3 to Day -1) to Visit 3 (Day 1), an End
-of-Baseline video- EEG (up to 72 hours of continuous 
recording with every attempt to obtain at least 48 hours of interpretable recording) will be performed. The Day 
-3
assessments should be conducted prior to the start of 
video -EEG monitoring. The video- EEG will be conducted 
in an inpatient setting.  Upon completion of the End -of-
Baseline video -EEG (Visits 2 and 3), the investigator will 
assess the electrographic seizure count and confirm the 
selection criteria have been met. If the subject meets all 
selection criteria, including the requisite number of 
seizures based on the End -of-Baseline video- EEG data, 
the subject may be randomized at Visit 3.From Visit 2 (Day -3 to Day -1) to Visit 3 (Day 1), an End
-of-Baseline video-EEG (up to 72 hours 
of continuous recording with every attempt to obtain at least 48 hours of interpretable recording) 
will be performed. The Day 
-3 assessments 
should be conducted prior to the start of video-EEG monitoring. The video
-EEG will be 
conducted in an inpatie nt setting.  Upon 
completion of the End -of-Baseline video- EEG 
(Visits 2 and 3), the investigator will assess the 
electrographic seizure count and confirm the 
selection criteria have been met. If the subject 
meets all selection criteria, including the requisite number of seizures based on the End
-of-Baseline 
video -EEG data, the subject may be randomized 
at Visit 3. Assessment of the video -EEG seizure 
count will also be performed locally by the 
investigator, subinvestigator, or qualified 
designated reader for the purpose of study 
analyses; however, completion of this review is not required prior to randomization.Address the high variability in video
-EEG 
seizure counts between the site and the central reader; 
clarify who is responsible 
for the assessment of the
video
-EEG seizure countREDACTEDed ed 
ofof--fff
ator wiator wi
nfirm thfirm th
t meet mee
D DCOPYn EE
continconti
obtainobtain
wilwiThis 
document 
cannot 
be 
used us
to support 
any 
marketing he 
ts all ts all 
r of r of 
EEG dEEG 
authill 
horizationn at leat l
ll be pebe pe
shouldshould
EEGEEGth
applicatioDay Day -tionab
a total a total
33
off-fBaseBas
uous reuous r
easea
tio
ando
d as ad as 
bnorbnor
anyizabizab
ntiguontiguo
extensions with orth or
during turing 
ectrogrctrog
blebl
ion
or 
variations 
onvavavava
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 140 of 144Appendix Table 2: Summary of changes in SP0967 Amendment 3
Protocol Section(s) 
impactedKey components of previous protocol text Key components of revised protocol text Rationale
Section 8.3.1 The Day 24 assessments should be conducted prior to the start of the End
-of Maintenance Period video-EEG 
monitoring (up to 72 hours of continuous recording with every attempt to obtain at least 48 hours of interpretable recording). The following assessments will be performed 
on Day 24 for all subjects:The Day 24 assessments should be conducted prior to the start of the End
-of Maintenance 
Period video -EEG monitoring (up to 72 hours of 
continuous recording with every attempt to obtain at least 48 hours of interpretable recording). 
Assessment of video
-EEG seizure count will be 
performed locally by the investigator, 
subinvestigator, or qualified designated reader for the purpose of the study analyses. The following 
assessments will be performed on Day 24 for all 
subjects:Address the high variability in video
-EEG 
seizure counts between the 
site and the central reader; clarify who is responsible 
for the assessment of the 
video
-EEG seizure count
Section 9.1Section 13.1.1 The video-EEG recordings will be evaluated by a central reader. The video-EEG recordings will be evaluated for seizure counts locally by the investigator, 
subinvestigator, or qualified designated reader.Address the high variability in video
-EEG 
seizure counts between the 
site and the central reader; 
clarify who is responsible 
for the assessment of the 
video-EEG seizure count
Section 11.6 Blood specimens for routine assay of hematology and clinical chemistry testing will be collected according to the 
tabular schedule of study procedures (Section 5.2). A 
central laboratory will perform the routine analysis of blood specimens. The procedures for handling and shipping these specimens will be provided to the sites.Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study 
procedures (Section 5.2). A central laboratory will perform the routine analysis of blood specimens. The procedures for handling and shipping these specimens
will be provided to the sites. In 
exceptional circumstances, local laboratory 
analysis may be performed. The medical monitor 
should be contacted before hand to discuss these 
circumstances.Prevent ineligibility of an otherwise eligible subject 
who has undergone the 
baseline EEG due to the narrow visit window for central laboratory measurements
Table 11-4 Hematology measurements: Eosinophil count Hematology measurements: Hematocrit, Hemoglobin, Platelet count, RBC count, WBC count, and Differential coun
tUpdate hematology measurements for the assessment of PDILI 
eventsREDACTED 
DR
COPThe vThe v
seizseiOPYsmm
bjects:bjectsOPThis 
document 
cannot ca
beeasurasur
usremremused us
to supportr hr h
providrovi
anyne anne a
handlhand
marketingy and gy and
ccordingcordin
ion 5.2on 5.
na
ting tin
authorization deodeo
zure coure co
subinvsubinvth
apEEEapplicationy th
or qualir qual
the studhe stu
s will bewill bap
ande
EG seG se
he inhe in
any ery ery at
table rable r
i
extensions nductenducte
ntenanntenan
up to 7p to 7
atttt
ion
or 
variations 
onvavavava
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 141 of 144Appendix Table 2: Summary of changes in SP0967 Amendment 3
Protocol Section(s) 
impactedKey components of previous protocol text Key components of revised protocol text Rationale
Table 11-4 Chemistry measurements: Amylase, If total bilirubin ≥1.5xULN, obtain fractionated b ilirubin to obtain % direct 
bilirubin, and Serum CPK and LDH to evaluate possible 
muscle inju
ry causing transaminase elevationChemistry measurements: Amylase, Bilirubin (if total bilirubin ≥1.5xULN, obtain fractionated 
bilirubin to obtain % dire ct bilirubin), Serum CPK 
and LDH to evaluate possible muscle injury causing transaminase elevation, AST, ALT, ALP, 
GGT, and AlbuminClarify and add chemistry measurements for the assessment of PDILI events
Section 13.1.1.1 Seizure ADF will be analyzed using analysis of covariance 
with terms for treatment and center (properly pooled), on 
log-transformed seizure ADF using the transformation of 
ln (X+1), where X is the seizure ADF.Seizure ADF will be analyzed using analysis of 
covariance with terms for treatment, age category 
(4 age stratification categories, pooled as 
appropriate), center (properly pooled ), on log-
transformed seizure ADF using the transformation of ln (X+1), where X is the seizure ADF.Add age group to the 
analysis of the primary 
efficacy variable since 
randomization is stratified 
by age group
Section 13.1.1.1Section 13.1.1.2 x Repeat the primary analysis using the FAS, except 
missing ADF of partial- onset seizures from the End-
of-Maintenance Period video- EEG will be replaced 
using multiple imputation by treatment arm and age 
group (≥1 month to <6 months of age, ≥6 months to 
<1 year of age, ≥1 year to <2 years of age, and ≥2 
years to <4 years of age) using a Markov chain Monte 
Carlo method assuming a log-normal distribution.x Repeat the primary analysis using the FAS, 
except missing ADF of partial- onset seizures 
from the End-of-Maintenance Per iod video-
EEG will be replaced using multiple 
imputation by treatment arm and age group 
(≥1 month to <6 months of age, ≥6 months to 
<1 year of age, ≥1 year to <2 years of age, 
and ≥2 years to <4 years of age) using 
monotone regression.Replaced Markov chain
Monte Carlo multiple 
imputation method with a 
more appropriate 
monotone regression method; further details to be described in the 
statistical analysis plan
Section 13.1.1.2 The proportion of responders between LCM and PBO will 
be analyzed using logistic regr ession with center (properly 
pooled) as a factor.The proportion of responders between LCM and 
PBO will be analyzed using logistic regression 
with age category (4 age stratification categories, pooled as appropriate) and center (properly 
pooled) as factors.Add age group to the 
analysis of the primary 
efficacy variable since randomization is stratified 
by age group
Section 13.1.2 For subjects who complete the Maintenance Period, the 
number and percentage of subjects who achieved “seizure -
free” status during the Maintenance Period will be 
tabulated and presented by treatment group.For subjects who complete the Maintenance 
Period, the number and percentage of subjects who achieved “seizure
-free” status from all 
seizure types, and from partial -onset seiz ure types 
only during the Maintenance Period will be 
tabulated and presented by treatment group.Clarify that “seizure -free” 
status during the Maintenance Period will 
be summarized by (1) all 
seizures types and (2) 
partial-onset seizures onlyREDACTED 
D
EndEnd-
eplacedplaced
m and m and 
momo
DDDDCOPYoprp
ansformnsfor
transftransf
ADADThis 
document 
cannotnd pred preca
being thing t
eses
usedmpletemplete
ntage tage
ddto tsupporteen Len L
ssion wision w
any LCMLCan
marketing ageage
nths to nths to
 and ≥2 and ≥
ov chainv cha
distribdistr
authorizationformarma
F.F.
d 
exxRRatth
application e an
erms foerms f
ation cation c
), center, cent
med seized sei
atioati
and at
nalynalyan
anymusmu
ion, Aion, A
extensions Bilirubilirub
actionaction
ubin), bin), 
sc
ion
or 
variations 
onvavavava
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 142 of 144Appendix Table 2: Summary of changes in SP0967 Amendment 3
Protocol Section(s) 
impactedKey components of previous protocol text Key components of revised protocol text Rationale
Section 13.6 Subjects are randomized into the study based on the investigator’s interpretation of the video EEG to meet study entry requirements; however, there may be a difference of interpretation of the number of seizures counted on the End
-of-Baseline Period video-EEG 
between the central reader and the investigator.Subjects are randomized into the study based on the initial interpretation of the video
-EEG to meet 
study entry requirements. However, the 
subsequent detailed assessment of seizure types and counts needed for the efficacy analyses could 
lead to a discrepancy in seizure counts (ie, a 
subject initially thought to be eligible is later 
found to have fewer than the required number of partial
-onset seizures during the End-of- Baseline 
Period video -EEG). To account for an anticipated 
difference of interpretation of the End of Baseline Period video
-EEG of 5% as well as the potential 
subject dropout rate of approximately 14%, the 
planned number of subjects to enroll is 122 subjects per treatment arm.To address removal of the central readerAC
DCOPYd d
fferencferen
PeriodPerio
subsubThis 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization vidvid
bject drect dr
planneplanne
122122hhhho
applicationughg
wer thanwer tha
eizures izures
o-EEG)EEG
e of inte of in
deodeo
ande
n seizuseizu
ht to t to
anynt of nt o
fficacyfficacy
extensiony basey base
oo-EEGEEG
ver, ther, th
fsf
ons ion
or 
variations 
onvavavava
thereof. 00
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 143 of 14418 DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, accordi ng to current Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as  the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.
All rights of publication of the results reside with  UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name Date/Signature
REDACTED COPY Date/SDate/SPY
This document cannot be used to support any marketing authorizationSignaignapplication atuatppand any extensionsbe 
ation ation
ents wnts wortreatrevariations thereof. 
UCB 05 Apr 2018
Clinical Study Protocol Lacosamide SP0967
Confidential Page 144 of 14419 SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: sp0967-protocol-amend-3
Version: 2. 0
Document Number: CLIN-000116615
Title: SP0967 protocol amendment 3
Approved Date: 15 Jun 2018
Document Approvals
Approval
Verdict: ApprovedName: Capacity: ClinicalDate of Signature: 15-Jun-2018 11:27:25 GMT+0000
ApprovalVerdict: ApprovedName: Capacity: ClinicalDate of Signature: 15-Jun-2018 12:02:34 GMT+0000
ApprovalVerdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 15-Jun-2018 13:00:15 GMT+0000DACTED 
REDADAOPYYAppApp
COOOCO
This document cannot be used to supppport ppany marketing mamanp
uthorization n
oriNam
Ca
aututapplication provalovaaand any extensions or variations thereof. 